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“b-wetenschap, ja, wat is dat nu eigenlijk?”a
Nou, zoiets dus……….
                                                 
a Permanent gespreksthema binnen de gelijknamige discussiegroep (Utrecht, 1995-2000)





The widespread and important role of X-ray crystallography in current structural research
has its origin in the discovery by Röntgen in the year 1895 of mysterious rays that passed
through the human body, which he termed ‘X-rays’. The first X-ray crystallographic
experiment was performed in 1912 by von Laue, Friedrich and Knipping. They measured the
X-ray diffraction pattern of a crystal of copper sulfate. The use of X-ray crystallography in
the biological sciences is marked by an impressive milestone in 1953. In that year Watson
and Crick1 published the structure of DNA based on diffraction data. The breakthrough in
protein crystallography came within one decade with the crystal-structure determinations of
hemoglobin and myoglobin as the important hallmark2,3. Nowadays, protein crystallography
has become a major technique for rational structure-based drug design, for the emerging field
of structural genomics and for understanding biological processes, with the structure
elucidation of the complete 50S subunit of the ribosome as a very recent and impressive
result4.
The increasing contribution of protein crystallography to structural studies of bio-
macromolecules is based on dramatic developments in data collection and structure
elucidation. Important developments have been third-generation synchrotron radiation5,6,
multiple anomalous dispersion (MAD)a technique7,8 and improvements both in phasing and
refinement methods9,10, that use the still increasing computer power. Furthermore, advances
in molecular biology enable the production of more and more complex proteins in sufficient
amounts. New crystallization techniques and increasing insights into protein crystallization11
result in faster screening and reproducible crystallization of nearly every protein of interest.
Current challenges in structural biology include structure elucidation of large functional
complexes consisting of multiple proteins and structure determination of eukaryotic integral
membrane proteins. For these studies protein crystallography remains the primary technique,
which can be combined with nuclear magnetic resonance (NMR) spectroscopy to study e.g.
the dynamic behavior of molecules, and may be complemented by electron microscopy in
the study of large structures (e.g. viruses and ribosomes). Progress in the field of
macromolecular structure determination is reflected by the nearly exponential increase in
known three-dimensional structures, i.e. ~300 in 1991, ~4,500 in 1997, ~12,000 in 2000
(Ref. 12).
X-ray crystallography in a nutshell
X-ray crystallography is a very powerful experimental technique that provides the three-
dimensional structure of (macro)molecules. Crystallography gives information ranging from
high-resolution structural details to global folds and quarternary structures of protein
complexes. The first requirement for a successful X-ray diffraction experiment is a high-
quality crystal. Such a crystal is a highly ordered array of unit cells containing one or more
molecules repeated in three-dimensions in identical orientations and conformations.
                                                 
a Abbreviations used: ab2ab, anti-b2gpI auto-antibody; aCL, anti-cardiolipin auto-antibody; aPL, anti-phospholipid
auto-antibody; APS, anti-phospholipid syndrome; AvWD; acquired von Willebrand disease; b2gpI, b2-glycoprotein
I; CK, cysteine knot; CL, cardiolipin; CNS, rystallography & NMR System; ESRF, European Synchrotron
Radiation Facility; gpIb, platelet-receptor glycoprotein Ib; HFH, human factor H; MAD, multiple anomalous
dispersion; MIDAS, metal-ion dependent adhesion-site; NMR, nuclear magnetic resonance; PS, phosphatidylserine;
SCR, short concensus repeat; SDS PAGE, sodiumdodecylsulphate polyacrylamide gel-electrophoresis; SLE,
systemic lupus erythematosus; TTP, thrombotic thrombocytopenic purpura; VCP, vaccinia virus complement
control protein; vWD, von Willebrand disease; vWf, von Willebrand factor.
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Comparing macromolecular X-ray crystallography with NMR spectroscopy reveals
two major differences13. Firstly, the X-ray diffraction technique provides less information on
the dynamic behavior of the molecule than is obtained from an NMR spectroscopy
experiment. Secondly, with NMR spectroscopy only structures of relatively small molecules
with an molecular weight of up to ~30 kDa can be solved, whereas X-ray crystallography is
used for structure solution of molecules as large as viruses and ribosomes.
With X-ray crystallography the average electron density of all periodically
assembled macromolecules in the crystal is reconstructed from diffraction data. A diffraction
experiment is based on the property of X-rays to be scattered upon hitting the electron clouds
of atoms whose distances are comparable to the wavelength of the X-rays (i.e. in the
Angstrom range). This scattering occurs only constructively in specific directions due to the
periodic nature of the crystal structure. Reconstruction of the molecular electron density
needs calculation of the electron density distribution in the unit cell using equation:
The observations obtained from the X-ray diffraction experiment are intensities I, that
diffract in directions specified by indices (hkl). From the measured intensities the amplitudes
|F(hkl)| can be derived. Phase angles j(hkl) of the diffracted rays, that are essential for
calculation of electron density with the equation, can, however not retrieved directly from
the experiment, which is known as the ‘phase problem’ in crystallography. Several methods
have been developed to circumvent this phase problem. These methods are all based on an
indirect and initial estimation of the phases: single or multiple wavelength anomalous
diffraction (SAD/MAD), single or multiple isomorphous replacement (SIR/MIR), sometimes
with the additional use of anomalous diffraction (SIRAS/MIRAS), and molecular
replacement. With a first estimation of the phases an electron-density map is calculated
which is used for construction of a first atomic model of the macromolecule. This initial
model is built automatically (ARP/wARP; 14, 15) or interactively with the use of computer
graphics16, dependent on data quality and resolution. Subsequent cycles of refinement and
rebuilding of the initial model, using measured X-ray diffraction data and available
geometrical information from data bases, are performed until convergence. Finally, the
refined model is validated using available biochemical data and databases with geometrical
data derived from high-resolution models (WHATIF, PROCHECK; 17,18).
Advantages of (third-generation) synchrotron-radiation sources
Nowadays, almost every published crystal structure of a protein has been elucidated with the
use of synchrotron radiation. Advantages of, especially, third-generation synchrotron
radiation over X-rays produced by conventional sources, such as rotating anodes, are
numerous5.
Third-generation synchrotron-radiation sources provide X-ray beams which have
orders of magnitude higher flux and brilliance over conventional X-ray sources. This allows
for higher resolution data sets to be collected. For example, crystals of fully-glycosylated
human plasma b2-glycoprotein I diffracted only to 3.8 Å resolution at our in-house X-ray
source, whereas 2.6-3.0 Å resolution data-sets were collected routinely at the European
Synchrotron Radiation Facility (ESRF) in Grenoble, France (beam lines ID14-EH1, -EH3
and -EH4, See Chapter II, Chapter IV and the Appendix to Chapter IV). The very high
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intensity of the beams also allows for structure determination using weakly diffracting
crystals of very large molecules. For example, the crystal structure of the 50S ribosomal
subunit has been elucidated to 2.7 Å resolution10. Very i tense synchrotron beams also allow
for data collection in time periods smaller than a second, opening the way to time-resolved
structural studies of, for example, enzymatic reactions5,6. In addition, the high brilliance of
current synchrotron beams makes data collection possible from crystals tens of cubic
microns in size19. The lower mosaicity of small crystals improves the quality of the data
collected.
Synchrotrons provide very intense and tunable beams. These are requirements for
using the MAD technique7,8. The major advantage of this technique is that phase
determinations are not hampered by non-isomorphism between crystals.
One disadvantage of intense X-ray sources is radiation damage, which causes a
global and non-specific decay of the crystal. This decay can be largely prevented by
measuring data at cryogenic temperature20,21. Rec nt studies on irradiation of protein crystals
with very intense beams of the third-generation synchrotron source at the ESRF (Grenoble,
France), showed that even cryo-cooling cannot prevent highly specific structural radiation
damage22-24. Specific damage to the protein molecule is observed as breaking of disulfide
bonds, decarboxylation of acidic amino-acid residues and release of hydroxyl groups and
thio groups from tyrosine and methionine residues, respectively. These insights initiated the
search for compounds that can act as preservatives against radiation damage.
The use of the highly intense synchrotron beams has been facilitated by advantages
of new detection systems25 and new data-processing software (DENZO; 26). In addition,
developments in data-collection technology have been complemented with important
developments in computer programs that aid phase determination (SOLVE: 10; SnB: 27, 28;
SHELXL: G.M. Sheldrick), model building (ARP/wARP: 14, 15) and model refinement
(Maximum Likelihood: 29; CNS: 9). Structure determinations described in this thesis made
fruitfully use of SOLVE and CNS. The program SOLVE fully automates the process of
crystal-structure solution using the MAD and MIR(AS) methods through integration of all
separate steps in an optimization procedure using Z-score criteria. The procedures used in
SOLVE have remarkably reduced the time needed for often difficult and time-consuming
elucidation of crystal structures. The quality of a calculated phase set is assessed directly
from electron-density output. With SOLVE we obtained an interpretable map with the
MIRAS method using data of poorly diffracting crystals of human plasma b2-glycoprotein I
(See Chapter II). An important advantage of the Crystallography & NMR System (CNS; 9)
for crystallographic refinement is its usage of the maximum likelihood procedure29. This
procedure maximizes the probability distribution of the observed amplitudes given the
calculated amplitudes from a model that may be partial or partially incorrect. In this way, the
effect of model bias is reduced in the refinement process.
In summary, advances of protein crystallography in structural biology are made
possible by improvements throughout all stages of the structure-determination process, i.e.
by dramatic developments in data-collection technology, in structure-determination




Primary structure of b2-glycoprotein I
b2-Glycoprotein I (b2gpI) is a mammalian glycoprotein present in blood plasma in a
concentration ranging from 10 to 200 mg ml-1 (0.25-5.0 mM)30-32. b2gpI is a monomer in
solution, whereas dimers33,34 and tetramers35 are observed during sodiumdodecyl-sulphate
polyacrylamide gel-electrophoresis (SDS PAGE). b2gpI mRNA is expressed in endothelial
cells36, central nervous-system cells37, hepatocytes38 and in the placenta39. b2gpI is
synthesized as a single-chain polypeptide consisting of 326 amino-acid residues and with a
calculated molecular mass of 36.3 kDa. Sequencing of human b2gpI DNA38, 40 and amino-
acid sequencing of human b2gpI41 and bovine b2gpI42 revealed 22 cysteines all involved in
intramolecular disulfide bonds, and a relatively high content of prolines (i.e. 31). In addition,
four potential Asn-X-Ser/Thr N-glycosylation motifs were identified in human b2gpI (Fig.
1). Lozier et al. (41) and Walsh et al. (43) showed that N-glycans were indeed attached to
these four sites. In addition, Gambino et al. (44, 45) indicated that b2gpI contains O-glycans.
The glycans account for approximately 20% w/w of the total molecular mass of b2gpI (42-
50 kDa), as observed with SDS PAGE32,35,41. Apart from variations in plasma levels of
b2gpI, carbohydrate heterogeneity among subfractions of b2gpI isolated from plasma of a
single donor46,47, as well as genetic heterogeneity in human populations48-50 have been
observed. Carbohydrates differed in their content of sialic acid residues. Observed genetic
heterogeneity in human b2gpI was a Val247Leu polymorphism38,51, a Cys306Gly mutation52
and a Trp316Ser mutation52,53.
Domain organization of b2gpI
The mature b2gpI sequence of 326 amino-acid residues consists of five contiguous repeating
units of the same type. These units are termed Sushi domains, complement control protein
domains or short concensus repeat (SCR) domains and are present in many proteins that
function in the complement system, as well as in many other mammalian adhesive proteins54.
SCR domains consist of about 60 residues and have two fully conserved disulfide bonds. In
many proteins consecutive repeating stretches of SCR domains are found, e.g. in
complement receptor 2, factor H and complement receptor 1, which contain up to 15, 20 and
30 SCR domains. Two structures of single SCR domains, domains 5 and 16 of human factor
H (HFH)55,56, and two structures of two SCR domains in tandem, domains 15-16 of HFH and
domains 3-4 of vaccinia virus complement control protein (VCP)57,58 have been determined
with NMR spectroscopy. Furthermore, crystal structures of a tandem of two SCR domains of
human CD46 (Ref. 59) and of a construct of a single SCR domain and a serine-protease
domain of human complement C1s (Ref. 60) have been reported. The structures of these
eight SCR domains revealed a common globular fold with a hydrophobic core, consisting of
a four-stranded central b-sheet flanked by two short two-stranded b-she ts (Fig. 1A).
Furthermore, sequence alignment based on sequential and structural homology revealed a set
of 16 conserved mainly hydrophobic residues and a sequence homology among SCR
domains ranging from 20 to 40%. (Fig. 1B). Alignment of the amino-acid sequence of b2gpI
to sequences of the eight SCR domains with known structure indicates that the first four SCR
domains of b2gpI have a regular fold (Fig. 1B). The amino-acid sequence of the C-terminal
fifth domain of b2gpI is aberrant. It contains a six-residue insertion and a 19-residue C-
terminal extension, which is C-terminally cross-linked by an additional disulfide bond. In
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Chapter II we present the three-dimensional model of human plasma b2gpI, obtained with
X-ray crystallography.
Adhesive properties of b2gpI: binding to anionic phospholipids
b2gpI is also referred to as ‘apolipoprotein H’, due to its property to adhere to
lipoproteins61,62. It has been established, however, that b2gpI not only binds to lipoproteins
but more in general to any negatively charged surface present in the blood circulation, i.e. it
also binds to apoptotic bodies63,64, chylomicrons65, blood platelets66,67, and liposomes68,69.
b2gpI adheres specifically to anionic phospholipids, i.e. cardiolipin (CL) and
phosphatidylserine (PS), exposed on the negatively charged membrane surfaces69-72. The
phospholipid-binding site of b2gpI has been mapped to its fifth aberrant SCR domain73-75.
Cationic residues Lys282, Lys284, Lys286, Lys287, Lys308 and Lys324 have been
implicated in charge interactions between b2gpI and negatively charged head groups of
anionic phosphoplipids34,73,76 (Fig. 1B). In addition, Wang et al. (77, 78) have shown that
hydrophobic interactions were also important in lipid adhesion, which has been confirmed by
mutagenesis studies that revealed a critical role for the hydrophobic sequence Leu313-Ala-
Phe-Trp316 (Ref. 52, 53, 79). The integrity of the fifth SCR domain is another important
factor in lipid adhesion. Enzymatic cleavage at one of two scissile bonds Leu314-Phe315 and
Lys317-Thr318 inhibits binding to anionic lipids32,80-82. Furthermore, genetically determined
mutation Cys306Gly present in part of the population disrupts a conserved disulfide bond
and affects the ability of b2gpI to adhere to anionic lipids52. We determined the crystal
structure of two isoforms of b2gpI (Chapter II and Chapter IV). Combined with available
biochemical data we proposed a model for membrane adhesion of b2gpI and f r inhibition of
membrane adhesion.
Adhesive properties of b2gpI: protein-protein interactions
b2gpI binds to several self-proteins in blood plasma and in kidney cells. It forms complexes
with protein C, protein S and C4B binding protein83-85, that function in the protein C-
dependent anticoagulant-pathway86-89. Klaerke et al. (90) and Rojkjaer et al. (91) reported
very high-affinity complexes between renal-filtered b2gpI and calmodulin, an intracellular
protein that plays a major role in the regulation of many enzymes and in a wide variety of
cellular events92. Renal filtered b2gpI also binds to the endocytic receptor megalin, which
actively transfers b2gpI from kidney cells back into the circulation93. b2gpI has been
identified as a physiological ligand for plasma lipoprotein(a) and binds specifically to the
kringle IV domain of the glycoprotein apolipoprotein(a) in this low-density lipoprotein-
apolipoprotein(a) complex94. Furthermore, b2gpI binds to the endothelial cell-surface protein
annexin II95. b2gpI also forms complexes with various non-self proteins, e.g. it binds to
surface protein Sbi of the bacterium Staphylococcus aureus96, to surface antigens of human
immuno-deficiency virus97 and to surface antigens of hepatitis B virus98,99. Although binding
properties of b2gpI to self- and non-self proteins have been extensively studied, for none of
the above listed protein-protein interactions the binding site of b2gpI has been determined.
We studied formation of complexes between 2gpI and several proteins present in blood
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Function of b2-glycoprotein I
Despite intensive research on human b2gpI, initiated by Schultze et al. (100), the
physiological function of this plasma protein is still not clear. Moreover, a b2gpI deficiency
does not result in noticeable complications30,31, prompting to the question whether b2gpI has
a physiological function at all. In contrast, an important role for b2gpI is suggested by the
observation that high plasma levels of b2gpI influence metabolism of triglyceride-rich
lipoproteins70,101 and cholesterol102. High plasma levels of b2gpI also correlate with several
diseases103,104, whereas decreased levels of b2gpI are associated with coagulation
disorders105,106. b2gpI synthesis in placenta and involvement of b2gpI in auto-immune
disease-related fetal loss indicate a putative, yet undetermined role in pregnancy39,107-109.
Connected with these observations, a variety of processes in haemostasis, metabolism and
apoptotic-cell clearance are identified in which a regulatory role for b2gpI is indicated.
Nowadays, the main research on b2gpI function addresses topics related to the
observation that autologous b2gpI appears highly immunogenic. Auto-antibodies elicited
against self-b2gpI are detected in plasma of subsets of patients with auto-immune disease
anti-phospholipid syndrome (APS)110-112 or with other disorders, e.g. non-auto-immune liver
disease113 and auto-immune disease systemic lupus erythematosus103,114-116, a  well as in
plasma of healthy subjects117. In addition, the presence of anti-b2gpI auto-antibodies (ab2ab)
in plasma is indicated as an important risk factor for myocardial infarction and
atherosclerosis118,119.
Procoagulant activity of b2gpI by inhibition of protein C-dependent anticoagulant
reactions upon passive occupation of anionic lipid surfaces by b2gpI has been observed in
vitro120,121. In contrast, b2gpI prevents coagulation by promoting anionic phospholipid
vesicles – macrophage interaction and likely by subsequently stimulating uptake of these
procoagulant lipid vesicles122. b2gpI has also been indicated as a direct inhibitor of a series
of anionic-membrane mediated coagulation processes66,67,123-130, as well as a positive cofactor
in protein C/protein S-dependent anticoagulant processes83,83,105,106. The influence of b2gpI
on coagulation processes is strongly dependent on the presence of anionic phospholipids,
suggesting that the regulatory role of b2gpI is associated with its adhesion to negatively
charged lipid layers. Both pro- and anticoagulant activity of b2gpI have only been
demonstrated in in vitro assays, whereas in vivo these activities have not yet been proven.
Whether b2gpI has a critical role in clearance of apoptotic cells from the circulation
is a matter of debate. Price et al. (31) showed that b2gpI binds specifically to the anionic
phospholipid surface of PS-expressing apoptotic bodies. Work of Balasubramanian et al. (63,
64) indicated that binding and subsequent internalization of apoptotic cells by macrophages
was enhanced after opsonization of these apoptotic cells with b2gpI. Although an absolute
requirement for b2gpI in clearance of apoptotic cells was not deduced, these results
suggested that b2gpI may at least serve a stimulatory role. In contrast, Dombroski et al.
(132) showed that b2gpI reduces uptake of membranes containing PS, that are
representatives for apoptotic cells, by endothelial cells. Manfredi et al. (133) indicated with
their experiments that b2gpI did not influence apoptotic cell clearance at all. Moreover, there
is for many years concensus in the field of research on apoptosis that PS is the specific ligand
at the surface of apoptotic cells which triggers recognition by macrophages134,135. Recently,
Fadok et al. (136) identified the specific PS receptor of the macrophages. These results
prompted further doubt whether b2gpI has a role in apoptotic cell clearance.
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In summary, in all proposed physiological functions the common activity of b2gpI
consists of a non-specific occupation or neutralization of anionic phospholipid layers105. In
addition, the important and well-characterized gain-of-function for b2gpI n the auto-immune
disease APS is also fully dependent on the availability of exposed anionic phospholipids111.
With the research described in this thesis we aimed at gaining more insight into potential
functions of b2gpI by studying protein-protein complexes involving b2gpI (Chapter III) and
by determining the aspects that influence the lipid-adhesive properties of b2gpI (Chapter IV).
b2gpI and auto-immunity
b2gpI has a well-defined gain-of-function associated with the presence of ab2ab in plasm  of
patients with the auto-immune disease APS111,137-140. Abnormalities associated with ab2ab-
b2gpI complexes in APS are arterial and venous thrombosis, thrombo-embolic complications
(e.g. cardial infarction), thrombocytopenia, neurological disorders and (recurrent) fetal
loss112. Intensive research focused on identification of the auto-antibodies and on the role of
auto-immunity to b2gpI in APS. It has become evident that ab2ab are not only markers of
APS but in fact (partly) cause the observed abnormalities110. The aspects responsible for the
high immunogenicity of b2gpI are not fully understood. The existence of genetically
determined features of b2gpI51,103,104,141 and several physiological abnormalities142-146
potentially cause APS by breaking the tolerance for autologous b2gpI.
Initially, auto-antibodies in APS were identified as anti-phospholipid auto-
antibodies (aPL) elicited against anionic lipid surfaces. Galli et al. (147), McNeill et al.
(148), and Koike and Matsuura (149) demonstrated that aPL were in fact ab2ab raised
against b2gpI bound to a lipid layer. ab2ab are an intra- and inter-individually heterogeneous
group of auto-antibodies. Epitopes for ab2ab are localized in all five SCR domains of
b2gpI150-153, including the C-terminal fifth domain, which contains the adhesion site for
anionic phospholipids154,155. This diversity may correlate with the observed variety of clinical
manifestations in patients with APS117,156. Controversy exists on the parameters that define
affinity of ab2ab for b2gpI, when b2gpI is membrane bound. High affinity of ab2ab for
immobilized b2gpI is possibly explained by exposure of cryptic epitopes upon adhesion of
b2gpI to anionic membranes, as evidenced by enzyme-linked immunosorbent assays75,157-161.
This hypothesis is supported by circular dichroism spectroscopy162. Alternatively or
additionally, occurrence of (ab2ab)2-b2gpI complexes at membrane surfaces and not free in
solution may depend on the increase in avidity provided by two ab2ab-2gpI interactions in
combination with two b2gpI-lipid interactions per complex110. Fab fragments of ab2ab do
not induce adhesion of b2gpI to anionic lipids upon binding to b2 pI, providing evidence for
this second potential mechanism163,164.
The central role for b2gpI in the auto-immune response leading to severe





Multimeric configuration of vWf
von Willebrand factor (vWf) is a glycoprotein present as multimers in endothelial cells,
megakaryocytes and platelets, and in plasma in an approximate concentration of 10 mg ml-1
with large variations among individuals (See for reviews: 166-168, and references therein).
The vWf gene is expressed in vascular endothelial cells and in bone-marrow megakaryocytes.
The resulting precursor polypeptide, referred to as pre-pro-vWf, consists of 2,813 amino-acid
residues, including a signal peptide of 22 amino-acid residues and a large propeptide of 741
residues169,170 (Fig. 2A). During biosynthesis of pre-pro-vWf the signal peptide and the
propeptide are released, resulting in fully processed mature vWf. This mature vWf subunit
consists of 2,050 amino-acid residues and has a molecular weight of 230-280 kDa. Ten to
twenty percent of the molecular mass is accounted by ten O-linked carbohydrates and twelve
N-linked carbohydrates, two of which are additionally sulfated. The N-linked carbohydrates
of vWf are part of the ABO-blood group determinants. The mature protein is highly cysteine
rich with most of the 169 cysteines involved in intramolecular disulfide bonds171.
Intermolecular disulfide bonds near the carboxy terminus of pro-vWf are formed in the
Endoplasmic Reticulum, forming vWf dimers (Fig. 2B). In the Golgi subsequent formation
of intermolecular disulfide bonds near the amino terminus links mature vWf-dimers to
higher-order multimers. These polymers consist of up to as many as 100 vWf monomers and
have molecular weights ranging from 1,000 kDa to over 20,000 kDa. In the circulation vWf
multimers have, either a compact ‘ball-of-yarn’ conformation, or an extended string-like
shape of the disulfide-bond-linked vWf monomers172-174. The latter conformation is formed
under influence of high shear stress at high blood pressure174.
Storage and secretion of vWf
Directly after synthesis in vascular endothelial cells major part of the vWf pool is secreted
constitutively175. The remainder part of vWf is stored in Weibel-Palade bodies inside the
endothelial cells. In megakaryocytes and platelets derived from them vWf is stored in
granules. After stimulation of cells during haemostatic imbalance stored vWf is released via
a regulated pathway. Secreted vWf, either by the constitutive pathway, or by the regulated
pathway, is released into the blood circulation and into the subendothelial matrix of the
vessel wall. vWf secreted upon activation consists of relatively large multimers, which are
more effective in the haemostatic system.
Domain organization of vWf and function of individual domains
A mature vWf subunit consists of domains D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK,
whereas pre-pro-vWf is N-terminally extended with the 22-residue signal sequence and with
the propeptide consisting of domains D1-D2 (Fig. 2). Evidence is evolving which suggests
that individual domains of vWf are independent structural motifs with discrete functional
activities176-180. Domains D1-D2 in the pro-vWf subunit have a function in the process of
multimerization by cross-linking vWf dimers via disulfide bonds. Domains D'-D3 contain
the binding site for coagulation cofactor VIII181 and a binding site for heparin. Mutations in
D' result in von Willebrand-disease (vWD) type 2N, resulting in a vWf molecule which can
not bind factor VIII (For reviews see: 182-184, and references therein). Cysteine residues in
D3 link N-termini of vWf dimers171. The A1 domain has a binding site for platelet-receptor
glycoprotein Ib (gpIb), heparin, that inhibits binding of A1 to platelet gpIb, collagen type
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VI185,186, sulfatides, snake venom botrocetin and antibiotic ristocetin, that induce binding of
vWf to platelets without prior immobilization of vWf187,188. Furthermore, A1 putatively
contains a cryptic binding site for the vWf-A3 domain, that may only then become available
after adhesion of vWf to collagen189. In addition, domain A1 is, like A2, prone to many vWD
mutations. No binding sites reside in the A2 domain, but it contains a cleavage site for a
metalloproteinase. This proteinase cleaves vWf under conditions of high shear stress, i.e.
when vWf has its extended conformation, resulting in decreased haemostatic activity of the
shortened vWf multimers. In this way, the proteinase prevents spontaneous platelet
aggregation by large multimers of vWf. The binding sites for collagen types I and III180,190
and for snake venom bitiscetin, that induces binding of platelets to the A1 domain189, r side
in domain A3. No functions and adhesion sites are designated to domains D4, B1, B2, B3
and C2. The C1 domain binds to the integrin platelet-surface receptor aIIbb3 once platelets
are activated. The RGD amino-acid sequence of C1 is essential for its cell-adhesive
properties191 and has been found in other proteins that interact with integrin receptors168. The
cysteine-knot (CK) domain near the carboxy terminus is involved in dimerization of vWf
molecules177 and has no additional adhesive function. Finally, vWf binds fibrin, but the
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Fig. 2. Domain organization of von Willebrand factor.(A) The domain structure of pre-pro-vWf is
shown, with a 22 amino-acid residue signal peptide, that is cleaved off in pro-vWf, and a 741 amino-
acid residue propeptide, that is subsequently cleaved off in the 2,050 amino-acid residue mature vWf
molecule. Location of domains is indicated by labeled boxes. Cysteines that link two pro-vWf
monomers forming dimers are located in the CK domain; disulfide bonds between dimers forming
higher-order multimers with varying size are formed between cysteines located in the D3 domain of
mature vWf. The location of cysteines that are involved in intermolecular disulfide bonds are indicated
with S-atoms. The scissors indicates the location of the metalloproteinase cleavage-site in domain A2.
(B) Schematic representation of a pro-vWf dimer (left) and a mature vWf multimer (right). Positions of
the D3 and CK domains are indicated. In healthy individuals vWf multimers consist of as many as up
to 100 monomers, whereas unusual or ultra large vWf multimers, found in plasma of patients suffering
from thrombotic thrombocytopenic purpura, consist of even higher numbers of monomers.
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Crystal structures of the vWf-A1 and A3 domain (Ref. 193-196; R. Romijn,
unpublished results) show a so-called Rossman fold, dinucleotide fold, or a/b fold consisting
of a central hydrophobic b-sheet flanked by a-helices on each side (Fig. 3). This classical
fold is also observed for the crystal structures of the I domains of integrins aMb2, aLb2 and
a2b1, of which the latter, like vWf-A3, binds to collagen197-199. In contrast to the I domains,
both the A1 and A3 domain lack the typical metal-ion dependent adhesion-site (MIDAS)
motif and a metal ion bound to this motif. For all known integrin I domains this motif,
located in the ‘top face’ of the molecule, and a bound divalent cation are involved in ligand
binding. The crystal structure of the I domain of integrin a2b1 in complex with a triple-
helical collagen peptide has confirmed the importance of the MIDAS motif in collagen
binding200. Comparison of the structure of the I domain of integrin a2b1 with the structure of
vWf-A3 revealed no shared features and, in addition, mutation of amino-acid residues in the
top face of A3 homologous to residues of a2b1 that are involved in collagen binding, had no
influence on collagen binding by A3193,201. These observations prompt doubt whether the
collagen-binding site of A3 is located in its top face (Fig. 3A). With a structural study by
means of X-ray crystallography, of the vWf-A3 domain in complex with a function-
inhibiting Fab fragment, we aimed at providing more insight into the binding site of A3 for
collagen (Chapter V).
Studies with A1 using site-directed mutagenesis188 and the crystal structure of the
vWf-A1 domain in complex with a Fab fragment of an antibody that blocks adhesion of A1
to gpIb195, have pointed to the binding sites for gpIb, ristocetin and botrocetin (Fig. 2B).
Binding sites for these three ligands are located outside the top face of A1 and do not involve
the vestigial MIDAS motif. The observations that gpIb, ristocetin and botrocetin do not bind
to the top face of A1 and that collagen likely does not bind to the top face of A3, leaves this
adhesion site in A1 and A3 available for putative alternative, yet unknown roles in functional
interactions.
The haemostatic balance
Plasma protein vWf has an important function in the very first response in case of vascular
damage. Thereby, activity of vWf is part of our haemostatic system, which is critical in
preservation of the integrity of the blood circulation and prevention of blood loss at sites of
vascular damage, termed physiological homeostasis. The haemostatic system is a complex
system consisting of five major components; blood vessel walls, blood platelets, pro- and
anticoagulation system, rheology and fibrinolytic factors, that act in concert in integrated
pathways during haemostasis. At a site of a ruptured blood vessel three mechanisms respond
instantaneously to arrest the blood loss; i. ves el wall contraction, i . formation of a plug by
platelet adhesion and aggregation, activities in which vWf plays an essential role, and iii.
blood coagulation, formation of a fibrin mesh. Anticoagulant proteins prevent occlusion of
veins and arteries by thrombi and prevent extension of the procoagulant response outside the
direct vicinity of the damaged vessel wall. Clot-dissolving fibrinolytic factors restore normal
blood flow by gradual lysis of a haemostatic plug, i.e. by fibrinolysis. Haemostasis is a
complex tightly balanced system of stimulating and inhibitory pathways that respond fast
and strict locally to arrest haemorrhage at sites of vascular damage and that initiate
subsequent longer-term restoring events. Imbalance in the haemostatic system may result in
excessive and life-threatening bleeding even from a trivial trauma, or may result in arrest of
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Fig. 3. Ribbon diagrams of the vWf-A1 domain and the vWf-A3 domain. Positio s of residues that
are involved in the vestigial MIDAS motif in the top face of the A1 and A3 domain are indicated with
gray spheres. The intramolecular disulfide bond within A1 and A3, located near the carboxy and amino
termini at the bottom face of both domains, is represented in ball-and-stick. Figures are generated with
MOLSCRIPT202 and RASTER3D203. (A) Schematic drawing of the human vWf-A3 domain (vWf
residues 920 to 1111) (pdb code 1ATZ, 194). The collagen-binding site in the top face of the
structurally related I domain of integrin a2b1200 is indicated with a circle in the model of A3. Amino-
acid mutations in the top face of A3 that had no influence on collagen binding by an A3 construct193, or
by full-length vWf201 are indicated by black spheres. Residues Asp934, Ser936 and Ser938, that form
the vestigial MIDAS motif, were also mutated and are represented as gray spheres. (B) Schematic
drawing of the human vWf-A1 domain (vWf residues 508 to 709, R. Romijn, unpublished data). The
putative binding sites for gpIb and for botrocetin, that induce spontaneous binding of A1 to gpIb,
determined by using point-mutated constructs of A1, are located on the front side of the domain, and
are indicated with boxes188,195,196. The position of vWD Type 2B mutations, that also induce
spontaneous platelet binding by A1, are located at the bottom and back side of A1, opposite to the
putative location of the gpIb and botrocetin binding sites.
Function of vWf in haemostasis
One of the two known haemostatic functions of vWf is to adhere to platelets and to plasma-
exposed subendothelial components of a damaged arterial vessel wall, thereby initiating
haemostasis under conditions of high shear stress166-168. At a site of vascular injury the A3
domain of vWf binds to collagen types I and III. Once vWf is bound to the subendothelial
connective tissue the A1 domain binds with high affinity and reversibly to the platelet
receptor gpIb. In this way tethered platelets are slowed down, which allows for their
irreversible adherence to components of the vessel wall via the platelet receptor aIIbb3. At
high shear stress, i.e. in small arterioles, arterial capillaries and next to atherosclerotic
plaques, binding of platelets to vWf is essential for the activity of vWf in haemostasis and
disease. When tethered to vWf, activated platelets aggregate and bind simultaneously to
fibrin that incorporates into a network, resulting in formation of a blood clot that closes the
ruptured vessel wall. In parallel, thrombin is formed by the coagulation cascade, which
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results in additional activation of platelets and conversion of soluble fibrinogen to fibrin.
This results in formation of a permanent and fibrous clot that arrests blood loss.
vWf also functions in the haemostatic system as the carrier molecule of glycoprotein
factor VIII204,205. When non-covalently bound to vWf factor VIII is protected for enzymatic
degradation by protein C. Factor VIII is a cofactor with procoagulant activity, that is
triggered upon cleavage by thrombin. The physiological reason of stabilization of factor VIII
by vWf is not known, but an important role for vWf in translocating factor VIII to sites of
vascular injury is suggestive.
Activation of vWf during haemostatic imbalance
vWf in the circulation does not bind spontaneously to platelet-receptor gpIb. Platelet
tethering to vWf occurs, i. upon binding of vWf to components of a damaged vessel wall, ii.
in case of naturally occurring so-called vWD ‘type 2B’ mutations in the ‘bottom face’ of
domain A1, or iii. upon binding of, either snake venom botrocetin, or antibiotic ristocetin to
A1. Another important aspect in activation of platelet adhesion by vWf is the presence of
shear stress167. At low blood pressure vWf has a globular ball-of-yarn conformation, that
does neither adhere to exposed constituents of the vessel wall at sites of vascular damage,
nor to platelets. In small arterioles and arterial capillaries, i.e. at high shear stress, multimeric
vWf adopts an extended chain conformation that allows for collagen binding and subsequent
gpIb binding. Furthermore, platelet adhesion depends on the multimeric size of vWf;
monomers are not functional active at all, activity increases with multimeric size and ultra-
large multimers are able to bind platelets spontaneously, an event that occurs in patients
suffering from thrombotic thrombocytopenic purpura (TTP). All data together may point to
activation of vWf by, either an allosterically controlled pathway, or an entropically
controlled pathway, or by an integrated pathway which contains contributions of both
models167.
The allosteric model has been proposed for the vWf-A1 domain195,196, based on the
crystal structure of A1 and based on the observed conformational changes upon ligand
binding in the structurally related I domain of integrin aMb2198,206,207. Activation mechanisms
of A1 indeed point to the possible existence of a low-affinity conformation that switches to a
high-affinity state upon, i. stimulation by modulators for which A1 has binding sites outside
its gpIb-binding site (e.g. botrocetin, ristocetin), ii. introduction of gain-of-function
mutations, also located outside the gpIb-binding site (e.g. vWD Type 2B), or, iii.
immobilization of vWf at a damaged vessel wall. A mechanism in which A3, adhered to
collagen, activates A1 by induction of conformational changes via direct A3-A1 interactions,
is often suggested189,193 but has not been proven. Indirect evidence that supports a mechanism
in which activity of A1 is modulated by A3, is provided by auto-antibodies that inhibit
binding of vWf to collagen as well as binding of vWf to gpIb upon binding of the antibodies
to epitopes in A1 or A3208,209. Additional support for the hypothesis comes from snake
venom bitiscetin, that binds to A3, thereby inhibiting platelet binding to the A1 domain189.
Alternatively or additionally, the entropic model is supported by the observations
that, i. larger vWf multimers are more active in haemostasis, ii. vWf exposes hidden domains
under high shear-rate conditions, and iii. u usually large vWf multimers bind to platelets
spontaneously, without the prior need of activation or immobilization of vWf. Affinity of
individual A1 domains for gpIb may be too low for effective binding, as is observed for
collagen binding by the isolated A3 domain201. Adhesion of stretched vWf multimers to sites
of vascular damage via multivalent A3-collagen interactions will effectively increase the
local concentration of A1 contact sites, available for interactions with gpIb. Intrinsic low
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affinity of A1 for gpIb is now circumvented by increased avidity of multiple A1-gpIb
interactions.
von Willebrand factor and blood-coagulation disorders
Qualitative and quantitative alterations of vWf have dramatic impact on its activity during
maintenance of homeostasis, resulting in a variety of haemostatic diseases. These diseases
are defined, either by bleeding tendencies (vWD, acquired vWD), or by thrombotic
complications (auto-immune response to vWf, e.g. in lupus anticoagulant, SLE, APS), or by
both (TTP).
The rare disease thrombotic thrombocytopenic purpura is defined by sustained
qualitative alterations of vWf accompanied by a periodic quantitative deficiency of vWf.
Patients with TTP show spontaneous intravascular aggregation of platelets in their
microcirculation resulting in severe thrombocytopenia, neurological disorders, haemolysis,
fever and renal dysfunction (For reviews see: 210-212). In most cases TTP is correlated with
the presence of auto-antibodies elicited against the metalloproteinase that specifically cleaves
the A2 domain of vWf. Impairment of proteolytic breakdown of vWf results in the presence
of ultra large vWf multimers in the circulation, that aggregate platelets spontaneously.
Absence of the metalloproteinase is permanent in plasma of patients with familial chronic
relapsing TTP210. A single acute episode of TTP seems correlated with the presence of
function-inhibiting auto-antibodies elicited against the enzyme. Acute TTP is often
associated with auto-immune diseases SLE and APS213, although direct correlation remains
doubtful214. In between episodes of TTP, the concentration of ultra large vWf multimers in
plasma is apparently below a threshold level, producing only non-severe amounts of platelet
aggregates. Increased endothelial cell activation or cell damage, possibly triggered by viral
or bacterial infection, auto-immune disorders, bone marrow transplantation, cancer,
therapeutics and pregnancy, releases additional stored ultra large vWf multimers form
endothelial cells, which then results in the observed aggregation of platelets and in the
pathogenic mechanisms of TTP.
Von Willebrand disease is a clinically heterogeneous and common inherited
bleeding disorder which originates from qualitative or quantitative defects of vWf, caused by
mutations in the vWfgene182-184. vWD has been classified in several subtypes based on the
observed molecular defects: vWD Type 1 (mild quantitative vWf deficiency), Type 2
(altered vWf function), Type 3 (severe quantitative vWf deficiency). vWD Type I is
characterized by a reduced amount of vWf multimers whereas the multimer distribution of
vWf is normal. vWD Type 3 is a rare disease but most life threatening among vWD variants.
Patients with vWD Type 3 suffer from severe bleeding correlated with the virtual absence of
vWf in the circulation. The qualitative Type 2 vWD variants have been further divided into
subgroups 2A, 2B, 2M, and 2N, based on heterogeneous pathophysiology. Bleeding
tendencies result from amino-acid point mutations or gene insertions or deletions in the D
domains or in the A domains (Fig. 2A). vWD Type 2A and B is characterized by the absence
of large multimers. For Type 2A the absence of large multimers is due to mutations in the A2
domain that result in increased susceptibility of vWf for the metalloproteinase, which cleaves
the A2 domain. For Type 2B the absence of large multimers is due to spontaneous binding of
the largest vWf multimers to platelets. In Type 2M activity of vWf is decreased, whereas
concentration and distribution of vWf over the normal range of multimer sizes is normal.
Patients with vWD Type 2N have a normal vWf multimer distribution, but binding of vWf to
factor VIII is reduced or abolished.
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Acquired von Willebrand disease (AvWD, auto-immune vWD) is a rare disease that
occurs in combination with an array of disorders, e.g. infectious diseases, tumours, metabolic
or hormonal disorders215-217. A predominant amount of cases is associated with auto-immune
disorders, including SLE and APS215,218,219. Clinical manifestations of AvWD are similar to
those observed in patients with inherited vWD. In most cases of AvWD abolished vWf
function, due to the lack of large vWf multimers, is observed accompanied by function-
inhibiting or vWf-clearance accelerating anti-vWf antibodies, or by a general auto-immune
response. Auto-antibodies specific for the A1 and A3 domains of vWf, which abolish
platelet-gpIb binding or collagen binding, or both, may be present208,209,220. Alternatively,
auto-antibodies in patients with APS, lupus anticoagulant or SLE, that are not elicited against
vWf, induce bleeding tendencies and thrombotic complications by stimulation of vWf
release from endothelial cells221-223.
Scope and outline of thesis
In this thesis crystallographic structure analyses are described of human plasma b2-
glycoprotein I and the recombinant A3 domain of human plasma von Willebrand factor.
Common aspects of b2gpI and vWf are, i. the necessity to adhere to a suitable surface as part
of their activation, ii. their interaction with multiple proteins that function in the haemostatic
system, and iii. their implication in several coagulation disorders. Five-domain b2gpI binds
specifically with its fifth short concensus repeat domain to anionic phospholipid layers. This
shielding of negatively charged surfaces in the circulation is likely the important aspect of
b2gpI in anti- and procoagulant processes. Multi-domain vWf contains a major binding site
for fibrilar collagen located in its A3 domain. When an arterial vessel wall is ruptured
binding of the A3 domain to exposed collagen is one of the first steps in haemostasis, that
facilitates recruitment of platelets from the circulation for formation of a blood clot.
Structural insights into the adhesive mechanisms of b2gpI to lipids and of vWf-A3 to
collagen are of valuable help in understanding the role of b2gpI and vWf in the haemostatic
balance and in diseases, that affect the integrity of the circulation.
In Chapter II elucidation of the crystal structure of fully-glycosylated b2gpI,
purified from human plasma, is reported. Based on the b2gpI structure and available
biochemical data a model for membrane adhesion is proposed. In Cha ter III investigation
by means of gel-filtration chromatography of the interaction of b2gpI with several proteins
that function in blood coagulation or in renal excretion is described. Chapter IV describes the
biophysical analysis and the crystal structure of an isoform of b2gpI that is present in plasma
of patients who suffered from severe oxidative stress. The structure and thin-layer
chromatography revealed that the b2gpI isoform contains a neutral phospholipid molecule,
with possible implications for the function of b2gpI. In the Appendix to Chapter IV effects of
radiation damage on the local and global structure of b2gpI are analyzed. This analysis was
required for a proper comparison of the structures of b2gpI is orms. In Chapter V we
address the localization of the collagen-binding site of the vWf-A3 domain. For this purpose
the crystal structure was solved of the recombinant seleno-methionine A3-domain of human
vWf in complex with a Fab fragment of antibody RU5, that blocks adhesion of vWf to
collagen.
--- Chapter II ---
Crystal structure of b2-glycoprotein I:
model for adhesion to phospholipids
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Human b2-glycoprotein I is a heavily glycosylated five-domain plasma membrane-
adhesion protein, that has been implicated in coagulation and clearance of apoptotic
bodies from the circulation. It is also the key antigen in the auto-immune disease anti-
phospholipid syndrome. The crystal structure of b2-glycoprotein I isolated from human
plasma reveals an elongated fish-hook like arrangement of the globular short-consensus
repeat domains. Half of the C-terminal fifth domain deviates strongly from the
standard fold, as observed in domains one to four. This aberrant half forms a specific
phospholipid-binding site. A large patch of 14 positively charged residues provides
electrostatic interations with anionic phospholipid headgroups and an exposed
membrane-insertion loop yields specificity for lipid layers. The observed spatial
arrangement of the five domains suggests a functional partitioning of protein adhesion
and membrane adhesion over the N- and C-terminal domains, respectively, separated
by glycosylated bridging domains. Coordinates are in the Protein Data Bank (accession
code 1QUB).
Keywords: anionic phospholipid, anti-phospholipid antibody, anti-phospholipid syndrome, apolipoprotein H, beta2
glycoprotein I, CCP domain, membrane binding, SCR domain, short consensus repeat, Sushi domain.
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Introduction
Human b2-glycoprotein I (b2gpI)a, also known as apolipoprotein H, is a membrane-adhesion
glycoprotein present in blood plasma in a concentration of ~150 to 300 mg ml-1 (Ref. 163). It
consists of 326 amino-acid residues40,41 with approximately 20% w/w carbohydrates
attached. b2gpI is the key antigen in the auto-immune disease anti-phospholipid syndrome
(APS), defined by thrombo-embolic complications and the presence of anti-phospholipid
auto-antibodies (aPL’s) in the blood. 2gpI has been indicated as a natural anticoagulant106
and has a role in clearance of apoptotic bodies from the circulation64,131,133. b2gpI belongs to
a super-family of proteins characterized by repeating stretches of ~60 amino-acid residues,
each with a set of 16 conserved residues and two fully conserved disulfide bonds. More than
50 mammalian, mainly complement, proteins belong to this family including CR2, factor H
and CR1, which contain up to 15, 20 and 30 of these consecutive repeating stretches,
respectively54. These repeating units have been termed short consensus repeat (SCR),
complement control protein or Sushi domains and are in many cases involved in protein-
protein interactions, with typically two to four consecutive domains forming an interaction
site59,224-227. NMR structures of two single SCR domains, domains 5 and 16 of human factor
H (HFH)55,56, and two SCR domains in tandem, domains 15-16 of HFH and domains 3-4 of
Vaccinia virus complement control protein (VCP)57,58, have been determined. Recently, the
crystal structure of the N-terminal two SCR domains of CD46 has been published59. b2g I
consists of five of these SCR domains. The first four domains are regular SCR domains with
respect to their amino-acid sequences. The fifth C-terminal domain contains a six-residue
insertion and a 19-residue C-terminal extension, which is C-terminally cross-linked by an
additional disulfide bond. This aberrant domain is responsible for adhesion to anionic
phospholipids34,73,76. Adhesion to membranes is very likely an essential aspect of b2gpI, that
is common to the observed effectso  b2gpI in APS, coagulation and apoptosis.
The auto-immune disorder APS is characterized by the presence of a group of
heterogeneous auto-antibodies in blood plasma and the occurrence of thrombo-embolic
complications in both the arterial and venous vasculature of patients112. The symptoms
appear predominantly in women at age 25-35. A particular problem in understanding the
pathophysiology of aPL’s has been the apparent contradiction between the i vivo observed
thrombosis and the in vitro observed prolonged coagulation time106. An important
observation has been that the real antigen for aPL’s is the plasma-protein b2gpI147 and not
phospholipids228. The affinity of b2gpI for anionic phospholipids increases strongly in the
presence of aPL’s, which is explained by the formation of divalent (b2gpI)2-aPL
complexes163. Binding of these complexes to phospholipids interferes with binding of other
phospholipid-binding proteins in plasma, such as coagulation proteins, resulting in the in
vitro prolongation of coagulation150. In vivo, the (b2gpI)2-aPL complexes possibly inhibit the
anticoagulant activity of protein C at phospholipid surfaces, explaining the thrombo-embolic
risk229.
                                                 
a Abbreviations used: Å, Angstrom, 10-10 m; aPL, anti-phospholipid auto-antibodies; APS, anti-phospholipid
syndrome; b2gpI, b2-glycoprotein I; GlcNAc, N-acetylglucosamine; HFH, human factor H; IEF, iso-electric
focusing; MALDI TOF, matrix-assisted laser/desorption time-of-flight; Man, mannose; MIRAS, multiple
isomorphous replacement method using anomalous scattering; r.m.s.d., root-mean-square deviation; SCR,




We have determined the crystal structure to 2.7 Å resolution of the glycosylated
five-domain human b2gpI purified from blood plasma. The structure aids in characterization
of the epitopes for the heterogeneous pool of aPL’s and yields insights into the spatial
arrangement and functional partitioning over the multiple consecutive SCR domains and the
mechanism of binding to anionic phospholipids.
Structure determination
Crystals of b2gpI grew in the orthorhombic space group C2221. Significant non-isomorphism
was observed between crystals, as indicated by an Riso of 20.9% between data sets Native I
and II (Table I). Structure determination of b2gpI with the multiple-isomorphous
replacement method using anomalous scattering (MIRAS) revealed one b2gpI molecule in
the asymmetric unit with a remarkably high solvent content of 86% and a large Vm of 8.5 Å
3
Da-1 (Table II, Fig. 1). The initial map using Native I and derivatives I was of low quality
due to poor phasing statistics (Table II) and was improved dramatically by solvent flattening
using a solvent fraction of 70%. A first model was built at 3.75 Å resolution using the NMR
structure of the 15th SCR domain of HFH57. Rigid-body refinement of this initial model
against data set Native II yielded a decrease in R-factor from 52.6% to 48.0% and in free R-
factor from 52.0% to 47.8%. Phase information to 2.7 Å resolution obtained at a later stage
(derivative sets II) was used to validate and correct the model (Fig. 2). Refinement used the
maximum-likelihood method and a bulk-solvent correction (see Materials & Methods).
Electron density corresponding to residues Ser311-Lys317 is not visible in the final 2|Fo|-|Fc|
map and, therefore, these residues have not been included in the final model. Seven
carbohydrate residues are identified in the electron-density maps at the four N-glycosylation
sites. The final structure is refined to 2.7 Å resolution with an R-factor of 24.9% and a free
R-factor of 26.9%, and displays good stereochemistry (Table II). Coordinates and structure
factors have been deposited with the Protein Data Bank (accession code 1QUB).
Table I
Crystal characteristics showing non-isomorphism
Crystal Res. (Å) m (°)* a, b, c (Å) DV/V§ T†
Native I 29-3.75 1.0 161.53    163.73    114.99 0.0 120
Native II 40-2.7 1.0 161.17    166.49    114.51 + 1.0 100
K2OsO4 (I) 39-3.0 0.6 160.95    161.33    114.65 - 2.1 100
Na3IrCl6 (I) 38-3.1 0.5 160.55    163.11    113.98 - 1.9 100
K2PtCl6 (I) 39-3.2 0.8 161.38    161.86    113.98 - 2.1 100
K2OsO4 (II) 40-2.7 0.4 160.86    166.26    115.35 + 1.0 100
K2PtCl6 (II) 40-2.9 0.5 162.43    165.42    114.76 + 1.0 100
* Mosaicity
§ Native I is taken as a reference, cell-volume differences are given as a percentage and are mainly caused by changes
in the b-axis
† Temperature in K during data collection
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Fig. 1. Structural representations of human blood-plasma b2gpI revealing the extended chain of
the five SCR domains. (A) Ribbon drawing of b2gpI with consecutive domains labeled I to V. N-
linked glycans as well as the position of the putative O-linked glycan, Thr130, are indicated by ball-
and-stick model. b-Strands are shown in green and helices in red. (B) Topology diagram of b2gpI. The
central b-sheets of all five domains are labeled B2(-B2”)-B3-B4(-B5), the N- and C-terminal b-sheets
are labeled B1’-B2’ and B4’-B5’, the a-helix and the 3/10 helix are denoted A1 and A2 and numbers
of residues delimiting secondary structure elements are given. Disulfide bonds are indicated with
dashed lines. Positions of N-glycosylation are given by hexagons; a diamond indicates the putative O-
glycan. Horizontal dashed lines mark domain boundaries. (C) Ribbon representation of domain III of
b2gpI with labeled secondary structure elements. The two fully conserved disulfide bonds are shown in
yellow. (D) Ribbon representation of domain V of b2gpI with labeled secondary structure elements.
The three disulfide bonds are indicated in yellow. The aberrant face, that contains the membrane-
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Fig. 2. Electron density map near Trp53 calculated with phases from the refined model. Th  2|Fo|-
|Fc| electron-density map at 2.7 Å resolution is contoured at 1 s.
Structure description
The structure of b2gpI shows an extended chain of five SCR domains with an overall fish-
hook like appearance with dimensions of 130 Å (vertical direction in Fig. 1A), 85 Å
(horizontal) and 130 Å from the N- to the C-terminal extremity. The distance from the N- to
the C-terminal end along the curve of the molecule is ~190 Å. The fish-hook shape is mostly
flat, but slightly bent around domain III. The elongated structure contradicts a hypothetical
model of Koike t al. (230), who describe the molecule as being folded into a compact
particle.
Domains I to IV of b2gpI have common SCR folds (Fig. 1B). They consist of a
central anti-parallel b-sheet, comprising strands B2-B3-B4, with two extended loops
typically flanked by short two-stranded anti-parallel b-sheets, B1’-B2’ and B4’-B5’, at the
N- and C-terminal side (Fig. 1C). Disulfide bridges located at opposite ends of a domain
cross-link the short flanking b-sheets with the central b-sheet (B1’ to B4 and B3 to B5’).
Domain II has slightly deviating structural elements; its central sheet is extended by one
more anti-parallel strand denoted B5 and residues at the position of strand B1’-B2’ do not
adopt a b-sheet conformation. These four domains of b2gpI have a sequence homology
ranging from 24 to 45%231 and superimpose within 1.2 to 1.9 Å root-mean-square (r.m.s.)
coordinate difference (see Methods section). A similar range of homology, 21 to 41%, and a
similar range of r.m.s. coordinate difference, 1.4 to 2.3 Å, is observed when comparing
b2gpI I-IV with SCR domains available in the Protein Data Bank, HFH-15, 16 (Ref. 57) and
VCP-3, 4 (Ref. 58). This indicates that the SCR fold is very well conserved. The largest
differences with respect to amino-acid length and structure are observed in the B2-B2’ loops,
referred to as ‘hyper-variable’ by Barlow et a . (57).
The fifth C-terminal domain deviates significantly from the common SCR fold (Fig.
1D). Similar to the SCR fold it has the central anti-parallel b-sheet ncompassing b-strands
B2, B3 and B4 and the two disulfide bonds common to all SCR domains. In domain V
strands B3 and B4 of the central sheet are extended and are part of a larger and strongly
twisted anti-parallel b-sheet. Domain V has an insertion of six residues in the region of the
hyper-variable loop. This region now forms an additional b-strand (B2”), that participates in
the central b-sheet, followed by a short a-helix (A1). The C-terminal extension contains a
short 3/10 helix (A2) and is C-terminally cross-linked by a third disulfide bond. Residues
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311-317 of this extension are not visible in the electron-density map. This exposed loop is
possibly mobile or disordered due to potential cleavage at Ala314-Phe315 or Lys317-Thr318
(Ref. 76, 80). In conclusion, domain V may be considered to consist of a core that is
reminiscent of the consensus SCR fold with unique structural elements A1, A2 and B2” and





Crystal Res. (Å) RedundancyNo. unique refl. <I>/<s(I)> Completeness (%)Rmerge2 (%)
Native I 29-3.75 4.0 15447 5.2 (4.1) 97.8 (97.7) 14.7 (31.1)
Native II 40-2.7 3.8 42494 5.8 (2.0) 99.8 (99.6) 8.9 (36.3)
K2OsO4 (I) 39-3.0 3.3 30431 8.8 (2.6) 96.6 (88.4) 7.4 (28.9)
Na3IrCl6 (I) 38-3.1 3.7 23790 9.0 (4.4) 83.8 (77.3) 6.9 (20.0)
K2PtCl6 (I) 39-3.2 3.2 23516 8.2 (2.6) 93.6 (67.0) 7.8 (25.1)
K2OsO4 (II) 40-2.7 8.9 42498 9.7 (3.3) 100 (99.8) 7.4 (40.3)
K2PtCl6 (II) 40-2.9 10.4 34609 12.0 (5.4) 99.5 (97.4) 8.9 (33.1)
Phasing statistics
Derivative Riso3 Rano4 No. sites Phasing power5
Cent.     Acent.
Rcullis6 FOM7
K2OsO4 (I) 0.230 0.050 3 0.65        0.73 0.67 0.43
Na3IrCl6 (I) 0.130 0.031 2 0.26        0.35 0.81 0.43
K2PtCl6 (I) 0.181 0.047 1 0.40        0.40 0.79 0.43
K2OsO4 (II) 0.207 0.063 4 0.68        0.76 0.70 0.34
K2PtCl6 (II) 0.213 0.056 1 0.47        0.53 0.76 0.34
Refinement statistics
Resolution 40-2.7 Å
R-factor/Rfree8 0.249 / 0.269
R.m.s.d. bond distances0.019 Å
R.m.s.d. angles 1.92°
Average B-factor 49 Å2
No. non-hydrogen atoms2,608
No. protein residues 319
No. sugar residues 7
No. solvent molecules 32
1 Numbers in parentheses indicate statistics for highest resolution shells.
2 Rmerge = åhåi|Ihi-<Ih>|/åhåi|Ihi|
3 Riso = å| Fph2 – Fp2 | / | å(Fph2 + Fp2)
4 Rano = å| F(+)2 – F(-)2 | / å(F(+)2 + F(-)2)
5 Phasing power is the r.m.s. value of the heavy-atom structure-factor amplitude divided by the r.m.s. residual lack-of-closure
6 Rcullis is the mean residual lack-of-closure error divided by the isomorphous difference
7 FOM , figure of merit




As indicated by Kristensen et al. (40), human b2gpI contains four N-glycosylation sites. The
electron density shows seven carbohydrate residues at these four sites, viz. GlcNAc-(b1-N)-
Asn143, GlcNAc-(b1-N)-Asn164, Man-(b1-4)-GlcNAc-(b1-4)-GlcNAc-(b1-N)-Asn174 and
GlcNAc-(b1-4)-GlcNAc-(b1-N)-Asn234. Weak density at Thr130 indicates the position of
an O-linked sugar45, which is in agreement with the sequence context of glycosylated
threonines232. Four glycans (at positions 130, 143, 164 and 174) are located on domain III
and one (at 234) on domain IV. Three glycans are positioned in the inner-curve of the fish-
hook, filling the niche formed by the molecule (Fig. 1A). The remaining two glycans are
located on domain III at the outer-curve of the fish-hook. The five glycans point into large
solvent channels present in the crystal. Crystal packing is dominated by interactions
involving domains I, II and V. Very few crystal contacts involve domains III and IV (Fig. 3).
Moreover, domains III and IV, which carry the glycans, appear to bridge between the
contacts made by the N- and C-terminal domains I, II and V. The observed shielding of the
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Fig. 3. Crystal packing of b2gpI. Shown are Ca-traces of one molecule with its four neighboring
molecules. Crystal contacts involve predominantly domains I, II and V. Contacts with glycosylated
domains III and IV are restricted to the N-terminal bottom and C-terminal top of the domains III and
IV, respectively. In the crystal the glycosylated domains bridge the crystal contacts made by the N- and
C-terminal domains.
Inter-domain flexibility
The domains in b2gpI are connected by short linker regions of three (domains IV-V) and
four residues (all others), i.e. counting the number of residues between the C-terminal cystine
of the first domain and the N-terminal cystine of the second domain. Between domains II-III
and III-IV these linking residues form b-strands that connect sheets B4’-B5’ of the N-
terminal domain with B1’-B2’ of the C-terminal domain (Fig. 1A, B). The interactions
observed at the interfaces are hydrophobic contacts and one hydrogen bond between domains
I-II, II-III and III-IV and two hydrogen bonds between domains IV-V. Only a small amount
(10 to 15%) of surface is buried at the inter-domain interfaces: 422, 242, 445 and 492 Å2 for
domains I-II up to IV-V, respectively.
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The four inter-domain orientations observed in b2gpI display tilt angles j varying
from 128 to 160° and twist angles y varying from 41 to 137° (Table III, Fig. 4). Slightly
different angles (up to 6° differences) are observed for the low-resolution data Native I, for
which the b-axis is 2.8 Å shorter. The observed tilt angles j i  all known SCR domain-
domain structures are obtuse and range from 120 to 162° (Table III). The range observed for
the twist angle y is much larger, 22 to 180°, which indicates a large variability in precise
domain-domain interactions. Electron microscopy for CR2 (Ref. 233) and HFH234, that
contain 15 and 20 SCR repeats, also shows elongated and winding structures. In these
proteins up to eight residues link the separate domains yielding further flexibility. These
electron microscopy, NMR and X-ray data suggest that multiple SCR repeats likely form
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Fig. 4. Domain-domain orientations in b2gpI. (A) Stereo view of domain-domain orientations of the
four sets of consecutive SCR domain pairs. The N-terminal domains of tandems II-III, III-IV and IV-V
are superposed on domain I of tandem I-II. C-termini are indicated with the domain labels II to V. (B)
The variation in domain orientations is expressed in a tilt angle j nd a twist angle y determined by the
principal inertia axes a and b (See the Methods section and Table III).
Membrane binding
The fifth domain of b2gpI has been implicated in membrane binding73. In b2gpI we observe
a large positively charged area of ~2,000 Å2 on domain V (Fig. 5). This patch is formed by
side chains of 12 lysines, one arginine and one histidine located at the outer-curve of the fish
hook. It includes four lysines from the loop Cys281-Cys288 and lysines 308 and 324, that are
important for phospholipid binding34,73,76. Other residues of this patch are Lys246, Lys250,
Lys251, Arg260, Lys262, Lys266, Lys268 and His310. The flexible loop Ser311-Lys317,
containing Trp316 that is essential for phospholipid binding52, is located within this charged
region (indicated in Fig. 5B).
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The structural and biochemical data indicate a relatively simple membrane-binding
mechanism. The positive charges on domain V interact with the anionic phospholipid
headgroups and the flexible loop Ser311-Ser-Leu-Ala-Phe-Trp-Lys317 putatively inserts into
the lipid layer and positions Trp316 at the interface region between acyl chains and
phosphate headgroups of the lipids, thereby anchoring the protein molecule to the membrane
(Fig. 5C). Furthermore, the combination of Trp, Phe or Tyr, followed by a Lys is of
particular importance for the interaction with the interfacial region between the lipid
phosphate group and the acyl chains of lipids235-238. Comparison of b2gpI sequences of
bovine, canine, mouse, rat and human shows that the putative membrane-insertion loop Ser
311-Lys 317 is identical among these species and that substitutions with respect to a
positively charged patch on domain V are conserved. Interestingly, all residues responsible
for the unique function in membrane binding of domain V are located on the aberrant non-
SCR like half of this domain.
Reduced affinity for anionic phospholipids, as observed for the two naturally
occurring mutants Cys306Gly and Trp316Ser52,53 and for two cleaved isoforms f b2gpI,
with scissile bonds between residues 314-315 and 317-318 (Ref. 76, 80), can readily be
explained by the proposed membrane-binding model. Both mutations and the two scissile
bonds disrupt the integrity of the putative membrane-insertion loop 311-317. We think that
in vitro observed binding properties to heparin of b2gpI with the single mutation
Trp316Ser53 and of two isoforms which are proteolytically cleaved between Lys317 and
Thr318, and native b2gpI32 show an aspecific behaviour of the protein, which is not affected
by alterations or disruptions of the membrane-insertion loop and which is brought about
solely by charge interactions. The loop Ser311-Ser-Leu-Ala-Phe-Trp-Lys317, then, gives
b2gpI its specificity for phospholipid interfaces by introducing specific hydrophobic
interactions between amino-acid residues and acyl chains of phospholipids, in addition to the
large number of charge interactions.
Table III
Inter-domain orientations
Tilt angle j (°) Twist angle y (°)
b2gpI†  I-II 160, 162 137, 136
b2gpI  II-III 160, 159 83, 78
b2gpI  III-IV 128, 125 41, 46
b2gpI  IV-V 131, 137 80, 76
HFH 15-16‡ 130 130
CD46 1-2§ 120 180
VCP 3-4* 121 22
† Two values are given: the first value is obtained from b2gpI in crystal
form II (cf. Native II), the second value refers to b2gpI in form I (Native I).
‡ Reported standard deviations are 13° in j and 17° in y58
§ Between the six copies of the molecule in the asymmetric unit a
difference of 15° in j is reported59
* Reported standard deviations are 4° in j and 6° in y58
Binding of anti-phospholipid auto-antibodies
The group of auto-antibodies, aPL’s, detected in blood plasma of patients with APS is both
inter- and intra-individually heterogeneous. Indeed, the extended shape of b2gpI offers many
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potential sites for antibody binding, particularly at the non-glycosylated domains I, II and V.
So far aPL binding to domains I, III, IV and V and to the inter-domain region between I and
II, has been reported76,151-154. Wang et al. (154) have identified two potential epitope
sequences, Gly274-Phe280 and Ala314-Pro325. Based on the structure both sequences are
unlikely to be epitopes of aPL’s. Gly274-Phe80 forms the central b-strand B3 of domain V,
which is largely inaccessible to the solvent (17% solvent accessibility). It is, thus, unlikely to
be, either an epitope, or a cryptic epitope, without fully disrupting the fifth domain. The
second peptide, Ala314-Pro325 contains part of the putative membrane-insertion loop
Ser311-Lys317. Binding of aPL to these residues will directly interfere with, if not fully
abolish, membrane binding of b2gpI. This analysis shows that the crystal structure of b2gpI
is an important tool for the evaluation of potential epitopes. It will guide mutational studies
of b2gpI and aid in characterization of antibodies related to APS.
Conclusions
The crystal structure of the intact and glycosylated adhesion protein b2gpI from human
blood plasma reveals that the five consecutive SCR domains of b2gpI form an elongated
chain yielding an overall fish-hook shape of the molecule. Multiple consecutively arranged
domains are common in adhesion molecules. However, very few structures of these
repetitive domains have been resolved (see e.g. Ref. 239-241), let alone of complete
adhesion molecules. The structure of complete b2g I shows that the first four domains
display regular SCR folds, that are common to many mammalian complement proteins. The
fifth domain has an aberrant fold. Constructed onto a SCR-like core, a six-residue insertion
and 19-residue C-terminal extension together with some rearrangement of existing elements
create a completely new face on this domain. Strikingly, the structural and biochemical data
strongly suggest that this new face of domain V is fully responsible for membrane binding of
b2gpI. The proposed mechanism of membrane binding consists of two major aspects: i. a
large positive patch of 14 charges binds to the anionic surface, and ii. a flexible and partly
hydrophobic loop inserts into the lipid layer and positions a Trp and a Lys at the interfacial
region, thereby providing specificity for negatively charged phospholipid layers. Membrane
adhesion of b2gpI very likely underlies the diverse effects of this protein in blood
coagulation, apoptosis and the APS immune disorder, in which auto-antibodies enhance
membrane affinity by divalent cross-linking of b2gpI. The observed crystal structure even
bears relevance for how b2gpI domains are positioned, when the molecule is membrane
bound. It implies that association of the binding site, located at the top and outer curve of the
fish hook of b2gpI, with a membrane layer results into pointing domain IV to I far into the
solution. Similar to what is observed in the crystal, the glycosylated domains III and IV are
partly shielded from protein-protein interactions by the glycans and may, therefore, possibly
be regarded as linker or ‘bridging’ domains. The N-terminal domains are exposed most to the
solution and most likely provide binding sites in e.g. apoptosis. Thus, the crystal structure of
the complete and glycosylated adhesion molecule b2gpI suggests a functional partitioning
over its three-dimensional structure, that is probably a general phenomenon for many
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Fig. 5. Binding of b2gpI to an anionic phospholipid surface. (A) Two views, related by 180°
rotation, of the electrostatic surface potential of b2gpI. Domains are labeled I to V. The electrostatic
potential is scaled from red for negative charge to blue for positive charge. (B) Positively charged patch
on the aberrant half of domain V. The 14 residues contributing to this patch and the position of the
disordered loop Ser311-Lys317 are indicated. (C) Cartoon of the proposed model for binding of b2gpI
to anionic phospholipids. The positively charged patch on the surface of domain V is indicated with
‘+’, acidic phospholipids are depicted with ‘-‘ and the putative membrane-insertion loop Ser311-Ser-
Leu-Ala-Phe-Trp-Lys317 is shown to insert into the phospholipid layer. Positions of N-glycans are
indicated with hexagons and the putative site for O-linked glycosylation is indicated with a diamond.
Materials and Methods
Protein purification
b2gpI was isolated from freshly-frozen citrated human plasma of three healthy donors
(Dutch Blood Bank) as described before242. Pu ified b2gpI appeared as a single band of 42
kDa on an SDS-PAGE gel under non-reducing conditions and as at least seven bands
between pH 5.3 and 6.8 on a silver-stained Pharmacia PhastGel IEF 3-9. MALDI-TOF mass-
spectrometry analysis revealed a protein mass of 45 ± 2 kDa (calculated mass 36.3 kDa),
indicative for heterogeneity of the carbohydrate content and the presence of approximately
40 to 60 carbohydrate residues.
Crystallization, heavy-atom derivatives and data collection
Crystallization trials using the hanging-drop vapor diffusion method at 4°C were performed
with b2gpI concentrated to 6.5 mg ml–1 in 150 mM NaCl, 50 mM Tris-HCl pH 7.3.
Crystallization conditions were essentially as described243. Reservoir solutions contained,
either 1.5 M (NH4)2SO4, 2% v/v glycerol, 20 mM CdCl2 and 0.1 M HEPES pH 7.5 (Native
II), or 1.5 M (NH4)2HPO4 and 0.1 M Na-acetate pH 5.6 (Native I). Large (0.4x0.4x0.3 mm
3)
crystals with irregular shape grew within 10 days in set-ups of 1 ml protein solution and 1 ml
reservoir solution. Crystals obtained with both conditions were in the orthorhombic space
group C2221 and were used for further experiments (Table I). Heavy-atom derivatives were
prepared by soaking crystals for four days in solutions containing, either 3 mM K2OsO4, or
Na3IrCl6, or K2PtCl6. Crystals were flash-frozen in a liquid nitrogen stream after
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equilibration in solutions with 43% v/v (Native I) or 30-35% v/v glycerol. X-ray data were
collected using a Mar345 imaging plate (Hamburg, EMBL outstation at the DESY
synchrotron, beamline BW7B for data sets K2O O4 (I), Na3IrCl6 (I) and K2PtCl6 (I)), a
MacScience DIP2020 imaging plate mounted on a Nonius FR-571 rotating anode (for Native
I) and an ADSC 2x2 CCD camera (Grenoble, EMBL outstation at the ESRF synchrotron,
beamline ID14-EH4, for Native II, K2OsO4 (II) and K2PtCl6 (II)). Data collection was aided
by use of STRATEGY244 and data were processed and scaled using, either DENZO and
SCALEPACK26, or the CCP4 Program Suite245. Unit-cell dimensions are given in Table I.
Differences in cell volumes of up to 3.1% were mainly caused by differences in the length of
the b-axis.
Structure determination
Three heavy-atom derivatives were used for phasing by the MIRAS method (Table II).
Heavy-atom positions were located and refined and a set of phases was calculated with
SOLVE10 using data sets Native I, K2OsO4 (I), Na3IrCl6 (I) and K2PtCl6 (I). We could
determine the presence of one b2gpI molecule in the asymmetric unit in the first electron
density map phased at 3.75 Å resolution. Phases were improved by solvent flattening with a
solvent fraction of 70% using the program suite CNS9. The NMR structure of SCR domain
15 of HFH57 was used for global positioning of the five SCR domains of b2gpI. A irst
model was constructed consisting of all 326 residues with 102 residues replaced by Ala. At a
later stage phase information to 2.7 Å resolution was obtained from K2OsO4 (II) and K2PtCl6
(II) using Native II (Table II). The model was validated and adjusted to the new map. The
initial model was for the most part correct with respect to domains I to IV and contained
chain-trace errors in domain V. Refinement was started with this adjusted model consisting
of residues 1-131, 139-203, 210-282, 287-298 and 300-326.
Structure refinement
The model was refined against the Native II data set at 2.7 Å resolution. Cycles of rebuilding
using O16 and positional- and B-factor refinement using model phases, using CNS, were
performed until convergence. Cross validation was used throughout the refinement.
Refinement used the Maximum Likelihood algorithm29 and bulk solvent correction was
applied as calculated by CNS. No electron density was visible for the loop Ser311-Lys317 in
the final 2|Fo -|Fc| electron-density map, although some density indicated its position in the
maps calculated with MIRAS phases at 2.7 and 3.75 Å resolution. This ill-defined solvent-
exposed region could not be modeled satisfactorily. In the vicinity of the four N-
glycosylation sites, electron density was seen accounting for a total of seven carbohydrate
residues, viz. GlcNAc-(b1-N)-Asn143, GlcNAc-(b1-N)-Asn164, Man-(b1-4)-GlcNAc-(b1-
4)-GlcNAc-(b1-N)-Asn174 and GlcNAc-(b1 4)-GlcNAc-(b1-N)-Asn234, which are
included in the model. No electron density accounting for fucose units, linked to GlcNac-
Asn, was seen. The mobility of the oligosaccharide antennae is reflected by high B-factors of
the carbohydrate units, ranging from 50 to 99 Å2. Between Thr130 and Gly1 of a symmetry
related molecule electron density was seen, which can possibly be ascribed to an O-linked
oligosaccharide antenna attached to Thr130 (Ref. 45, 232). Additional electron density, that
may be accounted for by cadmium ions, is observed near His172, His216 and near Glu309.
Near Tyr207’s hydroxyl group additional weak density is present which might be indicative
for partial sulfatation. Side-chain positions of residues Arg2, Arg39, Lys59, Lys110, Arg135,
Gln158, Lys177, Lys208, Lys251, Lys284, Glu285, Lys286, Lys287, Lys308 and Glu309 are
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poorly defined. The average B-factors for the main-chain atoms (Ca, C, O, N) of the domains
(labeled I to V) are 41.6 Å2 (I), 38.1 Å2 (II), 52.7 Å2 (III), 53.8 Å2 (IV) and 57.9 Å2 (V) with
an average B-factor for all domains of 46.9 Å2. For all non-hydrogen protein atoms (i.e.
excluding glycans) the B-factors are 42.1 Å2 (I), 39.3 Å2 (II), 53.8 Å2 (III), 54.8 Å2 (IV) and
59.2 Å2 (V), with an average B-factor for all domains of 48.0 Å2. The final model comprises
b2gpI residues Gly1-His310, residues Thr318-Cys326, one mannose and six N-
acetylglucosamine carbohydrate residues, which accounts for ~80% of the total mass of a
b2gpI molecule, and 32 ordered water molecules.
Crystal structure analysis
Superpositions of SCR domains are calculated in O using first cystine residues only,
followed by superpositioning of Ca positions of spatially related residues (distance cut-off
3.8 Å). Root-mean-square coordinate differences of 1.2 to 2.3 Å are observed for
superimposing 39 to 59 residues of b2gpI domains I to IV, HFH domains 15, 16 and VCP
domains 3, 4. Domain-domain orientations of b2gpI were calculated using 27 Ca-atoms from
each domain, which superimposed with r.m.s. coordinate differences of 1.17 to 1.50 Å , as
calculated with O. All domains were translated to one origin and for each domain inertia
tensors were calculated and diagonalized. One domain was rotated with respect to its
preceding domain in such a way that their eigenvectors with the smallest eigenvalues, i.e. th
main axis of the domains (labeled  and a’ in Fig. 4B), were aligned (tilt angle j). N xt, a
second rotation (twist angle y) was performed to align the eigenvectors (labeled b and b’ in
Fig. 4B) with the second-smallest eigenvalues. Definition of the tilt angle j and of the twist
angle y is according to Bork et al. (54). Molecular surfaces and electrostatic potentials were
calculated with GRASP246. The model quality was checked with WHATIF17 and
PROCHECK18. The Ramachandran plot for the final model comprising 319 amino-acid
residues, shows that 87.4% of these residues fall in the most favored region with no residues
in disallowed regions. Domain-domain contacts were calculated with LIGPLOT247. Fig. 1A,
C, D and 4A were generated using MOLSCRIPT202 and RASTER3D203.
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--- Chapter III ---
Interaction of human b2-glycoprotein I





Human b2-glycoprotein I (b2gpI) is a plasma protein that has been implicated in blood
coagulation, clearance of apoptotic bodies from the circulation, and in the auto-immune
disease anti-phospholipid syndrome. b2gpI binds to megalin, an endocytic receptor that
transfers renal-filtered b2gpI back into the circulation, to activated protein C, protein S
and C4B binding protein, that function in anticoagulant processes, to the cellular
protein calmodulin and to auto-antibodies in patients with the anti-phospholipid
syndrome in vitro, when b2gpI or its protein ligand is immobilized on a suitable surface.
In the present study we focussed on b2gpI-protein complex formation in solution using
gel-filtration chromatography. b2gpI formed a stable complex in solution with the
lupus anticoagulant-positive IgG 22F6. This indicates that adhesion to membranes is
not in all cases a prerequisite for formation of b2gpI-auto-antibody complexes. b2gpI
did not form complexes in solution with activated protein C and protein S. High-
affinity binding of a small fraction of b2gpI to C4B binding protein could not be
excluded based on our experiments. Even in the presence of b2gpI protein S-C4B
binding protein complex was very stable. Therefore, no further evidence was revealed
that supports an anticoagulant function of b2gpI by maintaining the level of free
protein S. Our binding experiments did not establish previously reported high-affinity
complex formation between b2gpI and calmodulin. Stable complexes putatively only
form in vivo when b2gpI is bound to a lipid surface. Binding of extreme negatively
charged calmodulin to the positively charged membrane-adhesion site of b2gpI may,
then, block b2gpI-lipid interaction. This may be a prerequisite for the translocation of
renal excreted b2gpI back into the circulation by the transporter megalin.
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Human b2-glycoprotein I (b2gpI)a is a heavily-glycosylated plasma protein that is present in
a concentration of ~150 to 300 mg ml-1 (~3.3-6.6 mM), of which about 4% is bound to
lipoproteins62. b2gpI is an important antigen in the auto-immune disease anti-phospholipid
syndrome (APS), defined by recurrent fetal loss, occurrence of thrombo-embolic
complications in both the arterial and venous vasculature and the presence of anti-
phospholipid auto-antibodies (aPL’s, lupus anticoagulants, LA’s) in the blood, of which a
subset is directed against b2gpI147,148. b2gpI has been indicated as an anticoagulant84,85,106,121,
as well as a procoagulant248,249. b2gpI may have a role in clearance of apoptotic bodies from
the circulation64,131,133. Recently, we elucidated the crystal structure of human b2gpI purified
from blood plasma250, which has been confirmed by Schwarzenbacher t al. (251) at a later
stage. Based on the crystal structure and available biochemical data, we proposed a
membrane-adhesion model for b2gpI in which the fifth C-terminal short concensus repeat
(SCR) domain binds specifically to anionic phospholipids. Spatial arrangement of the five
SCR domains of b2gpI suggested that adhesion of the fifth domain to phospholipids points
the four N-terminal domains away from the lipid surface. These four fully exposed N-
terminal SCR domains may then be available for protein-protein interactions.
The membrane-adhesion mechanism and lipid specificity of b2gpI have been
extensively investigated34,52,73,76-79. In contrast, little is known about protein ligands that may
form functional complexes with b2gpI in apoptosis or coagulation, and about the mechanism
that triggers formation of auto-antibodies that are elicited against b2gpI112,116,252.
The affinity of b2gpI for anionic phospholipids increases strongly in the presence of
aPL’s and LA’s. These aPL’s and LA’s have varying affinity for b2gpI and epitopes are
identified in all five SCR domains of b2gpI76,151-154. The increased affinity is explained by
formation of divalent (b2gpI)2-auto-antibody complexes163,253. Adhesion of these complexes
to phospholipid layers inhibits the protein C-dependent anticoagulant cascade248,249,254. Thi
may explain the observed thrombo-embolic complications in patients with APS229.
In vitro binding studies with immobilized proteins suggested that b2gpI in eracts
with protein S83-85, a positive cofactor in the protein C-dependent anticoagulant pathway86-89.
Complement-regulator C4B binding protein (C4Bbp) inhibits the stimulatory anticoagulant
activity of protein S by formation of C4Bbp-protein S complexes. Formation of b2gpI-
protein S complexes has shown to prevent formation of C4Bbp-protein S complexes, and,
thereby, may keep at least part of the protein S pool available for its anticoagulant function.
In addition to binding of b2gpI to protein S, Sim and Devine (85) reported binding of 2gpI
to activated protein C (APC) and to C4Bbp. Observed modulation of b2gpI-APC and b2gpI-
C4Bbp complex formation by protein S suggested a complicated allosterically controlled role
for b2gpI in the APC-dependent anticoagulant pathway. Binding of b2gpI to protein S has
been confirmed with an enzyme-linked immuno-sorbent assay (ELISA) set-up, whereas
binding of b2gpI to APC or to C4Bbp was not established (M. Simmelink, unpublished
results).
                                                 
a Abbreviations used: APC, activated protein C; aPL, anti-phospholipid auto-antibody; APS, anti-phospholipid
syndrome; b2gpI, b2-glycoprotein I; CaM, calmodulin; C4Bbp, C4B binding protein; ELISA, enzyme-linked
immuno-sorbent assay; IgG, immunoglobulin G; LA, lupus anticoagulant; MW, molecular weight; PDB, Protein




Klaerke et al. (90) and Rojkjaer et al. (91) reported very high-affinity complexes
between renal-filtered b2gpI and calmodulin (CaM). In contrast, low-affinity b2gpI-CaM
complex was observed in an ELISA set-up (M. Simmelink, unpublished results). CaM is a
ubiquitous intracellular protein that is found in all tissues and that plays a major role in the
Ca2+-dependent regulation of a multitude of enzymes and in a wide variety of cellular
events92. Renal filtered b2gpI also binds to the endocytic receptor megalin, which actively
transfers b2gpI from kidney cells back into the circulation93. Megalin is a large multi-domain
trans-membrane receptor of approx. 600 kDa. It is a member of the low-density lipoprotein
receptor family and was first identified as the antigen in the renal auto-immune disease
Heymann nephritis255. Megalin is a receptor for plasminogen and its activated form
plasmin256,257, of which the latter partly inactivates lipid-binding ability of b2gpI b  cleaving
it at Lys317-Thr318 in vitro32. Furthermore, megalin adheres to and facilitates cellular uptake
of lipoprotein(a) and low-density lipoproteins255,258, which are also known ligands for
b2gpI61,65,94.
In the present study, we focussed on interaction of b2gpI with proteins that function
in coagulation, APS and putatively renal filtering, i.e. protein S, activated protein C, C4B
binding protein, LA-active IgG 22F6 and calmodulin. Previously, several binding studies
were performed in which, either b2gpI, or its putative protein ligand was immobilized on a
solid surface. Addressing physiological relevance of observed b2gpI-protein interactions
needs consideration of experimental shortcomings that may result in artificial binding
properties. Firstly, it has previously been shown that absorption and immobilization of
proteins at a solid surface, as in an ELISA set-up, can induce denaturation and
conformational changes260,261. Absorption-induced exposure of artificial epitopes may,
therefore, result in non-physiological properties of the protein. Secondly, when one of the
proteins in a complex is immobilized on a solid surface, its effective concentration is
enormously enhanced. As a result, very low-affinity complexes can form that have no
functional relevance in vivo. Thirdly, Tsutsumi et al. (141) demonstrated that binding
properties of b2gpI from separate purifications can vary among different ELISA set-ups.
Furthermore, for formation of b2gpI-protein S complexes Merrill et a . (84) used b2gpI that
was purified from perchloric acid-treated plasma. This method introduces alterations in the
physical properties of the protein262 and may, therefore, give rise to new non-physiological
activities of b2gpI, due to conformational changes or chemical modifications. To gain further
insight into previously reported b2gpI-protein complex formations, we chose an
experimental set-up for direct detection of protein-protein interactions in solution, .e. gel-
filtration chromatography. Based on our results and previous reports we discuss a role for
b2gpI-CaM complexes in renal re-absorption by megalin, and for b2gpI-C4Bbp complexes
with respect to anticoagulant activity of b2gpI.
Methods
Protein solutions
b2gpI was purified from pooled plasma of three healthy human donors (designated ‘Pool A’)
(Dutch Blood Bank, Utrecht, the Netherlands) according to Horbach et al. (232).
Characterization of native b2gpI revealed that it was contaminated with a small amount of an
isoform of b2gpI, referred to as ‘b2gpI *1’ (Ref. 32; Chapter IV). b2gpI *1 is cleaved at
position Lys317-Thr318 and lost its ability to adhere to anionic membranes. b2gpI *1 was
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purified from a separate pool of blood plasma from three healthy human donors, which is
referred to as ‘Pool B’, and was a kind gift of D. Horbach (Haemostasis and Thrombosis
Laboratory, University Medical Center Utrecht). Purified b2gpI was stored in Tris-buffered
saline (TBS). Lyophilized CaM was purchased from Pharmacia Biotech (Uppsala, Sweden).
CaM was either dissolved in TBS, or in TBS with 10 mM CaCl2, and subsequently incubated
for 60 min. at room temperature, before use. Murine monoclonal IgG 22F6, that expresses
LA-activity, was obtained from J. Arnout (Center for Molecular and Vascular Biology,
University of Leuven, Belgium)164,253. 22F6 was supplied in TBS and tended to aggregate
severely. Incubating 22F6 for one week in a solution of 50 mM Tris-HCl pH 7.5, 30 mM
NaCl successfully dissolved these aggregates, according to analysis by sodiumdodecyl-
sulphate polyacrylamide gel electrophoresis and by gel-filtration chromatography. APC,
protein S and C4Bbp were a kind gift of R. van der Poel (Haemostasis and Thrombosis
Laboratory, University Medical Center Utrecht). Protein-stock solutions used for binding
experiments are listed in Table I.
Table I
Protein-stock solutions used for complex formation in solution
Protein MW (kDa) c (mM) c (mg ml-1) cplasma (mM)‡ Ve (ml)
†
native b2gpI 45 287 12.9 3.3-6.6 13.6
b2gpI *1 45 400 18.0 2E-3 13.6
IgG 22F6 160 81.0 13.0 n.d. 12.6
CaM 17 772 12.9 0.018 15.4
protein S 71 13.4 1.0 0.35 12.3
APC 58 3.5 0.20 0.017 14.1
C4Bbp 570 10.0 5.7 0.30 8.0
‡ n.d. not determined; For b2gpI *1 the concentration is given in plasma of healthy individuals. For CaM the concentration in
kidney is given.
† Elution volumes Ve of the free proteins after gel filtration on a Superdex 200 HR 10/30 column.
Complex formation in solution
Before qualitative analysis of b2gpI-protein complexes in solution, proteins were pre-
incubated for an indicated period of time to allow for complex formation. To this end, b2gpI
solutions were mixed with solutions of one of the various proteins (Table II). Complex
formations were initiated by a 10 min. incubation at 37°C r by a 60 min. incubation at room
temperature.
Immunoglobulin G 22F6
22F6 tended to aggregate in the presence of over 30 mM of NaCl. Complex formation
between b2gpI and 22F6 was, therefore, induced in buffer 1 containing 30 mM NaCl (Table
II, Exp. 1). To approximate physiological conditions b2gpI and 22F6 were also mixed in
TBS (Exp. 2). In both experiments, a four-fold molar excess of b2gpI was used.
Calmodulin
Incubation of b2gpI with CaM was without the presence of Ca2+ (Table II, Exp. 3), or in the
presence of 10 mM CaCl2 (Exp. 4-9). To study whether CaM has different affinity towards
b2gpI (poll A) and b2gpI *1 (pool B) we mixed CaM with b2gpI or with b2gpI *1 in a molar
ratio of 2.7:1. Furthermore, the influence of NaCl concentration on complex formation
between b2gpI and CaM was tested using buffers containing 15 or 150 mM NaCl (Exp. 4-,
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5). Complex formation was both initiated in the presence of a molar excess of CaM (E p. 3-
7,9) or of b2gpI (Exp. 8).
Activated protein C, protein S and C4B binding protein
Previous studies showed the importance of Ca2+ in complex formation between b2gpI and
protein S, APC or C4Bbp83-85. Therefore, we performed all incubations in the presence of 10
mM CaCl2. b2gpI was incubated with protein S in a ten-fold (Exp. 10, 12) or in a two-fold
molar excess (Exp. 11). For incubations with APC or C4Bbp a seven-fold (Exp. 13-14) and
fifteen-fold molar excess of b2gpI (Exp. 15) was used, respectively. For complex formation
of b2gpI with protein S or with C4Bbp, the molar ratio of b2gpI and protein S or C4Bbp
resembles physiological conditions, i.e. 10:1 (Table I). A preliminary competitive binding
study was performed to test the ability of 2gpI to disrupt previously formed protein S-
C4Bbp complex (Exp. 16). Protein S and C4Bbp were pre-incubated for 10 min. before
subsequent 10-min. incubation with b2gpI. Both incubations were at 37°C. Molar ratios of
1:1:1.4 for protein S, C4Bbp and b2gpI were used, respectively. As a positive control for the
method of complex formation protein S was incubated with C4Bbp (Exp. 17). In vivo protein
S binds to APC that is immobilized at a phospholipid surface. Whether protein S can bind to
APC when both proteins are in solution was studied by incubation of a four-times molar
excess of protein S with APC (Exp. 18).
Table II








Temp.   Time¶
 (°C)    (min.)
Buffer†
1 178 22F6 50 - 25        60 1
2 144 22F6 29 - 25        60 2
3 72 CaM 193 - 37        10 2
4 72 CaM 193 - 37        10 3
5 72 CaM 193 - 37        10 4
6 6.5 CaM 386 - 37        10 3
7 41 CaM 276 - 37        10 4
8 115 CaM 77 - 37        10 4
9 72 CaM 193 - 25        60 5
10 48 protein S 4.7 - 37        10 4
11 13 protein S 6.4 - 37        10 4
12 48 protein S 4.4 - 25        60 6
13 12 APC 1.6 - 37        10 4
14 12 APC 1.6 - 25        60 6
15 48 C4Bbp 3.3 - 37        10 4
16 3.2 protein S 2.4 C4Bbp 2.2       37     10/10 4
17 - protein S 1.4 C4Bbp 4.0       37        10 4
18 - protein S 3.5 APC 0.86       37        10 4
‡ Protein concentrations during complex formation.
¶ For Exp. 16 protein S was first incubated with C4Bbp for 10 min., followed by a 10 min. incubation
with b2gpI.
† Buffers used for incubations and subsequent gel-filtration chromatography. Buffer 1, 50 mM Tris-HCl
pH 7.5, 30 mM NaCl; Buffer 2, TBS; Buffer 3, 5 mM Tris-HCl pH 7.5, 15 mM NaCl, 10 mM CaCl2;
Buffer 4, TBS, 10 mM CaCl2; Buffer 5, 15 mM Tris-HCl pH 7.5, 125 mM NaCl, 10 mM CaCl2, 200 nM




Molecular-weight analyses of free proteins and qualitative analyses of protein-protein
complexes by means of gel-filtration chromatography was performed with a Superdex 200
HR 10/30 column (volume 24.0 ml, void volume 7.6 ml) (Pharmacia Biotech, Uppsala,
Sweden). Protein solutions were applied to the column using a 200-ml loop. All runs were
performed with a flow of 1 ml min-1 and a recorder speed of 0.5 cm ml-1. Elution of free
proteins and complexes was monitored with absorption measurements at 280 nm. Runs were
performed with free b2gpI (pool A), free b2gpI *1 (pool B), 22F6, CaM, protein S, APC and
C4Bbp, for comparison with elution volumes Ve of complexes. After applying to the gel-
filtration column low-affinity complexes will possibly rapidly dissociate due to dilution of
complex and due to separation of protein-protein complexes from the free proteins,. As a
consequence these low-affinity complexes, which may be initially present in the applied
solution, can not be detected. Th refore, for detection of low-affinity complexes, gel-
filtration experiments were performed with elution buffers that contained an excess of one of
the proteins. To prevent dissociation of b2gpI-CaM complexes, 200 nM CaM was present in
elution buffer 5 (Table II, Exp. 9). Binding of CaM to b2gpI *1 was also tested with elution
buffer 5. To prevent dissociation of complexes of b2gpI with protein S or with APC, 100 nM
b2gpI was present in buffer 6 (Exp. 12, 14). Concentrations of CaM and b2gpI in the elution
buffers were based on their approximate concentrations on the Superdex 200 column during
a gel-filtration run.
Table III
Qualitative analyses of protein-protein interactions
Exp.
         Peak 1§
Ve                  protein
         Peak 2
Ve                   protein
1 12.6               22F6 13.6                b2gpI
2 10.2               complex¶ 13.6                b2gpI
3 13.6               b2gpI 15.4                CaM
4 13.6               b2gpI 15.4                CaM
5 13.6               b2gpI 15.4                CaM
6 13.6               b2gpI 15.4                CaM
7 13.6               b2gpI 15.4                CaM
8 13.6               b2gpI 15.4                CaM
9 13.6               b2gpI 15.4                CaM
10 12.4               protein S 13.4                b2gpI
11 12.4               protein S 13.4                b2gpI
12 12.8               protein S 13.5                b2gpI
13 13.4               b2gpI 13.4†               APC
14 13.6               b2gpI 13.6†               APC
15 8.0                 C4Bbp 13.4               b2gpI
16 8.1                 complex‡ 13.4               b2gpI
17 8.1                 complex‡    -
18 12.5               protein S 14.0               APC
§ The elution volume Ve (in ml) of the peak and the protein that has been assigned to the
peak are listed.
¶ Complex between b2gpI and 22F6.
† The Ve’s of free b2gpI and free APC are similar and, therefore, these proteins are hardly
separated on the column, resulting in a broadened peak that contains both proteins.




Analysis of complexes in solution
In Table I elution volumes Ve of free proteins that are used for complex formation are listed.
b2gpI elutes at 13.6 ml, indicating an apparent molecular weight (MW) of approximately 60
kDa. Mass spectrometry with b2gpI revealed a MW of 45 kDa250. Elution of b2gpI as a
protein with a higher MW is likely due to the elongated non-globular shape of the
molecule250. C4Bbp elutes at 8.0 ml, in agreement with its MW of 570 kDa (maximum MW
for fractionation on the column used is 600 kDa). Binding characteristics of b2gpI towards
22F6, CaM, protein S, APC, C4Bbp, or a mixture of protein S and C4Bbp, as observed after
molecular-weight analyses with gel-filtration chromatography, are summarized in Table III
and Fig. 1-3.
Fig. 1. Gel-filtration of b2gpI-22F6 complex. (A) In the presence of 30 mM NaCl 22F6 does not bind
to b2gpI (Exp. 1). The peak at a Ve of 7.8 ml is assigned to aggregates of 22F6. (B) At 150 mM NaCl a
stable complex between b2gpI and 22F6 is formed, whereas no 22F6 aggregates are present (Exp. 2).
Fig. 2. b2gpI-CaM complex is not detected with gel-filtration chromatography. Low-affinity
complexes between b2gpI and CaM were not formed when CaM was continuously present at a
concentration of 200 nM during gel filtration (Exp. 9). The small peak at a Ve of 7.8 ml is ascribed to
b2gpI and/or CaM aggregates.





































b2gpI did not bind to 22F6 in the presence of 30 mM NaCl (Fig. 1A). A peak at a Ve of 7.8
ml indicated that again part of 22F6 was aggregated. At a physiological concentration of 150
mM NaCl the b2gpI-22F6 complex was formed and no aggregates were observed (Fig. 1B).
The elution volume of 10.2 ml of the b2gpI-22F6 complex corresponds to a molecular
weight of approximately 300 kDa, indicative for a 2:1 stoichiometry.
Fig. 3. Interactions of b2gpI and proteins that function in the APC-dependent anticoagulant
cascade. In A, B and E small peaks at a Ve of 7.8 ml are present that likely originate from aggregated
protein(s). (A) b2gpI did not complex with APC, irrespective of the continuous presence of 100 nM
b2gpI during gel filtration (Exp. 14). Peaks of b2gpI and APC are not base-line separated due to similar
MW’s. (B) Neither high-affinity, nor low-affinity complexes between b2gpI and protein S were
observed with gel-filtration chromatography. The chromatogram shows elution of b2gpI and protein S
after mixing the proteins in a molar ratio of 10:1 (Exp. 12). (C) Major amount of b2gpI does not form a
complex with C4Bbp (MW of 570 kDa). The peak at a Ve of 8.1 ml corresponds to elution of free
C4Bbp (See Table I) but may contain a small fraction of b2gpI that putatively formed a high-affinity
complex with C4Bbp (fractionation limit of the Superdex 200 column is 600 kDa) (Exp. 15). (D) b2gpI
had no noticeable influence on pre-formed protein S-C4Bbp complex. Protein S and C4Bbp solutions
were mixed prior to addition of a 1.4-times molar excess of b2gpI (Exp. 16). The protein S-C4Bbp
complex elutes at a Ve of 8.1 ml, similar to free C4Bbp. (E) Protein S and APC do not form a high-
affinity complex in solution, whereas formation of a low-affinity complex is not excluded (Exp. 18).
Calmodulin
CaM did neither bind with high affinity to b2gpI (Table II, Exp. 3-9 and Fig. 2), nor to b2gpI
*1 (not shown). Lowering the NaCl concentration from 150 mM to 15 mM did not induce
complex formation (Exp. 3-4). Presence of a molar excess of, either b2gpI or CaM had no
























present in the buffer during gel filtration (Exp. 9), no low-affinity binding between b2gpI
and CaM was detected. Very low signal of CaM at 280 nm results from the low content of
aromatic amino-acid residues, i.e. two tyrosines are present in the CaM sequence, and the
absence of disulfide bonds.
Activated protein C, protein S and C4B binding protein
Protein S readily formed a stable complex with C4Bbp (Table III, Exp. 16-17). Effective
binding of protein S to C4Bbp was shown by complete absence of the protein S peak at a Ve
of 12.3 ml. When b2gpI was incubated with, either APC, or protein S, or C4Bbp no high-
affinity binding was observed (Exp. 10-16, Fig. 3A-C). Exp. 15 does not exclude that a
minor amount of b2gpI is complexed with C4Bbp. Like the C4Bbp-protein S complex (Fig.
3D), a peak resulting from b2gpI-C4Bbp complex may be covered by the peak resulting
from the excess of free C4Bbp. Low-affinity complexes between b2gpI and protein S or
APC were not detected when a molar excess of b2gpI was present in the gel-filtration buffer
(Exp. 12 and 14). The results of Exp. 16 show that all protein S is still bound to C4Bbp after
introduction of b2gpI (Fig. 3D). In solution protein S did not bind with high affinity to APC
(Exp. 18, Fig 3E), whereas putative low-affinity complex could not be detected with the
system used, i.e. none of the two proteins was added to the elution buffer during gel
filtration.
Discussion
High-affinity (b2gpI)2-IgG 22F6 complex
b2gpI forms a high-affinity divalent complex with murine IgG 22F6, when b gpI is
immobilized253. Complexes tightly bound to an anionic lipid surface whereas 22F6 alone did
not bind to lipids. These observations indicated that the antibody-binding site on b2gpI is
located distant from the membrane-adhesion site in the fifth C-terminal SCR domain of
b2gpI. 22F6 was characterized as an LA based on its capacity to prolong phospholipid-
dependent clotting assays. We now demonstrated that b2gpI and 22F6 also form high-
affinity complexes in solution (Fig. 1B). Apparently, b2gpI does not necessarily need to
adhere to lipid layers, prior to complex formation with LA’s. This suggests that thrombotic
complications in the APS may not only be caused by (b2gpI)2-auto-antibody complexes that
shield catalytic lipid surfaces, which are essential for anticoagulant processes150,229.
Additionally or alternatively, coagulation disorders may be caused by inhibited formation of
b2gpI-protein ligand complexes upon formation of b2gpI-auto-antibody complexes.
b2gpI-CaM complex
Renal filtered b2gpI is partially associated with lipid layers90. Once excreted into kidney
cells, b2gpI is actively transported back into the circulation by renal endocytic transporter
megalin93. In vitro, b2gpI has been shown to interact with the cellular regulator CaM when
both proteins are in solution or when CaM was immobilized (Ref. 90, 91; M. Simmelink,
unpublished results). These observations may suggest that binding of CaM to b2gpI can play
a role in transport of renal-filtered b2gpI back into the circulation by megalin.
Our gel-filtration chromatography experiments revealed that high-affinity b2gpI-
CaM complexes are not formed in solution. Even in the continuous presence of a molar
excess of CaM on the gel-filtration column, the complex between b2gpI and CaM was not
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detected (Fig. 2). This suggests that CaM has at most very low affinity for b2gpI when both
proteins are in solution, in contradiction with the previously reported Kd of 3 nM for
complex formation in solution91. The low Kd, that implies very tight binding, was determined
from fluorescence measurements and competitive immuno-precipitations. Apparently, these
methods gave an overestimated value for the Kd. If not, the reported high affinity of CaM for
b2gpI would have resulted in detectable amounts of complex in our assay. Binding of b2gpI
to CaM in an ELISA set-up (M. Simmelink, unpublished data) or on a CaM-affinity
column90 may indicate that in vivo immobilization of b2gpI at a lipid surface is a necessary
step prior to binding of CaM.
Amino-acid residue Trp53 of b2gpI has previously been indicated to be involved in
interaction with CaM91. Furthermore, peptide KPGYVSRGGMRKFI corresponding to
amino-acid residues 33-46 of b2gpI strongly inhibited binding of b2gpI to CaM, suggesting
that these residues are also involved in interaction with CaM. According to Rojkjaer et al.,
sequence 33-46 in b2gpI potentially forms a basic amphiphilic a-helix, either intrinsically, or
upon binding of CaM. Such a helix would be a typical binding site for CaM. However, the
crystal structure of b2gpI shows that residues 33-46 are part of a structurally rigid entity of
the N-terminal SCR domain250. These residues take part in two b-sheets that are fully
conserved amongst known SCR-domain structures. Therefore, conformational rearrangement
of three b-strands, in order to facilitate formation of an a-helix upon CaM binding, seems
very unlikely. Trp53 is, in addition, completely buried in the hydrophobic core of the N-
terminal SCR domain and is one out of nine highly conserved residues amongst SCR
domains. Exposure of Trp53 upon binding of CaM seems, therefore, also rather unlikely.
Cationic amino-acid residues of b2gpI are important in CaM binding and the local
environment of at least one Trp residue is influenced by binding of b2gpI to CaM91. These
observations strongly suggest that the extreme negatively charged surface of CaM,
comprising 17 Asp and 21 Glu amino-acid residues (pdb code 1CLL, Ref. 263), may, in an
alternative way, interact with the positively charged membrane-adhesion patch on the surface
of the fifth SRC domain of b2gpI (12 Lys, 1 Arg, 1 His). Fully exposed Trp316 of b2gpI,
that is positioned close to the positively charged patch, then, possibly accounts for the
observed change in Trp fluorescence.
In our alternative model for b2gpI-CaM complex formation, the membrane-
adhesion site of b2gpI coincides at least partly with the CaM-binding site. Therefore, we
suppose that binding of CaM to b2gpI may interfere with adhesion of b2gpI to phospholipid
layers in the kidney and/or may release membrane-bound b2gpI. Freely circulating b2 pI-
CaM complexes in the kidney cells, then, may facilitate transport of b2gpI back into the
circulation by megalin93.
Binding of b2gpI to regulators of the protein C-dependent anticoagulant pathway
b2gpI has pro- and anticoagulant activity105,123,248,249,252,264. The ability of b2gpI to prolong or
shorten coagulation time has previously been explained by a passive and aspecific
mechanism in which b2gpI shields the catalytic surface for coagulation reactions by
adhesion to anionic phospholipid layers150,229. Recent reports on binding of b2gpI to
activated protein C, protein S and C4B binding protein, that function in the APC-dependent
anticoagulant pathway, suggested an additional or alternative active and more specific role
for b2gpI in coagulation83-85. M. Simmelink confirmed binding of b2gpI to protein S in an
ELISA, whereas binding to C4Bbp or to APC was not observed (unpublished results). To
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gain more insight into these conflicting results, we have chosen for an assay system that
enabled us to directly detect b2gpI-protein complexes in solution.
With gel-filtration chromatography we did not detect high-affinity complexes (Fig.
3A) or low-affinity complexes between APC and b2gpI. Putatively, efficient and specific
binding of APC to b2gpI as observed by Sim and Devine (85), only occurs when, either
APC, or b2gpI is bound to a suitable lipid surface in vivo, thereby creating a high local
concentration of one of the components in the protein-protein complex. Immobilization of
b2gpI in an ELISA set-up may mimick adhesion to lipids, whereas affinity of b2gpI for APC
may be too low for complex formation in solution. The in vivorol of b2gpI-APC complexes
bound to lipid layers is yet unknown. Pr tein S and APC also did not form complexes in
solution (Fig. 3E), suggesting that they may need to adhere to a lipid surface prior to
complex formation, like we propose for formation of APC-b2gpI complexes.
The studies of Atsumi et al. (83), Merrill et al. (84) and M. Simmelink (unpublished
results) suggested a regulatory role for b2gpI-protein S complex in preventing inhibition of
protein S activity in APC-dependent anticoagulation by the circulating protein S-inhibitor
C4Bbp. Maintenance of the level of free protein S requires high-affinity binding between
b2gpI and protein S to effectively prevent formation of very stable C4Bbp-protein S
complexes. When we incubated a ten-times molar excess of free b2gpI with free protein S, a
molar ratio that resembles physiological conditions, no complex was formed, irrespective of
the continuous presence of b2gpI during gel filtration (Exp. 10-12, Fig. 3B). In addition,
b2gpI had no influence on previously formed protein S-C4Bbp complex (Fig. 3D). These
results do not support a suggested role for b2gpI as an anticoagulant by regulating free
protein S levels upon binding to protein S. Our experiments did, however, not exclude that a
small amount of b2gpI has bound with high affinity to C4Bbp. Binding of b2gpI t  C4Bbp in
plasma may, in an alternative way, prevent a small fraction of protein S for complex
formation with C4Bbp, that in turn may be a sufficient amount for proper functioning in the
anticoagulant cascade.
--- Chapter IV ---
Inactive b2-glycoprotein I carries a
neutral phospholipid molecule
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Human plasma b2-glycoprotein I (b2gpI) adheres to anionic phospholipids and is
implied in blood coagulation, in removal of apoptotic bodies from the circulation and in
the auto-immune disease anti-phospholipid syndrome. An isoform of b2gpI that does
not bind to anionic lipids, accumulates in man during severe oxidative stress, i.e. during
sepsis, drowning and after streptokinase treatment of myocardial infarction. We
analyzed this isoform by biophysical and crystallographic methods. With gas
chromatography-mass spectrometry and with thin-layer chromatography we revealed
that the isoform has phosphatidylcholine or choline plasmalogen and, to a lesser extent,
sphingomyelin bound. The crystal structure of the b2gpI-lipid complex at 3.0 Å
resolution indicated a binding pocket for a glycerophosphorylcholine moiety located
within the adhesion site for anionic membranes. The specific binding site shows minor
structural rearrangements to fit a neutral phospholipid, when compared with the
structure of intact b2gpI. C-terminal amino-acid sequence analysis confirmed cleavage
of scissile bond Lys317-Thr318 and revealed that sequence Phe315-Trp-Lys317, which
is essential for lipid binding, was not released from the isoform, excluding additional
cleavage of scissile bond Ala314-Phe315. Furthermore, sequencing showed that
genetically determined mutation Trp316Ser, which abolishes membrane adhesion, was
not present in the pool of b2gpI used for our analyses. Carbohydrate analysis and mass
spectrometry with the b2gpI isoform and intact b2gpI revealed that similar numbers of
sialic acid residues were present and that these isoforms were fully glycosylated at their
four N-glycosylation sites. Therefore, reduced glycan content or putative absence of
sialic acid residues do not account for abolished lipid affinity of the isoform. The crystal
structure of the b2gpI-lipid complex and the biophysical data suggest that specific
binding of a neutral phospholipid blocks adhesion of b2gpI to anionic lipids. The b2gpI-
lipid complex with its abolished membrane-adhesion ability may play a role in specific
defense mechanisms during periods of oxidative stress.
Key words: apolipoprotein H, beta2 glycoprotein I, carbohydrate analysis, choline plasmalogen, crystal structure,
inactive isoform, membrane adhesion, oxidative stress, phosphatidylcholine, phospholipid binding, sphingomyelin,
thin-layer chromatography
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Introduction
Human b2-glycoprotein I (b2gpI)a is a heavily glycosylated plasma protein that has affinity
for negatively charged surfaces. b2gpI is implied in a variety of processes in which its
adhesion to anionic lipids is an important aspect. It has proposed functions in pro- and
anticoagulant processes84,85,106,121,123,124,248,249. Noteworthy, several roles for b2gpI in
coagulation were suggested by in vitro experiments120,128,249, whereas b2gpI deficiency seems
not to influence these activities n vivo30,31. b2gpI has also been implicated in clearance of
apoptotic bodies64,131,133,265 and non-self particles68 from the circulation. Recent determination
of a specific b2gpI-independent receptor for clearance of apoptotic cells has prompted doubt
on the proposed role that non-discriminatory binding of b2gpI to anionic lipids may play in
clearance of apoptotic bodies136. b2gpI is a key antigen in the auto-immune disease anti-
phospholipid syndrome (APS), defined by thrombo-embolic complications and recurrent
fetal loss116. Additionally, b2gpI is implicated in responses to oxidative stress32,118,119,266,267.
b2gpI mainly circulates free in blood while 4-13% of the molecules is associated with
lipoproteins62,94,268, which bind with high affinity after oxidation266,268. b2gpI has affinity for
negatively charged lipids phosphatidylserine (PS), phosphatidic acid and cardiolipin71,
present in e.g. lipoproteins, chylomicrons61,65,72, blood platelets66,67, liposomes68, and
apoptotic bodies135.
The phospholipid-binding site of b2gpI has been mapped to the fifth C-terminal
short concensus repeat (SCR) domain75. Based on the crystal structure of human b2gpI and
on additional biochemical data we proposed a membrane-adhesion model250. A large
positively charged patch forms a membrane-adhesion site on the fifth SCR domain that
provides electrostatic interactions with anionic phospholipid head-groups. The exposed
membrane-insertion loop Leu313-Ala-Phe-Trp-Lys317 yields specificity for phospholipid
layers. This synergistic model is supported by studies that revealed both the hydrophobic
interactions and the electrostatic interactions77,78. Two co-factors in coagulation, factor Va
and factor VIIIa regulate their binding to anionic phospholipids in a reminiscent way269-271.
Activity of b2gpI in apoptosis, APS and blood coagulation depends on its ability to
adhere to negatively charged lipid surfaces68,111,116,123,131. Affinity of b2gpI for these anionic
phospholipids is affected by the content of sialic acid (Neu5Ac) residues of the four N-
glycans69,262 and by enzymatic cleavage of scissile bonds Ala314-Phe315 and Lys317-Thr318
in the fifth SCR domain76,80. Asialo-b2gpI, containing less negative charges, has lower
affinity for anionic phospholipids than fully sialydated b2gpI. Scissile bonds between
residues Ala314-Phe315 and between Lys317-Thr318 likely induce conformational
flexibility of the membrane-insertion loop, resulting in reduced affinity of ‘cleaved’ b2gpI76
for anionic membranes. Simultaneous cleavage of both scissile bonds will release the
membrane anchor Trp316-Lys317, which provides specificity for anionic phospholipids.
b2gpI carrying genetically determined mutation Cys306Gly52 or Trp316Ser52,53 also has
                                                 
a Abbreviations used: APS, anti-phospholipid syndrome; b2gpI, b2-glycoprotein I; CP, choline plasmalogen; ELISA,
enzyme-linked immuno-sorbent assay; Fuc, fucose; GalNAc, N-acetylgalactosamine; GC-MS, gas-liquid
chromatography-mass spectrometry; GlcNAc, N-acetylglucosamine; MALDI TOF MS, matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry; Man, mannose; PC, phosphatidylcholine; Neu5Ac, N-acetyl
neuraminicacid (sialic acid); PS, phosphatidylserine; r.m.s., root-mean-square; SCR, short concensus repeat; SM,




decreased affinity for negatively charged lipids. b2gpI mutant Trp316Ser lacks the Trp that
provides specificity for phospholipids to the membrane-insertion loop Leu313-Ala-Phe-Trp-
Lys317. b2gpI mutant Cys306Gly lacks disulfide bond Cys287-Cys306 that is essential for
conformational stability of the fifth SCR domain. Furthermore, site-directed mutagenesis
studies showed the importance of residues Ly 284, Lys286, Lys287, Leu313 and Phe315 in
adhesion of b2gpI to anionic layers34,79.
Recently, Horbach et al. (32) described a novel isoform of human b2gpI, designated
‘b2gpI *1’, which was present in plasma of patients with sepsis, after streptokinase treatment
of myocardial infarction, and after rescue from drowning, i.e. patients that had been
subjected to severe oxidative stress. An isoform with so far identical characteristics was
formed in vitro, under influence of a proteinase and an undetermined plasma component,
from b2gpI that was isolated from plasma of healthy human individuals. This isoform does
not bind to anionic phospholipids and has a cleaved scissile bond at Lys317-Thr318.
Furthermore, the isoform is specifically recognized by murine monoclonal antibody 13A10.
In plasma of healthy individuals the level of b2gpI *1 is approximately 0.1 mg ml-1, whereas
the level increases ten- to hundred-fold in plasma of patients. During sepsis and in plasma of
a patient rescued from drowning an increased concentration of the isoform was accompanied
with a 50% decreased level of intact b2gpI. Horbach et al. (32) suggested that this decrease
may result from binding of intact b2gpI to apoptotic bodies, that are abundantly generated
during sepsis and subsequently cleared from the circulation. They also speculated that a
decreased level of intact b2gpI may be due to accelerated formation of the new isoform
during stress in vivo, that might be a prerequisite for clearance of this modified b2gpI from
the circulation.
In the present study we focussed on the underlying structural differences between
human intact b2gpI and the new isoform b2gpI *1, that may account for the observed
differences in affinity for anionic lipid layers. With C-terminal amino-acid sequencing we
checked for cleaved scissile bonds and for the potential presence of the genetically defined
mutation Trp316Ser. Putative differences in carbohydrate composition were analyzed with
gas-liquid chromatography (GC). Subsequent mass spectrometry (MS) was performed to
identify peaks in the gas chromatogram of b2gpI *1 that could not be assigned to glycan
moieties. Thin-layer chromatography (TLC) was used for analysis of lipids that were bound
to b2gpI isoforms. We determined the crystal structure of the new isoform of b2gpI to define
the potential location of the binding site(s) for neutral phospholipids and to establish whether
conformational alterations have occurred that may cause declined lipid affinity.
Methods
Characterization of b2gpI purified from human plasma
The three b2gpI isoforms, i.e. intact b2gpI, ‘cleaved’ b2gpI76, and isoform b2gpI *1 (Ref.
32) were purified as described by Horbach et al. (242) from two pools of blood plasma, each
from three healthy human donors (Dutch Blood Bank, The Netherlands). Purified b2gpI was
characterized with ELISA’s using two antibodies: murine monoclonal antibody 13A10 that
has specificity for isoform b2gpI *1, and phage-display scFv-antibody fragment F3 that has
specificity for intact b2gpI (i.e. with intact Lys317-Thr318 peptide bond). N-terminal amino-
acid sequences of the b2gpI isoforms were also analyzed. Intact b2gpI has one N-terminus
starting with NH2-Gly1, whereas cleaved b2gpI and isoform b2gpI *1 have an additional N-
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terminus starting with NH2-Thr318, due to enzymatic cleavage of scissile bond Lys317-
Thr318. Additionally, the isoforms were checked for their lipid affinity in an ELISA set-up.
Intact b2gpI shows relatively high affinity for an anionic lipid layer, cleaved b2gpI has
decreased affinity, whereas b2gpI *1 can not bind to lipids.
One pool of plasma (‘pool A’) was used to purify intact b2gpI. However, after
storage of the purified material over six months, presence of N-terminal amino-acid sequence
starting with NH2-Thr318 showed that half of the b2gpI molecules was cleaved at Lys317-
Thr318. Significant binding of both 13A10, as well as of F3 was observed at this stage.
Material of this purified batch, that contains a mixture of b2gpI isoforms, was previously
used for crystal-structure determination reported by Bouma et al. (250). The second pool
(‘pool B’) was used to purify the three separate forms intact b2gpI, cleaved b2gpI and b2gpI
*1. The latter isoforms were initially not present but were formed during purification. N-
terminal sequence analysis and ELISA’s with intact b2gpI using 13A10 and F3 confirmed
that this form was not cleaved at Lys317-Thr318. Solutions of purified b2gpI isoforms were
stored in Tris-buffered saline (TBS).
C-terminal amino-acid sequencing
The C-terminal amino-acid sequence of b2gpI *1was determined with automated C-terminal
sequencing. It was performed by Eurosequence (Groningen, The Netherlands) with an
Automated Sequenator model 477A (Applied Biosystems, CA, USA). For analysis 2.1 nmol
lyophilized b2gpI *1 in TBS was used. Before lyophilization, b2gpI *1 was incubated for 60
min. at 37°C with 150 mM dithiothreitol to reduce disulfide bonds.
Carbohydrate analysis
Carbohydrate analysis was performed by GC-MS272,273. For the analyses, 2.8 nmol b2gpI
(pool A), 3.3 nmol intact b2gpI, two times 1.5 nmol cleaved b2gpI, and 3.3 nmol and 8.8
nmol of isoform b2gpI *1, all from pool B, was used. Samples were desalted before use and
10 nmol internal standard (mannitol) was added. Each sample was lyophilized and dried over
P2O5. Methanolysis was performed with 0.5 ml of 1.0 M methanolic-HCl for 24 h at 85
oC.
After cooling to room temperature, solutions were neutralized with solid silver carbonate.
Acetic anhydride (20 ml) was added for re-N-acetylation (24 h at room temperature). After
centrifugation (3 min. at 2500 rpm), supernatants were collected. The residue of silver salts
was washed twice with 0.5 ml of dry methanol. Pooled supernatants were evaporated under
reduced pressure. The residue was dried over P2O5. Finally, samples were trimethylsilylated
for 30 min. at room temperature with 50 ml of a mixture of pyridine, hexamethyldisilazane
and chlorotrimethylsilane (volume ratio of 5:1:1). Quantitative analysis of trimethylsilylated-
(methylester)methyl glycosides was carried out by GC-MS using a Fisons Instruments GC
8060 / MD 800 System (Interscience, Ontario, Canada). The GC column was a CP-Sil 5 CB
of 25 m x 0.25 mm (Varian Chrompack Benelux, Bergen op Zoom, The Netherlands) and the
temperature program was 140 to 240oC at o min.-1. Molar ratios of fucose (Fuc), xylose
(Xyl), mannose (Man), galactose (Gal), glucose (Glc), N-acetylgalactosamine (GalNAc), -
acetylglucosamine (GlcNAc) and Neu5Ac were calculated. The molar ratio of Man residues
was normalized to 3, based on the presence of three Man units in the most common N-glycan
core structure attached to plasma glycoproteins, i.e. (Ma -)(Man-)Man-GlcNAc-GlcNAc-
Asn (Fig. 1). Whether the core glycan structures are di-, tri- and tetra-antennary branched can
be deduced from the relative contents of GlcNAc, Man, and Gal units in a preparation of
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b2gpI. Peaks in the gas chromatogram of b2gpI *1 that could not be assigned to sugar
residues were subsequently analyzed with MS (F sons Instruments GC 8060 / MD 800
System, Interscience, Ontario, Canada).
Molecular masses of the mixture of b2gpI isoforms from pool A and of cleaved b2gpI and
b2gpI *1 from pool B were measured with matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI TOF MS; Ref. 274, 275). The average glycan content
of the b2gpI isoforms can be deduced from the measurements and from the calculated
molecular mass of b2gpI based on amino-acid residues only (36.3 kDa)40.
Fig. 1. Isoforms of b2gpI have, on average, three di-antennary N-linked carbohydrate structures
attached and one tri-antennary structure. These N-glycans are partially fucosylated and partially
desialylated, with on average one or two sialic acid residues cleaved off from the four antennae. (A) Di-
antennary N-linked carbohydrate structure. (B) Tri-antennary N-glycan. (C) Electron-density
accounting for the N-glycan attached to Asn143 of b2gpI *1. The 2|Fo|-|Fc| map at 3.0 Å resolution is
contoured at 0.7 s  The partially visible N-glycan forms bridging crystal contacts between Gly1' and
Thr130" of two separate symmetry-related molecules.
Lipid analysis
Aliquots of 10 nmol b2gpI (pool A), 9.3 nmol intact b2gpI and 10 nmol and 5 nmol b2gpI *1
from pool B were used for qualitative lipid analysis by TLC. Lipid extraction was performed
according to the protocol described by Bligh and Dyer (276). After extraction lipids were
dried under a nitrogen flow, dissolved in 50 ml of chloroform, and loaded on silica gel
HPTLC-Fertig plates (Merck, Darmstadt, Germany). Reference lipids lyso-
phosphatidylcholine (l-PC), sphingomyelin (SM), PS, PC, phosphatidylglycerol and
phosphatidylethanolamine were from Sigma Aldrich (Zwijndrecht, The Netherlands). The
mobile phase was chloroform-water-methanol (65:4:25 v/v/v). After approximately 30 min.
A       B
 Neu5Ac-Gal-GlcNAc-Man                Neu5Ac-Gal-GlcNAc-Man
   |                  |
                                Man-GlcNAc-GlcNAc-Asn            Man-GlcNAc-GlcNAc-Asn
                     |        |                  |      |
 Neu5Ac-Gal-GlcNAc-Man     Fuc                Neu5Ac-Gal-GlcNAc-Man              Fuc
    |
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of migration plates were stained with iodo vapor, ninhydrin(Merck, Darmstadt, Germany),
phosphor reagent Molybdenum Blue (Sigma Chemical Co., St. Louis, MO, USA) and by
heating in the presence of sulfuric acid.
Crystallization and X-ray data collection
Crystallization trials with isoform b2gpI *1 were performed with protein concentrated to 9
mg ml-1. The hanging-drop vapor-diffusion method at 4°C w s used with set-ups of 2 ml
protein solution and 2 ml reservoir solution over 750 ml reservoir solution. The crystallization
condition was as described before (Ref. 259; pdb code 1QUB), i.e. 1.5 M (NH4)2HPO4, 0.1
M NaOAc pH 5.6. Crystals with a pyramidal shape grew within 10 days in space group
C2221, like 1QUB, and had a size of approximately 0.3x0.4x0.4 mm
3. Unit-cell dimensions
were also similar to those reported for b2gpI 1QUB and the crystals contained one b2gpI
molecule in the asymmetric unit. X-ray diffraction data were collected using a crystal that
was equilibrated for 20 sec. in 1.65 M (NH4)2SO4, 35% v/v glycerol, 20 mM HEPES pH 7.5,
and that was subsequently frozen in a gaseous nitrogen stream at 100 K. X-ray data were
collected on beam line ID14-EH1 (European Synchrotron Radiation Facility (ESRF),
Grenoble, France) using a MarCCD detector. Data collection was aided by use of
STRATEGY244. Data were processed and scaled using DENZO and SCALEPACK26. See
Table I for data-collection statistics.
At an early stage, a data set was collected from another crystal of b2gpI *1, on
beam line ID14-EH3 (ESRF, Grenoble, France). This first data set was subjected to radiation
damage. Comparison of data sets collected at ID14-EH1 and -EH3, with respect to effects of
non-specific and specific radiation damage on data quality and on the refined structure of
b2gpI *1, is described in the App ndix to this chapter.
Table I
Diffraction-data statistics and structure-refinement statistics
Data statistics† Refinement statistics
Resolution (Å) 36.0 – 3.0 Resolution (Å) 36.0 – 3.0
Mosaicity (º) 0.71 R-factor/Rfree 0.238/0.260
Space group C2221 r.m.s.d. bond distances (Å)0.008
Unit cell: ab c (Å) 159.0 165.9 115.0r.m.s.d. angles (º) 1.4
Redundancy 4.9 Average B-factor (Å2)¥ 60
No. unique reflections30,789 Solvent content (%) 86
<I>/<s(I)> 20.5 (6.0) No. non-hydrogen atoms2,709
Completeness (%) 99.4 (99.2) No. protein residues 318
Rmerge (%) 5.6 (21.4) No. sugar residues‡ 15
No. lipid molecules¶ 1
No. sulfate ions 4
No. solvent molecules 5
† Numbers in parentheses indicate statistics for the highest resolution shell (3.11-3.00 Å). Diffraction data were
collected on beam line ID14-EH1 of the ESRF (Grenoble, France).
¥ Average B-factor for all atoms in the model.
‡ Forty to sixty sugar residues are expected, based on MALDI-TOF MS.
¶ A glycerophosphorylcholine moiety is built into the structure. Acyl chains of the PC, CP or SM molecule were
not observed in the electron density.
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Crystal-structure refinement and interpretation
Rigid-body refinement, positional refinement and B-factor refinement, using the model of
b2gpI 1QUB250 was performed with CNS9. The initial model consisted of amino-acid
residues 1-310 and 318-326 and seven carbohydrate moieties. Carbohydrate antennae were
subsequently lengthened according to extended electron density in difference maps. Four
sulfate ions and a glycerophosphorylcholine moiety were built into the structure. Water
molecules were defined in difference maps, and B-factors and positions were refined with
CNS. The search criteria for water molecules were a peak height > 4.0 s, a distance of 2.5-
3.3 Å to the hydrogen acceptor or donor, and a B-factor smaller than 60 Å2. Rebuilding of
carbohydrates, the glycerophosphorylcholine moiety and parts of the protein structure was
aided by O16. Refinement used the maximum-likelihood algorithm29 and during refinement
cross validation was used. Bulk solvent correction was applied as calculated by CNS. The
model quality was checked with WHATIF17 and PROCHECK18. Electrostatic potentials
were calculated with GRASP246. Fig. 1C, 4A and 4B were generated with BOBSCRIPT277
and RASTER3D203. Fig. 3A was generated using MOLSCRIPT202 and RASTER3D. Fig. 3B
and 4C were generated using MOLSCRIPT.
Results
C-terminal amino-acid sequencing of isoform b2gpI *1
C-terminal amino-acid sequencing of isoform b2gpI *1 yielded a single sequence of COOH-
Lys317-Trp-Phe-Ala314. Cys326, corresponding to the C-terminus of the native sequence40,
was not observed, because cysteine residues are hardly detected by the sequenator used and
presence of a Pro residue at position 325 terminates the sequencing process, altogether.
Carbohydrate analysis
Molar ratios of carbohydrate-building blocks of the mixture of b2gpI isoforms from pool A
and intact b2gpI, cleaved b2gpI and isoform b2gpI *1 (pool B) were determined with GC
(See Table II). Molar ratios of Fuc, Man, Gal and GlcNAc residues were very similar for
intact b2gpI, cleaved b2gpI and b2gpI *1. The content of Fuc residues indicates that on
average one Fuc residue is attached to approximately 20% of the b gpI molecules. The
relative amounts of Man, Gal and GlcNAc residues indicate the presence of on average three
di-antennary carbohydrate structures (Fig. 1A) and one tri- or tri'-antennary structure (Fig.
1B), in accordance with previous findings43. The ialic acid residue content varied among the
three b2gpI isoforms from pool B, and correspond to the presence of nine, seven and eight
Neu5Ac residues for intact b2gpI, cleaved b2gpI and b2gpI *1, respectively. This observed
difference is, however, not significant. Carbohydrate antennae are intrinsically susceptible
for chemical cleavage of Neu5Ac residues. Variation in the degree of Neu5Ac cleavage
among the isoforms is potentially due to differences in treatment with respect to purification
and storage. The sialic acid residue content of the mixture of b2gpI isof rms isolated from
pool A was similar to the average content of Neu5Ac residues of the separate isoforms of
pool B, and corresponds to the presence of eight or nine Neu5Ac residues. GalNAc was
absent in all preparations of the b2gpI isoforms, indicating that O-linked carbohydrate
antennae278 were not attached. Xyl and Glc residues are a common contamination,
originating from column or filter material that was used during purification242. Apart from
peaks originating from carbohydrate residues, additional peaks in the gas chromatogram
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were observed in the preparation of the isoform b2gpI *1, which were absent for the other
isoforms. Subsequent MS analysis identified these peaks as C16:0-, C18:0-, C18:1-, C18:2-
acyl chains and putatively alkene C16H32.
MALDI TOF MS analysi of b2gpI isoforms revealed a mean molecular mass of 45
(± 2) kDa for cleaved b2gpI (pool B), isoform b2gpI *1 (pool B) and the mixture of isoforms
(pool A). This mass is similar to the molecular mass of approximately 43 kDa obtained with
gel electrophoresis32. Based on the MS analysis b2gpI contains approximately 9 kDa (~20%
w/w) N-glycans. Furthermore, the carbohydrate analysis revealed an (maximum) N-glycan
content of 18% w/w. The glycan mass is in agreement with the presence of partially
fucosylated and desialylated carbohydrates of which three are di-antennary structures (MW
1.8-2.6 kDa) and one is tri-antennary branched (MW 2.2-3.3 kDa), which is in












Man‡ 3 3 3 3
Fuc 0.2 0.2 0.2 0.1
GlcNAc 4.2 4.4 4.4 4.4
Gal 2.0 2.2 2.0 2.1
Neu5Ac¥ 2.2 2.4 1.7 2.0
GalNAc# 0.0 0.0 0.0 0.0
Xyl$ 0.3 0.1 0.3 0.2
Glc 0.4 0.2 0.6 1.0
† Carbohydrate contents are in molar ratios. Molar ratios for b2gpI (po l A), cleaved b2gpI and b2gpI *1 (pool B) are
averages over two, two and three analyses, respectively. In b2gpI *1 C16:0, C18:0, C18:1, C18:2 acyl-chains and
putatively alkene C16H32 were additionally present.
¶ b2gpI purified from plasma pool A consisted of a mixture of isoforms. The isoforms were purified separately from
plasma pool B.
‡ The molar ratio of Man was normalized to 3, based on the presence of three Man residues in the most common N-
glycan core in plasma glycoproteins. The relative contents of Man, GlcNAc and Gal are indicative for the presence of, on
average, three di-antennary carbohydrate structures and one tri-antennary structure43.
¥ Differences in sialic acid residue content among b2gpI isoforms purified from pool B are not significant. N-glycans are
highly susceptible for cleavage of the peripheral Neu5Ac residues. Differences in the degree of Neu5Ac cleavage among
the isoforms likely originate from differences in purification and storage.
# The absence of GalNAc indicates that O-glycans are not linked to the b2gpI isoforms278.
$ Xyl and Glc are a contamination originating from column and filter material used during purification of b2gpI.
Lipid extraction and thin-layer chromatography with b2gpI isoforms
Lipid extraction followed by thin-layer chromatography revealed two large spots for isoform
b2gpI *1 that co-migrated with PC and SM standards (Fig. 2). Spot 1 is far more abundant in
b2gpI *1 than spot 2, according to the relative intensities of the two spots using iodo staining
or spraying with phosphor reagent. Two weak spots were observed for the mixture of b2gpI
isoforms from pool A, that co-migrated with the two spots of b2gpI *1 and with PC and SM
standards. Rf values of the two spots and of reference phospholipids are given in Table III.
Both spot 1 and spot 2 were visible after staining with iodo vapor, with Molybdenum Blue,
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Fig. 2. Thin-layer chromatogram. Phospholipids were extracted from a mixture of b2gpI isoforms
purified from plasma pool A and from b2gpI *1 purified from plasma pool B. Lipids were
chromatographed in chloroform-water-methanol (65:4:25 v/v/v) and visualized with iodo vapor. Lane
1, lipids extracted from the mixture of b2gpI isoforms; 2, b2gpI *1; 3, PE/PG/PC; 4, PS; 5, PC/l-PC; 6,
b2gpI *1; 7, SM. Spot 1 from the mixture of b2gpI isoforms and b2gpI *1 co-migrates with the PC
standard, indicative for the presence of PC and choline plasmalogen, spot 2 co-migrates with SM.
Table III
TLC with phospholipids bound to b2gpI
Lipids in b2gpI¶ Rf† Standards‡ Rf
Spot 1 11 lyso-PC 8





¶ TLC analysis with b2gpI *1from plasma pool B and the mixture of b2gpI
isoforms from pool A revealed that these preparations have the same lipids
bound. Lipids were abundant in b2gpI *1, whereas only traces of lipids were
observed for the mixture of b2gpI isoforms. Phospholipids were not detected in
intact b2gpI.
† Rf is the migrated distance of the lipid spot on the TLC plate divided by the
migrated distance of the mobile phase.
‡ The Rf values of lyso-PC, PS, PC, PG and PE standards are averages over two,
four, four, two and two analyses, respectively. SM was analyzed once. PC co-
migrates with choline plasmalogens, which were putatively present.
phospholipids containing unsaturated acyl chains. The spots were not stained with ninhydrin,
excluding the presence of lipids that contain amino groups. PC and choline plasmalogens
(CP), which are PC analogues that contain an alk-1-enyl group instead of an alkyl moiety at
their sn-1 position279, co-migrate during one-dimensional TLC280,281. Therefore, spot 1, which
co-migrates with a PC standard, may in fact contain PC and/or choline plasmalogens. No
spots co-migrating with phospholipids were observed for intact b2gpI from pool B (not
shown). Cleaved b2gpI was not analyzed with TLC due to limited amount of protein.
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Crystal structure determination and analysis of b2gpI *1
The crystal structure of isoform b2gpI *1 was determined using the model of b2gpI 1QUB250
as a starting point for refinement. The structure has been refined to a final R-factor of 23.8%
and a free R-factor of 26.0% (5% of the data) using diffraction data to 3.0 Å resolution. The
structure displays good model geometry with 84% of the residues in most favored regions of
the Ramachandran plot and 16% in generously allowed regions. Statistics for the refined
model are given in Table I.
The overall structure of b2gpI *1 is identical to previously reported structures ( Ref.
250, 251; pdb code 1QUB, 1C1Z), showing the typical fish-hook like appearance (Fig. 3A).
We do not observe residues 310-317 in the electron density for b2gpI *1. This encompasses
the membrane-insertion loop 313-317 that provides specificity for anionic layers79,250.
Enzymatic cleavage of this solvent-exposed loop at scissile bond Lys317-Thr318 likely
results in mobility or disorder. Position of terminal Thr318, next to the cleavage site, is
defined by the electron density and appears fixed by a crystal contact with Glu259 of a
symmetry-related molecule. Electron density for the side chain of amino-acid residues
Lys59, Arg135, Lys138, Lys177, Lys250, Lys251, Lys284 and Lys286 is incomplete.
Additional density near Thr204/Tyr206 and near Tyr207 reveal that sulfate ions form
hydrogen bonds with hydroxyl groups of these amino-acid residues instead of being covalent
bound, as was suggested previously250. Two additional sulfate ions are built into the structure
near Arg191/His216 and near Lys208/Glu228, of which the latter two residues form an intra-
molecular salt bridge. B-factors of the four sulfate ions are relatively high and suggest partial
occupation or disorder.
Electron density near Asn143, Asn164, Asn174 and Asn234 allowed for building of




GlcNAc-(1à4)-b-D-GlcNAc-(1àN)-Asn234. In comparison, only seven and eleven
carbohydrate residues were incorporated in the b2gpI models 1QUB and 1C1Z, respectively.
Weak electron density near Thr130" and Gly1' of two symmetry-related molecule originates
from an extension of the N-linked glycan linked to Asn143 of a third symmetry-related
molecule (Fig. 1C). Electron density indicative of Fuc residues linked to GlcNAc-Asn was
not observed at any of the four N-glycosylation sites.
Weak non-continuous electron density was observed in a pocket in the fifth SCR
domain of b2gpI *1 (Fig. 4). The pocket is located in the center of the positively charged
patch, that forms the adhesion site for anionic layers, and is positioned next to the (cleaved)
membrane-insertion loop Leu313-Lys317 (Fig. 3A, 4C). The bottom of this pocket is formed
by Phe280, Phe307, the carbonyl oxygen of Lys308, and Asp319. The sides of the pocket are
lined by Ala252, Thr253, Gln264, Glu265 and Ser321. Its rim is formed by Lys251 and
Lys262, that are part of the membrane-adhesion site. The observed electron density inside
this pocket was putatively assigned to a glycerophosphorylcholine moiety of a phospholipid
molecule. The choline moiety is buried deeply inside the pocket, near aromatic residues
Phe280 and Phe307 and negatively charged Asp319. The phosphate is located close to
residues Thr253 and Gln264 and is putatively hydrogen-bonded to Og1 of Thr253 and Ne2 of
Gln264. The glycerol moiety of the phospholipid is located at the surface of the molecule
and is putatively hydrogen-bonded to Oe2 of Glu265. Acyl chains of the lipid molecule are
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Fig. 3. Structural representation of b2gpI *1. (A) Ribbon drawing of b2gpI *1 with SCR domains
labeled I-V. The glycerophosphorylcholine moiety of the bound neutral phospholipid is located in a
pocket in the fifth domain. The four N-linked glycans are indicated with ball-and-stick models.
Residues 310-317 are not observed in the electron density. (B) St reo drawing of the structural overlay
of Ca-atoms of the fifth SCR domain of b2gpI *1 (in gray, this work) and intact b2gpI 1C1Z (in black,
Ref. 251). Ca-atoms of amino-acid residues 245-309 and 318-326 are used in the superposition. The
overall fold of the fifth SCR domain is well conserved among the two models, despite the location of a
lipid molecule in the interior of the domain in b2gpI *1. This isoform is cleaved at scissile bond
Lys317-Thr318 likely resulting in high mobility of loop 310-317. The three disulfide bonds present in
the domain are represented with ball-and-stick models in the model of intact b2gpI.
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Fig. 4. A neutral phospholipid molecule is specifically bound in a pocket within the anionic
membrane-adhesion site of b2gpI *1. (A) Electron-density inside the specific binding pocket for a
neutral phospholipid, calculated with phases of the refined model, including the
glycerophosphorylcholine moiety. The 2|Fo|-|Fc| map at 3.0 Å resolution is contoured at 0.7 s. Electron
density accounting for the glycerophosphorylcholine moiety is weak and non-continuous, likely due to
mobility of the phospholipid and a low occupancy. (B) Difference electron-density inside the pocket
calculated with phases of the refined model omitting the glycerophosphorylcholine. The |Fo|-|Fc| map at
3.0 Å resolution is contoured at 2.5 s. The refined model of the glycerophosphorylcholine moiety is
shown for clarity. (C) Stereo drawing showing the residues of b2gpI *1 involved in
glycerophosphorylcholine binding. Side chains of amino-acid residues of b2gpI *1 that interact with




The final model of b2gpI *1 comprises amino-acid residues 1-309, 318-326, nine
GlcNAc residues, six Man residues, four sulfate ions and one glycerophosphorylcholine
moiety.
Comparison of b2gpI crystal structures
For the whole b2gpI *1 molecule root-mean-square (r.m.s.) coordinate differences of Ca-
atoms are 0.31 and 0.65 Å when compared with the crystal structures of b2gpI 1QUB and
b2gpI 1C1Z, respectively. For individual domains r.m.s. coordinate differences after
superimposing Ca-atoms are approximately 0.15-0.25 Å. Significant differences between
structures of b2gpI are restricted to the region of the membrane-insertion loop 313-317,
which is observed in 1C1Z, but which was not visible in b2gpI *1 and 1QUB (Fig. 3B).
b2gpI *1 and b2gpI 1QUB differ slightly in the position of residues His310 and Thr318 that
precede and follow the membrane-insertion loop, respectively. Electron density accounting
for His310 is not observed for b2gpI *1 and the position of Thr318 differ between the two
structures. Differences between structures of b2gpI *1 and of intact b2gpI 1C1Z are
restricted to the position of residues Gly1-Arg2, and to loop 310-317. In the crystal structure
of intact b2gpI 1C1Z this loop was not cleaved at Lys317-Thr318 and its position was
deduced from the electron density (Fig. 5). His310 forms an intra-molecular salt bridge with
Asp319 in 1C1Z. In b2gpI *1 residues 310-317 could not be located in the structure and the
salt bridge between His310 and Asp319 is, as a consequence, not observed. Structures 1QUB
and 1C1Z of b2gpI have different positions of His310, but in both structures this residue
forms a salt bridge with Asp319.
Structures of b2gpI *1 and of b2gpI 1QUB show weak non-continuous electron
density in the pocket that is located within the positively charged membrane-adhesion patch.
Structure factors of intact b2gpI 1C1Z251 were not made available by the authors upon
request and, therefore, we could not include analysis of the electron density in the pocket of
intact b2gpI 1C1Z in our comparison.
Electrostatic surface potentials of the membrane-adhesion site at the fifth SCR
domain, calculated from the b2gpI *1 and 1QUB models, are very similar, showing a large
positively charged patch (Fig. 5). In contrast, the electrostatic surface potential calculated
from the 1C1Z model shows a much smaller patch (Fig. 5B). The loop Lys282-Asn-Lys-Glu-
Lys-Lys287 and residues Lys308 and Lys324 yield a local potential that is common among
the three structures. Residues Lys246, Lys250, Lys251, Arg260, Lys262 and Lys266 enlarge
the large positively charged patch in b2gpI *1 and b2gpI 1QUB. The absence or presence of
the mainly hydrophobic loop Ser311-Ser-Leu-Ala-Phe-Trp-Lys317, which encompasses the
intact membrane-insertion loop 313-317, accounts for the observed differences.
Discussion
With the current study we aimed at characterizing human b2gpI *1 that has lost its ability to
adhere to anionic membranes. b2gpI *1 is formed in vitro during purification of b2gpI from
plasma of healthy human individuals under influence of an undetermined proteinase and an
unknown plasma component32. Based on abolished binding to negatively charged
phospholipids, specific recognition by antibody 13A10 and cleavage at scissile bond Lys317-
Thr318, Horbach et al. (32) reported similarity between the in vitro formed b2gpI *1 and an
isoform that was detected in patients who suffered from life-threatening oxidative stress. We,
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now, used b2gpI *1 that was formed in vitro for further biophysical and crystallographic
analyses.
C-terminal amino-acid sequence analysis confirmed that b2gpI *1 is cleaved at
Lys317-Thr318, and revealed that it is not additionally cleaved at Ala314-Phe315. Cleavage
at scissile bond Ala314-Phe315 would release residues Trp316-Lys317, that form the
specific anchor for anionic membranes250, d residue Phe315, that is, in addition, essential
for binding79. The determined C-terminal sequence COOH-Lys317-Trp-Phe-Ala314 also
implicates presence of a Trp at position 316, excluding the genetically determined mutation
Trp316Ser, which is present in part of the population. Heterozygotes carrying this mutation
show decreased binding of b2gpI to lipid layers, whereas lipid binding is inhibited in
homozygotes52,53. Thus, these data show that abolished membrane-adhesion ability of b2gpI
*1 is neither due to enzymatic release of sequence Phe315-Trp-Lys317, nor due to the
presence of a Ser residue at position 316.
Carbohydrate analysis revealed that b2gpI *1, cleaved b2gpI and intact b2gpI from
pool B and a mixture of these b2gpI isoforms from pool A contain very similar relative
amounts of the N-glycan building blocks Man, Gal, Fuc, GlcNAc, and Neu5Ac. In addition,
our analysis indicated that none of the b2gpI isoforms has O-glycans attached, in contrast to
previous results reported by Gambino et al. (44, 45). The relative amounts of Man, Gal and
GlcNAc units indicated that on average three di-antennary glycan structures and one tri-
antennary structure (See Fig. 1) are attached to the four N-glycosylation sites Asn143,
Asn164, Asn174 and Asn234 of b2gpI. MALDI TOF MS analysis revealed an identical
average N-glycan content of approximately 20% w/w for b2gpI isoforms, in agreement with
the total carbohydrate content of 18% w/w determined with GC-MS. Horbach et al. (32)
speculated that affinity of b2gpI for anionic lipids may be regulated by the degree of
glycosylation. However, the total glycan mass of 9 kDa indicated that each of the four N-
glycosylation sites of cleaved b2gpI and isoform b2gpI *1 was fully occupied with
carbohydrate antennae. Hagihara et l. (69) and Brighton et al. (262) have shown that
complete cleavage of peripheral sialic acid residues decreases affinity of b2gpI for anionic
lipids. Our carbohydrate analyses revealed that sialic acid residues are cleaved off to some
extent but that eight out of nine Neu5Ac are still present in the preparation of b2gpI *1
(Table II). Thus, our data show that reduced affinity of b2gpI *1 for lipid layers neither
results from variation in N-glycan content, nor from cleavage of Neu5Ac residues.
GC-MS analysis with carbohydrate preparations from b2gpI *1 pointed to the
presence of C16 and C18 acyl chains, likely originating from lipids or fat molecules. Alkene
C16H32 may originate from the alk-1-enyl group of CP or from part of the sphingosine group
of an SM molecule. TLC analysis confirmed the presence of PC/CP and SM in the b2gpI *1
preparation. In addition, with TLC these lipids were identified in the mixture of b2gpI
isoforms (pool A), that was used previously for the crystal structure determination reported
by Bouma et al. (250). In difference maps calculated with b2gpI *1 and b2gpI 1QUB weak
and non-continuous electron density was observed in a pocket in the fifth SCR domain (Fig.
4B). The pocket is located within the positively charged patch that forms the adhesion site
for anionic membranes (Fig. 5A), and next to the anionic-membrane insertion loop Leu313-
Ala-Phe-Trp-Lys317 (Fig. 3A, 5C). Density inside the pocket could account for a
glycerophosphorylcholine moiety. This indicates that the pocket is a potential binding site for
one neutral phospholipid molecule, i.e. SM, CP or PC. This binding site provides no
specificity for the two acyl chains of the neutral lipid, which point away from the protein
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surface. Aromatic residues Phe280 and Phe307 and negatively charged Asp319 are
positioned inside the pocket and provide specificity for the choline moiety in a way
reminiscent to commonly observed protein-choline interactions282,283. Similar phosphatidyl-
choline binding is observed for the Fab fragment of antibody McPC603 (Ref. 284; pdb code
2MCP), Staphylococcal LukF (Ref. 285; pdb code 3LKF) and human C-reactive protein
(Ref. 286; pdb code 1BO9). Apparently, b2gpI specifically binds a neutral phospholipid,
whereas it has a well-characterized specificity for lipid layers containing anionic PS or
CL71,76. Adhesion of b2gpI to these anionic membranes is extensively discussed in
literature34,69,71,76-80,116,250, whereas the mechanism that regulates binding of a neutral lipid is
not yet known. Work of Horbach et al. (32) indicated that cleavage of scissile bond Lys317-
Thr318 is a necessary prerequisite for uptake of a lipid molecule. Here we have shown that
the neutral phospholipid molecule is bound within the non-specific binding site for anionic
lipid layers.
A membrane-adhesion model has been proposed for b2gpI based on the crystal
structure and available biochemical data250. In this model a large positively charged patched
located at the fifth SCR domain has charge interactions with head groups of anionic
phospholipids. The mainly hydrophobic membrane-insertion loop Leu313-Ala-Phe-Trp-
Lys317, containing a typical Trp-Lys membrane anchor, provides specificity for lipid layers.
Crystal structures of b2gpI *1 (this work) and intact b2gpI251 add new insights contributing
to a more detailed lipid adhesion model. The electrostatic surface potentials calculated with
the models of b2gpI *1, b2gpI 1QUB and intact b2gpI (Fig. 5 A-C) suggest a potential three-
step membrane-adhesion model. Free in solution, a primary positively charged patch located
at the C-terminal top of domain V is fully exposed (Fig. 5B) and can interact with any
negatively charged surface present in the circulation. Binding to anionic lipids exposed on
blood platelets, lipoproteins or apoptotic cells possibly induces membrane insertion of loop
Leu313-Ala-Phe-Trp-Lys317, providing specificity for phospholipid layers. Wang et al.
(162) reported an increase in a-helical content after lipid adhesion of b2gpI. Possibly,
interaction of the primary patch with phospholipids not only orients the membrane anchor
prior to insertion, but additionally induces conformational changes in b2gpI in favor of
membrane insertion. After insertion of loop 313-317, mimicked by deletion of the loop in the
b2gpI *1 and b2gpI 1QUB models, a secondary positively charged patch becomes exposed
for additional charge interactions with negatively charged head groups of anionic
phospholipids (Fig. 5A, C). This will provide further specificity of b2gpI t wards
phospholipid membranes. Apparently, the positive electrostatic surface potential of the
secondary patch remains shielded by the mainly hydrophobic loop 313-317 in solution or
when b2gpI adheres non-specifically to any negatively charged surface other than provided
by anionic lipids, e.g. when it binds to DNA and heparin (Fig. 5B).
Our data indicate that specific uptake of a neutral phospholipid blocks adhesion of
b2gpI to anionic lipids. In this inactive state the glycerophosphorylcholine moiety is
positioned inside the pocket between the primary and secondary membrane-adhesion
patches, whereas the two acyl chains point away from the protein surface (Fig. 3A, 5A).
These long hydrophobic acyl chains may inhibit adhesion to lipid layers by interacting with
the mainly hydrophobic membrane-insertion loop Leu313-Ala-Phe-Trp-Lys317, by steric
hindrance, or by shielding the positive electrostatic surface potential of the primary patch,
analogous to observed shielding of the secondary membrane-adhesion patch by the insertion
loop 313-317 (Fig. 5B).
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b2gpI *1 is present in plasma of patients who suffered from oxidative stress. Severe
complications induced by this oxidative stress are, among others, i. undesir d uptake of
oxidized lipoproteins by macrophages119, and ii. auto-immune responses against oxidized
lipoproteins118,119, abundantly present apoptotic cells131,142,142,265 and b2gpI266,267,287,288. Two
defense mechanisms are known that prevent damage induced by oxidized lipoproteins.
Firstly, (choline) plasmalogens in lipoproteins are oxidized and act as antioxidant279,289.
Secondly, oxidized lipoproteins are prevented from uptake through the binding of b2gpI to
cardiolipin72,75 and to adducts of oxidized lipids and proteins267,268,290 present in the
lipoproteins paricles. Our findings show that b2gpI *1 has a neutral phospholipid bound.
This suggests new potential functions for b2gpI *1 in reversal of oxidative stress; i. uptake of
CL may be directly involved in removal of oxidized CL from the lipoproteins, ii. reduc d
affinity of b2gpI *1 for anionic lipids prevents formation of highly immunogenic complexes
of its precursor b2gpI with apoptotic bodies or oxidized lipoproteins, and iii. upt ke of
neutral lipids by 2gpI may induce clearance of apoptotic bodies by enlargement of their
anionic receptor-recognition site135,136.
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Fig. 5. Electrostatic surface potential at the positively charged membrane-adhesion patch,
calculated with three models of b2gpI. Positive charge is encoded in blue, negative charge is in red,
neutral patches are in white. (A) Primary and secondary positively charged membrane-adhesion patches
on the fifth SCR domain of b2gpI *1 (This work). Loop 310-317 was not visible in the electron density
and is not implied in the model. The bound glycerophosphorylcholine moiety is positioned deeply in
the interior of the pocket, located in the center of the positively charged patch. Residue Asp319, that
interacts with the choline moiety and that is located at the bottom of the neutral-lipid binding pocket is
indicated. (B) Membrane-adhesion site of intact b2gpI 1C1Z251. The position of loop 311-317 was
indicated by the electron density, most likely aided by an intact scissile bond Lys317-Thr318. The
primary positively charged membrane-adhesion site is exposed in solution and is available for charged
interactions with negatively charged surfaces. The secondary patch is largely shielded likely by the
presence of the exposed and mainly hydrophobic membrane-insertion loop Leu313-Ala-Phe-Trp-Lys
317. The electrostatic surface potential calculated with the model of intact b2gpI mitting residues 311-
317 (not shown), resembles the potential calculated for b2gpI 1QUB and b2gpI *1 (Fig. A and C), and
may mimic the expanded membrane-adhesion patch involved in protein-lipid interactions in the
membrane-bound state. (C) Membrane-adhesion site of b2gpI 1QUB250. Loop 311-317 was disordered
or mobile in the structure and is not implied in the model. Residues that contribute to the primary and
secondary adhesion patches are indicated. (D) Ribbon drawing of SCR domain V of intact b2gpI. The
orientation of the domain is similar to the orientations in figures A-C.
--- Appendix to Chapter IV ---
Analysis of the influence of structural
radiation damage on b2-glycoprotein I
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Brief introduction to radiation damage
X-ray diffraction experiments suffer from radiation damage. Important indicators for
radiation damage are, i. a decrease in resolution limit, ii. an increasing overall B-factor, and
iii. an increasing mosaicity. Cryo-cooling largely suppresses the globular effects of radiation
damage; in particular yielding a significant prolonged life time of the crystals during data
collection20,21. Recently however, Weik et al. (22), Burmeister (24) and Ravelli and
McSweeny (23) reported insights into highly specific effects of X-rays on the structure of
protein molecules. In particular, these effects are observed when crystals are irradiated with
very intense X-ray beams of third generation synchrotrons, e.g. using the beam lines of ID14
at the European Synchrotron Radiation Facility (ESRF, Grenoble, France)a. The occurrence
of specific structural radiation damage calls for careful consideration of data-collection
strategy and subsequent structure determination, validation and interpretation.
In a protein structure, effects of specific structural radiation damage can be
recognized by diminished electron density at the expected position of S-S, C=O, OH and S-C
groups and by relatively high corresponding B-factors. These observations indicate breaking
of disulfide bonds, decarboxylation of aspartate and glutamate residues, and release of
hydroxyl and methylthio groups of tyrosines and methionines, respectively.
Ravelli and McSweeny (23) suggested that several published crystal structures are
likely affected by radiation damage, without being noticed. In Chapt r II the crystal structure
of human b2-glycoprotein I (b2gpI) is presented (pdb code 1QUB, Ref. 250). X-ray data used
for refinement of the b2gpI model were collected on beam line ID14-EH4 (ESRF).
Reconsideration of the disulfide bonds in b2gpI model 1QUB revealed that all 22 cystines
were possibly affected to some extent by the intense X-ray beam, as indicated by relatively
high B-factors for Sg-atoms with respect to those for Cb-atoms. In addition, positions of
carboxyl groups of Glu285 and Glu309 were poorly defined by the electron density,
indicating that they may also be affected by the intense beam. These observations prompted
us to further investigate data sets measured from two crystals of an isoform of b2gpI and the
models obtained with these data, in reference to the markers that identify specific structural
radiation damage. A method is suggested and described for refinement of partially affected
disulfide bonds. Effects of local and specific radiation damage on the global fold of the
b2gpI structures and on local structural details were considered. The effects and the degree
of radiation damage should be taken into account when comparing models.
Data sets from b2gpI *1 crystals
In Chapter IV we described the crystal structure of an isoform of b2gpI, designated ‘b2gpI
*1’. Diffraction data from two crystals of b2gpI *1 were collected on ESRF beam line ID14-
EH1, referred to as ‘crystal 1’ (See Chapter IV) and on ID14-EH3, designated ‘crystal 2’.
Details on data collection are shown in Table I. The intensity ratio between beam lines ID14-
EH1 and ID14-EH3 is approximately 3:1. Crystal 1 had a ~15 times bigger volume than
crystal 2. For both data sets slit sizes used were smaller than the crystal sizes, thus only part
of the crystals was irradiated. Crystal 1 was exposed for in total 1,080 sec. to the beam of
                                                 
a Abbreviations used: b2gpI, b2-glycoprotein I; ESRF, European synchrotron radiation facility; ID14-EH#, insertion
device 14-experimental hutch number #; PDB, protein data bank; r.m.s., root-mean-square; SCR, short concensus
repeat.
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EH1, crystal 2 was exposed for in total 3,690 sec. to the beam of EH3. Diffraction data were
processed and scaled using DENZO and SCALEPACK26 and similar statistics were observed
for the two crystals (See Table I in Chapter IV and Table II).
Table I
Settings for data collection
b2gpI *1 crystal 1 b2gpI *1 crystal 2
Beam line† ID14-EH1 ID14-EH3
Relative intensity ~3 1
Wavelength (Å) 0.934 0.931
Slits (mm x mm) 200 x 200 100 x 100
Oscillation range (°) 1 1
Oscillation step (°) 1 1
Exposure time per image (sec.) 6 30
No. of images 180 123
No. of images used for structure refinement140 110
Temperature (K) 100 100
Crystal volume (mm3) ~36 ~2.2
Change of cell volume (%) +0.6 +1.2
Relative global B-factor (Å2)¶ 2.9 (1.0) 10.6 (8.5)
† Data sets were collected at the ESRF (Grenoble, France).
¶ Relative global B-factors are given for the last recorded image. For the first image the overall B-factor is
set to 0. Numbers between parentheses give the relative global B-factor for the last recorded image that is
used for structure refinement.
Data set collected on ID14-EH1 from crystal 1
The data set collected on beam line ID14-EH1 from crystal 1 comprised 180 images. The
first 140 images were used for structure refinement. The relative global B-factor varied non-
monotonously (Fig. 1A ). The length of the a-axis varied discontinuously (Fig. 1B). An
initial decrease of the B-factor (images 1-80) was accompanied by lengthening of the a-axis,
whereas a subsequent slight increase of the B-factor (images 80-180) was accompanied by
shortening of the a-axis. The observed effects represented in Fig. 1A and B are influenced by
the inaccuracies in their determination due to the limited amount of data used in processing a
single image. Additionally, the anisotropy of the crystal shape may also be of influence.
Variations in the length of the b- and c-axis were relatively small during the course of data
collection (Fig. 1C, D). The increase in cell volume was 0.6% from image 1 to 180 and 0.4%
for images 1-140 (Fig. 1E). The high-resolution limit did not noticeably drop during data
collection.
Data set collected on ID14-EH3 from crystal 2
In total, 123 images were recorded from crystal 2 of which the first 110 were used for
structure refinement. See Table II for the diffraction-data statistics. Crystal 2 proved to be
subjected to severe radiation damage. During data collection non-specific radiation damage
was indicated within the data set by an increase of the relative global B-factor to 10.6 Å2 for
the last image (Fig. 1A, Table I). Simultaneously, the length of the a-axis and the c-axis
increased gradually by 0.8% and 0.5%, respectively (Fig. 1B, D). Alternatively, the length of
the b-axis increased by 0.3% up to image 65 and then decreased again by 0.3% (Fig. 1C).
The increase in cell volume was more than 1% for images 1-123 (Fig. 1E). The high-
resolution limit slightly dropped with 0.1 Å.
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Fig. 1. Global non-specific radiation damage and specific structural radiation damage for
diffraction data of b2gpI *1 collected on beam line ID14-EH1 from crystal 1 and on ID14-EH3
from crystal 2. Curves for data collected on ID14-EH1 (ESRF, Grenoble, France) are in gray, curves
for data collected on ID14-EH3 are in black. (A) Relative global B-factor in Å2, as printed per image in
the SCALEPACK output26 (B) Length of the a-axis during the course of the data collection. (C) Length
of the b-axis. (D) Length of the c-axis. (E) Total cell volume during the course of data collection. Cell
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Structure refinement
Two models of b2gpI *1 were refined using diffraction data from crystal 1 (ID14-EH1) and
crystal 2 (ID14-EH3) and using the structure of b2gpI reported by Bouma et l.(250) as a
starting point (See Chapter IV). Rigid-body refinement, positional refinement and atomic B-
factor refinement were performed with CNS9. Refinement statistics for the two independent
models are similar and are shown in Table I in Chapter IV and in Table II, respectively. After
refinement of the models markers for the occurrence of specific structural radiation damage
were investigated.
Table II
Data-collection and structure-refinement statistics for diffraction data collected on
beam line ID14-EH3 from crystal 2
Diffraction-data statistics† Refinement statistics§
Resolution (Å) 38.4 – 3.0 Resolution (Å) 38.4 – 3.0
Mosaicity (º) 0.7 R-factor/Rfree 0.248/0.272
Space group C2221 r.m.s.d. bond distances (Å)0.008
Unit cell: a b c (Å) 160.5 165.7 115.5r.m.s.d. angles (º) 1.4
Redundancy 3.9 Average B-factor (Å2)¥ 59
No. unique reflections29,965 Solvent content (%) 88
<I>/<s(I)> 16.6 (3.0) No. non-hydrogen atoms 2,701
Completeness (%) 96.3 (94.5) No. protein residues 319
Rmerge (%) 6.3 (43.3) No. sugar residues‡ 12
No. sulfate ions 2
No. lipid molecules¶ 1
† Numbers in parentheses indicate statistics for the highest resolution shell (3.11-3.00 Å). Data were collected on
ESRF beam line ID14-EH3. See Chapter IV for comparison of the statistics with those of data collected on ID14-EH1
from crystal 1.
§ Disulfide bonds were not specified in the model and, instead cysteines were refined. The van der Waals radius of the
Sg-atoms was set to 0.
¥ Average atomic B-factor for all atoms in the model.
‡ Forty to sixty sugar residues are expected, based on MALDI-TOF mass spectrometry.
¶ A glycerophosphorylcholine moiety, which is part of, either phosphatidylcholine, sphingomyelin, or choline
plasmalogen, was built in the structure.
Methionines and tyrosines
For both models the four methionine residues and 14 tyrosine residues present were not
affected by radiation, as judged from the electron density and from atomic B-factors for S-C
and O-H groups.
Aspartates and glutamates
Complete and unaltered electron density at positions of side chains of the 14 Asp and 20 Glu
amino-acid residues was observed for crystal 1. Complete electron density at the side-chain
positions of 13 Asp and 11 Glu residues in the model from crystal 2 indicated that most of
these residues were not severely affected by the intense X-ray beam. Weak electron density
for the carboxyl groups of Asp9 and Glu108, Glu154, Glu180, Glu225, Glu259, Glu265,
Glu292 and Glu302, however, indicated that the carboxyl group of these residues was, either
partially cleaved off , or disordered or mobile. The carboxyl group of solvent exposed
Glu114 was apparently cleaved off completely, according to the absence of electron density
(Fig. 2A). Noteworthy, the position of a water molecule that likely forms a hydrogen bond
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with atom Oe1 or Oe2 of Glu114 is still indicated in the electron-density map. This water
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Fig. 2. Weak electron density for solvent exposed cystines in disulfide bond 281-306 and
glutamate 114 indicated that b2gpI *1 (crystal 2) suffered from severe specific structural
radiation damage. The figure is generated with BOBSCRIPT277 and RASTER3D203. (A) Electron
density contoured at 1 s accounting for the carboxyl group of Glu114 of b2gpI *1, (crystal 2, left). The
density indicates that the carboxy group is at least partially cleaved off. The position of a water
molecule that putatively forms a hydrogen bond with atom Oe1 or Oe2 of Glu114, is still manifest. For
comparison Glu114 of the structure derived from data collected on ID14-EH1 from crystal 1 is shown
(right). (B) Electron density for the strongly affected disulfide bond Cys281-Cys306 in b2gpI *1
(crystal 2, ID14-EH3, left). The Sg-Sg distance is 3.31 Å. For comparison the less affected disulfide
bond Cys281-Cys306 in the structure derived from data collected on ID14-EH1 from crystal 1 is shown
(right).
Cystines
The fish-hook shaped b2gpI molecule consists of five short consensus repeat (SCR) domains
arranged in tandem. Half of the fifth C-terminal domain has an aberrant fold, whereas the
other half has a fold similar to domain I-IV (Fig. 3). The standard SCR domains contain two
disulfide bonds (Fig. 3). Nine of the ten disulfide bonds in b2gpI *1 are located in the core of
the domains surrounded by hydrophobic side chains, whereas in domain V disulfide bond
281-306 is highly solvent exposed and partially surrounded by charged side chains. The
aberrant domain V contains an additional third disulfide bond 288-326. This disulfide bond
is fully solvent exposed (Fig. 3) and partially surrounded by charged amino-acid side chains.
For crystal 1 complete electron density was observed for all eleven disulfide bonds
in a 2|Fo|-|Fc| map. Negative electron density is observed for Sg of Cys281 in an |Fo|-| c|
difference map. Atomic B-factors were slightly increased (+2 to +9 Å2) with respect to Cb-
atoms for 14 out of 22 cystine Sg-atoms. These observations indicated an early stage of
specific and localized structural radiation damage. Weik et al. (22) and Ravelli and
McSweeney (23) addressed severe damage of disulfide bonds, expressed as the lost
definition of the Sg-atom in the electron density, by refining alanine residues instead of
cystines. In our case this procedure was at forehand not recommendable because disulfide
bonds appeared predominantly intact in this structure. To take into account that disulfide
Specific structural radiation damage
67
bonds were potentially partially broken we replaced all cystines by cysteines with the van der
Waals radius of Sg-atoms set to 0. After positional refinement Sg-Sg dis ances were all still
close to 2.05 Å with somewhat larger distances observed for Cys155-Cys181, Cys245-
Cys296 and Cys281-Cys306 (Table III). Atomic B-factors for the Sg-atoms did not differ
significantly from those when positions of Sg-atoms were restrained during refinement of
specified disulfide bonds. The R-factor increased from 0.238 to 0.246, the free R-factor
increased from 0.260 to 0.270, when refining cysteines. These results for crystal 1 suggested
that breaking of disulfide bonds had not yet occurred to a large extent for most of the bonds.
Similar positions of the Sg-atoms for eight out of the eleven disulfide bonds present indicated
that cysteine refinement (van der Waals radius of Sg-atoms set to 0) does not influence
disulfide bonds which are not or hardly effected by radiation damage. Moreover, for b2gpI
*1 (crystal 1) the observed increase in free R-factor validates restrained refinement of the Sg-
atoms in disulfide bonds, as performed previously with this model (Chapter IV).
During early stages of refinement of the model obtained with crystal 2 disulfide
bonds were specified and, therefore, positions of Sg-atoms were restrained. In the structure,
disulfide bonds of b2gpI *1 proved to be affected by specific structural radiation damage.
Negative peaks in |Fo|-| c| difference-density maps were observed near each of the eleven
disulfide bonds. Electron density in 2|Fo|-|Fc| maps at the positions of disulfide bonds 91-118,
155-181, 186-229, 245-296 was weak compared to maps calculated with the model from
crystal 1, and electron density for disulfide bonds 281-306 (Fig. 2B) and 288-326 in domain
V was very weak. B-factors for the Sg-atoms were slightly increased (+2 to +14 Å
2)
compared to B-factors for the Cb-atoms. These observations indicated that at least the six
bonds that show weak electron density were partially broken. Replacement of cystines by
alanines and subsequent positional and atomic B-factor refinement resulted in positive peaks
in |Fo|-|Fc| difference density maps at each of the 22 expected positions of the Sg-at ms. The
R-factor increased from 0.248 to 0.269, the free R-factor increased from 0.272 to 0.290.
These observations indicated that disulfide bonds were not completely broken. After
refinement with cysteines instead of cystines and with the van der Waals radius of Sg-atoms
set to 0, the R- and free R-factor were not influenced. Occurrence of specific damage was,
however, clearly indicated by (large) movements of all Sg-atoms except for disulfide bond
Cys65-Cys105 (Table III). Despite new positions for the Sg-atoms, the electron density in the
regions of the disulfide bonds was not significantly altered in the 2|Fo|-|Fc| maps at 3.0 Å
resolution.
Comparison of the eleven disulfide bonds of severely damaged crystal 2 showed
that these bonds have varying susceptibilities to radiation (Table III). In summary, largest
movements of Sg-atoms were observed for solvent exposed disulfide bonds 281-306 and 288-
326 in domain V accompanied with relatively weak electron density at the expected position
of the bonds. This observation indicates that these two disulfide bonds are relatively highly
susceptible to radiation. This may be correlated with their high solvent accessibility or
possibly by the surrounding charged side chains. Cys65-Cys105 in SCR domain II is the only
disulfide bond that stays intact when Sg-atoms were not restrained in disulfide bonds. The
electron density is virtually unaltered at the position of this bond. This indicates that Cys65-
Cys105 is the least susceptible disulfide bond of b2gpI *1. The remaining eight disulfide
bonds were to various degrees affected by radiation damage. In contrast to the high solvent
accessibility of the two most susceptible disulfide bonds in domain V, the other nine
disulfide bonds are all located inside the hydrophobic core of the SCR domains and are
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surrounded by hydrophobic side chains. Therefore, observed differences in susceptibility for
radiation among these disulfide links may depend on different aspects of the micro-
environment of the bonds. The limiting resolution of the diffraction data (3 Å) hamper
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Fig. 3. Location of disulfide bonds in the short consensus repeat domains of b2gpI *1. Ca-trace
representation of SCR domain I of b2gpI *1, that is representative for the fold of domains II-IV (left),
and Ca-trace representation of domain V (right). One half of domain V has a fold reminiscent to the
fold of domains I-IV, whereas the other half has an aberrant fold. Fully exposed disulfide bond
Cys288-Cys326 is unique to domain V. Solvent exposed disulfide bonds Cys281-Cys306 and Cys288-
Cys326 are most susceptible to radiation among the eleven bonds of b2gpI. Glu309 and Thr318
indicate the position of loop 310-317 that is not observed in the electron density. Disulfide bonds are
indicated by ball-and-stick models and are labeled with their residue numbers. The figure is generated
with MOLSCRIPT202 and RASTER3D.
Comparison of available models of b2gpI
A similar range of root-mean-square (r.m.s.) coordinate differences are observed after
superimposing Ca-atoms of the five individual SCR domains of the two b2gpI *1 models
(Table IV), despite varying degrees of specific structural radiation damage. In addition,
superposition of the Ca-atoms of each of the SCR domains of the two b2gpI *1 models and
of b2gpI models 1QUB and 1C1Z reported by Bouma et al. (250) and Schwarzenbacher et
al. (251) respectively, revealed a similar range of r.m.s. coordinate differences. This
demonstrated that the global conformation of b2gpI *1 is not influenced by specific local
radiation damage. The relatively large r.m.s. coordinate differences of 0.3 Å after
superimposing Ca-atoms of the fifth SCR domain of the two b2gpI *1 models (Table IV)
resulted mainly from deviating positions of Ca-atoms of residues Cys245 and Cys306, and of
residues Glu309 and Thr318. In both structures Glu309 and Thr318 precede and follow a
highly flexible or disordered loop of b2gpI (See Chapter II and Chapter IV), which likely
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resulted in intrinsic mobility of these two flanking residues. The slight difference in positions
of Ca-atoms of Cys245 and Cys306 is due to the fact that crystal 2 was more damaged than
crystal 1. Positions of Ca-atoms of amino-acid residues flanking these cysteines are very
similar among the two models, further indicating that the effects of specific structural
radiation damage were very locally restricted.
Table III
Relative susceptibility to radiation of disulfide bonds in b2gpI
*1 as indicated by Sg-Sg distances and electron density
Disulfide bonds
Cys-Cys
           Sg-Sg distance (Å)†
        Crystal 1    Crystal 2
Electron density in the
region of disulfide bonds‡
4-47 2.23 2.45 Virtually unaltered
32-60 2.12 2.57 Virtually unaltered
65-105 2.18 2.16 Virtually unaltered
91-118 2.23 3.09 Weak
123-169 2.09 2.35 Virtually unaltered
155-181 2.39 2.93 Weak
186-229 2.19 2.52 Weak
215-241 2.22 2.50 Virtually unaltered
245-296 2.40 2.85 Weak
281-306 2.59 3.31 Very weak
288-326 2.24 3.32 Very weak
† During refinement disulfide bonds were not specified and the van der Waals radius of
Sg-atoms in cysteines was set to 0. The Sg-Sg distance in a non-affected disulfide bond is
2.05 Å. Data from crystal 1 are collected at ESRF beam line ID14-EH1 (Grenoble,
France), data from crystal 2 are collected at ID14-EH3.
‡ The classification is based on a comparison of the observed electron density near the
disulfide bonds of crystal 1 with density accounting for the bonds in crystal 2 in a 2|Fo|-|Fc|
map.
Table IV
Superposition of Ca-atoms of individual SCR
domains using two b2gpI *1 models









† Ca-atoms of each of the SCR domains of the model refined using data collected on ESRF
beam line ID14-EH3 from crystal 2 are superimposed on the Ca-at ms of the equivalent SCR
domains of the model refined using data collected on ESRF beam line ID14-EH1 from crystal
1.
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Conclusion
In this Appendix a new refinement protocol is used for structures with partially broken
disulfide bonds upon irradiation with intense X-ray beams. During refinement cysteines with
a van der Waals radius of 0 were incorporated in the model instead of cystines. After
positional and atomic B-factor refinement the procedure was validated by investigation of
changes in Sg- g distances, of peaks in |Fo|-|Fc| difference maps, of relative values of the B-
factors for Ca, Cb and Sg-atoms, and of 2|Fo|- c| electron density accounting for the partially
broken disulfide bonds. Applying the refinement method to crystal 1 revealed that all
disulfide bonds were affected to a minor extent. The procedure was also applied to crystal 2
obtained with data from ID14-EH3. For five out of six disulfide bonds for which weak
electron density was present, relatively large movements of the Sg-atoms were observed,
whereas no large movements were observed for disulfide bonds with virtually unaltered
electron density (Table III). These observations proved that the refinement method was
useful for our model containing partially broken disulfide bonds (crystal 2). For this model
the moved positions of Sg-atoms of the refined cysteines and weak electron density for
several partially broken disulfide bonds allowed for a first classification of the eleven
disulfide bonds of b2gpI *1 with respect to their susceptibility to radiation. Comparison
suggested that solvent exposed disulfide bonds partly surrounded by charged side chains of
amino-acid residues were more susceptible than buried disulfide bonds surrounded by
hydrophobic side chains. A detailed analysis of the micro-environment of disulfide bonds
requires high-resolution diffraction data and is necessary for identification of parameters that
determine the apparent differences in susceptibility.
Comparison of the severely affected model of b2gpI *1 with available models of
b2gpI showed that specific structural radiation damage (at 100 K) is localized to a few types
of amino-acid residues, i. . acidic residues and cystines. No changes in global conformation
of b2gpI *1 were observed. Thus, the structural implications presented in Chapter IV were
not compromised by specific radiation damage.
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Von Willebrand factor (vWf) is a multimeric glycoprotein that mediates platelet
adhesion and thrombus formation at sites of vascular injury. vWf functions as a
molecular bridge that binds to collagen that is exposed by the damaged vessel wall, and
to glycoprotein Ib at the platelet surface. The major collagen-binding site of vWf is
contained within the A3 domain, but its precise location is not known. To localize the
collagen-binding site, we determined the crystal structure of A3 in complex with a Fab
fragment of antibody RU5 that inhibits binding of vWf to collagen. The structure was
solved at 2.0 Å resolution by molecular replacement, aided by the anomalous signal of
seleno-methionines in A3. The epitope of RU5 involves residues 962-966, 981-997 and
1022-1026 that are part of a-helix 2 and loops a1b2, b3a2 and a3b4, located at the
‘bottom’ side of A3, but opposite to the N- and C-terminus. Comparison with other
structures of A3 shows that RU5 binding does not induce long-range conformational
changes. Instead, RU5 most likely blocks collagen binding by steric hindrance, which
implies that the collagen-binding site is located at or close to the epitope of RU5 near
the bottom side of A3. Surprisingly, the collagen-binding site of vWf-A3 is located
distant from the top face of the domain where collagen-binding sites are found in
homologous integrin I-domains. Apparently, vWf-A3 and integrin I-domains bind
collagen in fundamentally different ways. Coordinates are in the Protein Data Bank
(accession code 1FE8).
Key words: A domain, A3 domain, collagen binding, conformational changes, crystal structure, Fab fragment of
antibody RU5, I domain, integrin, mutations, von Willebrand factor
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Introduction
Platelet adhesion to damaged vessel walls is the first step in the formation of an occluding
platelet plug, which leads to the arrest of bleeding during normal haemostasis. Platelet
adhesion can also cause thrombotic complications such as the occlusion of aetherosclerotic
arteries183. The multimeric glycoprotein von Willebrand factor (vWf)a plays an essential role
in platelet adhesion under conditions of high shear stress166,167. In this process vWf serves as
a molecular bridge that links collagen exposed by the damaged vessel wall to glycoprotein Ib
(gpIb) located on the platelet surface. Collagen types that act as binding sites for vWf include
collagen I and III in perivascular connective tissue and collagen type VI in the sub-
endothelial matrix167,168.
Mature vWf consists of a 2,050 residue monomer that contains multiple copies of so
called A, B, C and D-type domains and one CK (cystine knot) domain arranged in the order
D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK167,183. Disulfide-bond formation between N-
terminal D3 domains and between C-terminal CK domains generates vWf multimers that
consist of up to 80 monomers. The A1 domain contains the binding site for gpIb291. Th  A3
domain (residues 920-1111) contains the major binding site for collagen types I and III180.
The multimeric structure of vWf is essential for high-affinity collagen binding. Multimeric
vWf binds collagen with an apparent Kd of 1-7 nM
201, while a recombinant A3 domain has a
much higher Kd of 2 mM292. Deletion of the A2 and D4 domains, that flank the A3 domain, or
deletion of the A1 domain does not decrease collagen binding of multimeric vWf180,201.
These data show that a monomeric A3 domain contains a fully active collagen-binding site,
the only requirement for tight binding to collagen being the presence of multiple A3 domains
within one vWf multimer.
Integrin I-type domains are homologous to vWf A-type domains293,294. I-domains of
integrin a-chains a1, a2, a10 and a11 all possess collagen-binding sites. A crystal structure
of the a2 I-domain reveals binding of a collagen-like peptide to a groove in the surface of the
‘top’ face of the domain200. This groove contains a so-called metal ion-dependent adhesion
site (MIDAS) motif198,295 which engages a glutamate residue of collagen.
The location of the collagen-binding site in the vWf A3 domain is not known.
Crystal structures of A3 do not display a collagen-binding groove in the top face, instead the
surface of A3 is rather smooth193,194. Although the MIDAS motif is partly conserved, binding
of A3 to collagen does not require a metal ion296 and no metal ion is observed in crystal
structures of A3. Moreover, point mutations in the MIDAS motif of A3 (D934A,
D934A/S936A, S938R, S1005V, D1039Q, D1039A) do not disrupt collagen binding193,201
showing that the motif is not involved in collagen binding, at all. Site-directed mutagenesis
studies of other residues in the top face of A3 have yielded conflicting results. Cruz et al.
(297) reported in abstract form that amino-acid substitutions D1069R, R1074D, R1090D and
E1092R resulted in a 50% reduction in binding of monomeric A3 to collagen. Van der Plas
et al. (201), however, observed normal collagen binding of fully processed multimeric vWf
                                                 
a Abbreviations used: a.u., asymmetric unit; CDR, complementarity determining region; CH1, co stant domain H1 of
an immunoglobulin heavy chain; CK, cystine knot; CL, constant domain of an immunoglobulin light chain; DLS,
dynamic light scattering; Fuc, fucose; GlcNAc, N-acetylglucosamine; gpIb, platelet glycoprotein Ib; IEF, iso-electric
focussing; MPD, 2-methyl-2,4-pentanediol; MW, molecular weight; n.c.s., non-crystallographic symmetry; PBS,
phosphate-buffered saline; PCR, polymerase-chain reaction; r.m.s., root-mean-square; SDS PAGE, sodium
dodecylsulfate poly-acrylamide gel electrophoresis; Se-Met, seleno-methionine; Ve, elution volume; VH, variable




containing mutations D1069A, D1069R or R1074A. In the same study, mutations
V1040A/V1042A, D1046A and D1066A also displayed normal collagen binding, suggesting
that the collagen-binding site of vWf-A3 is not located in its top face.
The crystallographic study presented here was conducted to provide new clues on
the location of the collagen-binding site of the vWf-A3 domain. We determined the structure
of the A3 domain in complex with a Fab fragment of antibody RU5, which inhibits binding
of vWf-A3 to collagen. The crystal structure of A3-RU5 now provides strong evidence for an
alternative location of the collagen-binding site, located distant from the top face of A3.
Experimental procedures
Protein purification
Recombinant seleno-methionine (Se-Met) A3, comprising residues 920 to 1111 of human
von Willebrand factor, was produced in Escherichia coli strain B834 and subsequently
folded and purified as described before194. The histidine tag was removed by thrombin
digestion. (Se-Met) A3 appeared as one band with a molecular weight (MW) of 22 kDa after
sodium dodecylsulfate poly-acrylamide gel electrophoresis (SDS PAGE). On an iso-electric
focussing gel (IEF), four bands with similar intensities were visible with a pI ranging from
4.6 to 5.2.
For production of monoclonal antibody RU5 (IgG2a, k) hybridoma cells were
injected in mice and ascites fluid was collected (Eurogentec, Seraing, Belgium). The ascites
fluid was diluted with an equal volume of loading buffer (phosphate-buffered saline pH 7.3,
PBS) before purification of IgG on a 5 ml protein G-Sepharose column (Pierce, Rockford IL,
USA). Elution buffer was 0.1 M glycine pH 2.7. Fab fragments were generated, using an
ImmunoPure Fab Kit according to the manufacturers recommendations (Pierce, Rockford IL,
USA). In short, IgG was incubated with papain-coated beads for 6 h at 37ºC, and Fc
fragments and uncut IgG were removed on a Protein A-Sepharose column. RU5 Fab was
further purified with A3-affinity chromatography. For that end, 10 mg of A3194 was
irreversibly bound via its N-terminal histidine tag to cobalt(III)-iminodiacetate chelating
Sepharose (Pharmacia Biotech, Uppsala, Sweden), according to a procedure described by
Hale (298). A 2.5 ml column was equilibrated with PBS before use. Solution containing Fab
fragments was loaded and the column was washed with 10 ml of PBS, 10 ml of a 2 M NaCl
solution, and 10 ml of PBS, respectively. Bound RU5 Fab fragments were eluted with 7.5 ml
of a 50 mM tri-ethylamine solution (pH 10.0). Some aggregates were removed on a
Superdex 75 HR 10/30 gel-filtration column (Pharmacia, Uppsala, Sweden). Running buffer
was 10 mM Tris-HCl pH 8.0, 25 mM NaCl. RU5 Fab was concentrated to 10 mg ml-1 using
Centriplus and Centricon concentrators with a molecular-weight cut-off of 30 kDa (Amicon,
Beverly MA, USA). After SDS PAGE, RU5 Fab appeared as one band with an MW of 55
kDa. On IEF gel RU5 Fab appeared as eight bands with a pI ranging from 4.5 to 5.9.
Complex formation of (Se-Met) A3 and RU5
For isolation of A3-RU5 complexes, Fab was mixed with a twofold molar excess of (Se-Met)
A3. Solutions containing 10 mg ml-1 of RU5 and 10 mg ml-1 of (Se-Met) A3 in 10 mM Tris-
HCl pH 8.0, 25 mM NaCl were used for 5 min. incubations at room temperature. Complexes
of A3-RU5 were separated from the excess of A3 on a Superdex 75 10/30 gel-filtration
column (Pharmacia, Uppsala, Sweden) using 10 mM Tris-HCl pH 8.0, 25 mM NaCl as
running buffer. The complex eluted separately from the excess of A3 at an elution volume of
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9.1 ml (A3 eluted at 11.8 ml). No peak that could account for free RU5 was visible in the
elution pattern indicating that all Fab was complexed (free RU5 eluted at 9.5 ml). The
complex was concentrated to 10 or 15 mg ml-1 prior to crystallization, using Micro-
concentrators with a molecular-weight cut-off of 30 kDa (Microsep, Northborough MA,
USA). Dynamic-light scattering (DLS) measurements on a Dynapro-801 DLS Instrument
(Protein Solutions, Charlottesville VA, USA) indicated the presence of 69-kDa particles in
agreement with the expected molecular weight of about 72 kDa of the complex between A3
and RU5.
Determination of RU5 heavy-chain and light-chain variable domain sequences
The amino-acid sequence of the variable domain of the heavy chain (VH) of RU5 was
deduced from a cDNA nucleotide sequence. Cloning and sequencing was carried out using
established procedures. Total mRNA was extracted from 4*106 RU5 hybridoma cells with
RNAzol using the RNA-isolation protocol of the supplier (Campro Scientific, Veenendaal,
The Netherlands). First-strand cDNA was synthesized from mRNA using Superscript II
reverse transcriptase (Gibco, Rockville MD, USA). During first-strand cDNA synthesis, 3.2
U ml-l of RNase-inhibitor RNaseOUT (Gibco, Rockville MD, USA) was added. cDNA
encoding the VH domain was amplified by polymerase chain reaction (PCR) with Pwo DNA
polymerase (Boehringer, Mannheim, Germany). A 5' variable-region concensus primer ‘VH-
back’ was used together with a forward primer ‘VH-for’ that hydridizes with a consensus
sequence in the JH region (Ref. 299; Table I). The PCR product was extended with a 3'-A
overhang with Taq DNA polymerase (Promega, Madison WI, USA). The PCR product with
3'-A overhang was cloned into the pCR2.1-TOPO Vector according to the manufacturer’s
protocol (Invitrogen, Leek, The Netherlands). Nucleotide sequences of three clones were
determined using the di-deoxy method (Hubrecht Laboratories, Utrecht, The Netherlands)
(Fig. 1A)b.
For determination of the sequence of the variable domain (VL) of the RU5 k-light
chain, the same procedure was used as for the VH domain. For cloning of the VL gene, one
variable region concensus primer ‘VL-back’ and two variable region concensus primers ‘VL-
for’ were used (Table I). However, determination of the sequence was hampered by the
abundance of mRNA encoding the light chain of the non-producing myeloma fusion partner
in the cytoplasm of the RU5 hybridoma cell, which is a known feature when using the
myeloma cell line P363Ag8.653 (Ref. 300).
Table I
Primers for amplification of RU5 VH and VL domains
†
B3c VH-for 5'-d(CGG ATG GCC AGG T(C/G)(A/C) AGC TGC AG(C/G) AGT C(A/T)G G)
B4   VH-back 5'-d(CCA GGG GCC AGT GGA TAG ACA AGC TTG GGT GTC GTT TT)
PD3 VL-for 5'-d(CAG GAA ACA GCT ATG ACC GAG CTC GTG ATC ACC CAG TCT CC)
PD4 VL-for 5'-d(TGT AAA ACG ACG GCC AGT TCT AGA TGG TGG GAA GAT GGA)
PD1 VL-back 5'-d(GAT ATT GTG ATG ACC CAG TCT (C/G)T)
† See Ref. 299
                                                 
b The nucleotide sequence for the variable domain VH of the monoclonal antibody RU5 has been deposited in the




Initial crystallization trials were performed using various sparse-matrix crystal screens with
solutions containing 10 mg ml-1 of A3-RU5 complex, both at room temperature and at 4°C.
No crystals were obtained with the very soluble complex. Additional screening with a
complex concentration of 15 mg ml-1 also gave no crystals and hardly any precipitates. The
few conditions in which the complex precipitated as white powder, however, predominantly
contained iso-propanol and had pH’s around 5. These leads were used for subsequent grid
screens with various precipitants and buffers/pH’s. Crystalline thin four-sided or six-sided
plates were obtained in 27% v/v iso-propanol, 100 mM cacodylic acid pH 5.5, at 4°C using a
solution containing 15 mg ml-1 of A3-Fab. Further refinement of this initial condition
resulted in crystals grown in 13% iso-propanol, 22% v/v 2-methyl-2,4-pentanediol (MPD),
100 mM cacodylic acid pH 5.3 that were suitable for X-ray data collection. The crystal used
for structure determination had a size of 0.1x0.1x0.2 mm3 and was equilibrated in a cryo-
protectant solution consisting of 8% iso-propanol, 30% MPD, 100 mM cacodylic acid pH
5.3, and subsequently stored in liquid nitrogen.
Fig. 1. Amino-acid sequences of RU5 VL and VH domains. CDRs (underlined) were defined
according to Kabat et al. (301). Strict sequential numbering (#) is used throughout the text. Numbering
according to the convention of Kabat et l. (301) (#K) is also shown. (A) The amino-acid sequence of
VH was deduced from cDNA. Residues 1 to 7 could not be deduced precisely due to the use of a primer
complementary to the 5’ coding region. Asn56 in CDRH2 (shaded) is N-glycosylated. The nucleotide
sequence for the variable domain VH of the monoclonal antibody RU5 has been deposited in the
GenBank database under GenBank Accession Number AF286587. (B) The sequence of the VL domain
was deduced from electron density. The sequence was adjusted according to a consensus sequence
based on a multiple sequence alignment of 110 Fabs.
Data Collection
The crystal of the A3-RU5 complex belonged to space group C2 with unit cell dimensions of
a = 121.8 Å, b = 183.4 Å, c = 131.8 Å and b = 116.2°. A self-rotation function, calculated
with POLARRFN245 and the unit-cell volume suggested the presence of three A3-RU5
complexes in the asymmetric unit (a.u.). X-ray diffraction data were collected on beam line
BW7B of the synchrotron-radiation facility of the EMBL outstation (Hamburg, Germany)
with a Mar345 imaging plate (Mar, Evanston IL, USA). Data reduction, merging and scaling
were performed with DENZO and SCALEPACK26. Diffraction-data statistics can be found
in Table II. Diffraction of the A3-RU5 crystal was anisotropic. This anisotropy effected data
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resolution shell (Table II). For structure determination, anisotropic B-factors were applied
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No. of unique reflections 143,255
<I>/<s(I)> 20.4 (2.4)†
Completeness (%) 85.9 (51.5)‡
Rmerge (%)¶ 6.1 (40.4)
‡ Data completeness is 100% between 29.9-2.56 Å resolution and drops to 51.5%
between 2.56-2.03 Å resolution, due to anisotropic diffraction.
† Numbers in parentheses indicate statistics for the highest resolution shell (2.10-
2.03 Å).
¶ Rmerge = åhåi|Ihi-<Ih>| / åhåi|Ihi|
Structure determination and refinement
Initially, we tried to solve the structure of the complex of vWf- (Se-Met) A3 and RU5 Fab by
conventional molecular replacement using the programs AMoRe302 and CNS9. As search
model native A3194 and a number of different Fab structures12 wer  used. Molecular
replacement failed, most likely due to the large number of molecules present in the a.u.
The A3 domain contains five methionine residues. One of these derives from the
pET-15b vector and remains attached to the N-terminus of the molecule after removal of the
histidine-tag by thrombin194. This methionine is disordered in the structure of native A3.
Determination of the positions of at least three out of the four remaining Se atoms uniquely
defines the position and orientation of an A3 molecule. Therefore, we attempted to use the
weak anomalous signal (<Dfano/s(F)> = 1.18) in the diffraction data that arose from the
presence of (Se-Met) A3.
The program RSPS303 was used to identify Se sites from an anomalous Patterson
map calculated with data between 30 and 2.5 Å resolution. A consistent set of seven Se sites
was found. All Harker peaks had values of 3 s ab ve mean and the majority of cross vectors
had values above 1 s. Next, we attempted to attribute each Se site to a specific methionine
residue on the basis of inter-atomic distances. It was assumed that distances between Se
atoms within A3 in the A3-Fab complex were similar to the known distances between
methionine sulphur atoms in the structure of native A3. The distances between Se atoms
within two pairs of sites were consistent with the distance between the sulphur atoms of
Met947 and Met998. Other distances between these four Se sites indicated that they were
located in two molecules related by two-fold non-crystallographic symmetry (n.c.s.).
In the structure of native A3 sulphur atoms of Met947 and Met998 have B-factors of
7.3 and 8.1 Å2, respectively. The sulphur atoms of Met1022 and Met1097 have higher B-
values of 10.3 and 14.7 Å2, respectively. The higher mobility of the Se atoms in Met1022
and Met1097 leads to a reduced height of the corresponding Harker peaks most probably
causing RSPS to fail in identifying these Se sites. A systematic analysis of cross vectors to
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the four known Se sites was performed, based on the expected cross vectors for sulphur sites
of methionines in A3. Only cross-vectors with a length close to one of the expected inter-
atomic distances were considered. In total, 352 possible Se sites were generated. Two of
these sites met the distance criteria for the Se atom in Met1097 and also obeyed the two-fold
n.c.s. The Harker peaks of these sites are indeed low being 0.7 s and –1.7 s. Identification of
six Se sites allowed for positioning of two A3 molecules in the a.u. With hindsight it turns
out that the selenium atom of Met1022 is shifted by approximately 6 Å relative to the
sulphur atom of Met1022 in the structure of native A3, hampering a straight forward
assignment of all Se peaks within an A3 molecule using the described procedure.
Next, a rotation function was calculated with the program AMoRe using the Fab-
fragment of protein data bank entry 2MPA as a search model12,304. The 50 highest-ranking
solutions from the rotation function were subjected to Patterson correlation refinement305
using CNS. During Patterson correlation refinement the orientations and relative positions of
the four individual immunoglobulin domains were optimised. Cross-translation functions
were calculated with CNS. Solutions 1, 7 and 25 from the rotation function produced the
lowest R-factors in the translation search, namely 51.7%, 51.9% and 52.3%, respectively.
Other solutions from the rotation function gave R-factors in the translation function between
53.1 and 54.3%. When a translation function was calculated without the prior placement of
the two A3 domains no correct translation vectors were obtained. In combination with the
two A3 domains the three Fab molecules that produced the lowest R-factors were
successfully positioned in the a.u. A model consisting of two A3 domains and the three Fab-
fragments was subjected to rigid body refinement resulting in a free R-factor of 45.4%. Next,
a third A3 molecule was generated on the basis of n.c.s. observed for two of the Fab-
fragments. The a.u. finally contained three A3-RU5 complexes. Rigid body refinement of
this model gave a free R-factor f 42.8%.
Further refinement of the initial model was carried out with CNS9. Cycles of
rebuilding using O16 and positional and B-factor refinement using CNS, were performed
until convergence. Cross validation was used throughout refinement, using a 5% test set of
reflections. Refinement used the maximum-likelihood algorithm29 nd bulk-solvent
correction was applied as calculated by CNS. During structure refinement, diffraction data
between 29.9 and 2.0 Å resolution were anisotropically scaled with CNS. During the first
cycles of refinement, n.c.s. restraints were used for the three A3-RU5 complexes. Based on
the behaviour of the free R-factor, these restraints were omitted during final stages of
refinement. Sequences of the constant domain of the light chain (CL) and of the constant
domain of the heavy chain (CH1) of RU5 were taken from IgG2a, k monoclonal antibody 4-4-
20 (Ref. 306, 307). Residues 1 to 110 of the VL domain of RU5 were built in the structure
based on electron density, aided by the consensus sequence of Fabs after alignment of 110
sequences (Fig. 1B). At Asn56 of the VH domain, located within complementarity
determining region H2 (CDRH2) of RU5, additional electron density indicated the presence of
an N-linked glycan. N-acetylglucosamine and fucose residues were built into the structure,
according to the electron density. Water molecules were defined in a difference electron-
density map, placed in the structure, and subsequently, B-factors and positions were refined
with CNS. The search criteria for water molecules were a peak height of 2.8 s, a dis ance of
2.5-3.4 Å to the hydrogen donor or acceptor and a B-factor smaller than 65 Å2. A cacodylate
ion ([(CH3)2AsO2]
-) was built into the structure based on a strong peak in the difference map.
Coordinates of cacodylate were taken from pdb code 1BEH308 and conformational and non-
bonded energy parameters of phosphate, arsenicum and CH3 moieties from CNS were used
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during refinement of the position of the cacodylate ion. Coordinates are in the Protein Data
Bank (accession code 1QUB).
Results
Structure determination and refinement
The crystal structure of a complex between the vWf (Se-Met) A3-domain and a Fab-
fragment of RU5, an antibody that inhibits binding of vWf to collagen, was determined by
molecular replacement. Structure determination was aided by the anomalous signal from
selenium atoms in (Se-Met) A3, which was used to find the positions of two out of the three
A3 molecules in the a.u. The structure has been refined to an R-factor of 22.7% and a free R-
factor of 26.4% using diffraction data to a maximal resolution of 2.0 Å (Table III). R-factors
are somewhat higher than could be expected for a 2.0 Å resolution structure. This is possibly
caused by, i. anisotropy of the diffraction that reduced data completeness between 2.0 and
2.6 Å (Table II), and ii. the fact that the sequence of the RU5 VL domain was deduced from
electron density and, therefore, may contain errors. The structure displays good model
geometry with 88.8% of the residues in the most favored region of the Ramachandran plot
and 10.8% in the additionally allowed region. Residue Thr51 of RU5 VL domains occurs in
the disallowed region of the Ramachandran plot, but its electron density is convincing.
The a.u. consists of three A3-RU5 complexes that are denoted A, B a d C. The
overall structure of the (Se-Met) A3 molecule is the same as the structure of native A3193,194.
It consists of a central six-stranded b-sh et on both sides flanked by a-helices. The final
model comprises amino-acid residues 921-1110 of A3 molecules in complex A a d B and
residues 920-1110 of the A3 molecule in complex C. Positions of the N- and C-termini of
A3, including disulfide bond Cys923-Cys1109 that connects these termini, are poorly
defined. The model of RU5 consists of residues 1 to 211 of the light chains and residues 1 to
129 and 136 to 216 of the heavy chains. Residues 130-135 of the heavy chains display very
weak electron density and are excluded from the model. Disorder of this loop is a commonly
observed feature in Fab structures309. Asn56 of the VH domain is N-glycosylated. Electron
density near Asn56 accounted for a GlcNAc(-Fuc)-GlcNAc moiety in complexes A and B
and only a GlcNAc-Fuc moiety in complex C. B-factors of these moieties are relatively high,
i.e. approximately 60 Å2, compared to an average overall B-factor of 38 Å2. The model
contains one cacodylate ion from the crystallization solution.
Table III
Refinement statistics





r.m.s.d. bond distances (Å)0.007
r.m.s.d. angles (°) 1.41
Average overall B-factor (Å2) 38
No. of protein atoms† 13,889
No. of carbohydrate atoms 100
No. of cacodylate ions 1
No. of solvent molecules 878
† An asymmetric unit contains three A3-RU5 complexes.
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Crystal packing and differences between complexes
In the a.u. A3-RU5 complexes B and C form a tightly interacting anti-parallel dimer and are
related by two-fold n.c.s. A3-RU5 complex A forms a similar anti-parallel dimer with a
crystallographically related complex A'. Complexes within dimers B-C and A-A' have large
contact areas of 932 Å2 and 1,454 Å2, respectively (GRASP; Ref. 246). These large
interaction-surface areas suggest that the dimer of A3-RU5 complexes may also be stable in
solution. DLS measurements, however, clearly indicated that the A3-RU5 complex does not
form dimers in solution. Therefore, dimers observed in the crystal are a result of crystal
packing.
Superposition of Ca-atoms of the three A3-RU5 complexes gives large root-mean-
square (r.m.s.) coordinate differences ranging from 0.7 to 0.9 Å. When superpositions are
limited to A3 molecules with bound VH and VL domains r.m.s. coordinate differences of 0.5-
0.6 Å are obtained. Visual inspection of these superpositions (Fig. 2) shows that the A3-RU5
interaction region is well conserved, whereas regions of A3 and the variable domains located
further away from the interaction region superimpose less well. More detailed inspection of
the A3-RU5 binding region reveals that all side chain conformations are very similar (not
shown). In conclusion, the A3-RU5 interaction region is well conserved among the three
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Fig. 2. Structural overlay of Ca-traces of the three A3-RU5 Fab complexes in the asymmetric
unit. For calculation of the best superposition Ca-a ms of A3 and variable domains of RU5 were used.
The A3-RU5 interaction region is well conserved amongst the three complexes, while relatively large
differences are shown in orientations of the RU5 constant domains with respect to its variable domains
and A3.
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Fig. 3. Ribbon diagram of A3 and RU5 variable domains. Residues of A3 that are part of the epitope
of RU5 are indicated by green spheres. Regions of RU5 CDRs that interact with A3 are color-coded in
light-blue. Regions of A3 that show different conformations among four crystal structures are shown in
purple trace. Residues that have been mutated in previous studies (See discussion) are located in the top
face of A3, opposite to the RU5-binding site, and are indicated by black spheres. Disulfide bond
Cys923-Cys1109 is shown in ball-and-stick. The a-helic s and b-strands of A3 are depicted in blue and
red, respectively. For clarity, -helix 2 is not shown by a ribbon, but in ‘coil’ representation. The VH





The epitope of RU5
A3 interacts with RU5 through a non-linear epitope comprising residues in loop a1b2, loop
b3a2 followed by helix a2 and loop a3b4 (Table IV). All three loops that are engaged in the
epitope are located in the bottom face of A3 (Fig. 3). The N- and C-termini of A3 that are
also located in the bottom face do not interact with RU5. This observation is in agreement
with the fact that RU5 was raised against complete vWf in which the termini connect A3 to
flanking A2 and D4 domains. Residues of RU5 that interact with loops a1b2 and a3b4 are
located in CDRL1 and CDRL2. All six CDRs interact with residues in the contiguous segment
formed by loop b3a2 and helix a2. The A3-RU5 interactions involve five hydrogen bonds
and one salt bridge. Interestingly, the fucose residue attached to residue Asn56 in CDRH2 of
complex A interacts with Lys988-Ala989 of A3. The carbohydrate residues attached to
Asn56 in complex B and C do not interact with A3. The buried surface area of A3 molecules
in the complex is approximately 1,200 Å2, which is about 7% of the total surface area of A3.
Conformational changes in A3
To analyze whether binding of RU5 causes conformational changes in A3 we compared
models of A3 in the A3-RU5 complex with two structures of free A3193,194. The two
structures of free A3 were determined from different crystal forms with unrelated crystal
packing interactions. In both crystal forms two molecules are present in the a.u. Since the
A3-RU5 complex was obtained with (Se-Met) A3 we also included the structure of free (Se-
Met) A3 (E.G. Huizinga, unpublished results) in the analysis to detect possible structural
differences caused by Se-Met. R.m.s. coordinate differences after pair-wise superposing Ca-
atoms of all eight models range from 0.24 to 0.81 Å. Large differences are restricted to three
loops, located within the RU5-binding site, and to two loops that are located distant from the
epitope (Fig. 3, Table IV). The three conformational diverse loops that are located in the
RU5 epitope are shown in Fig. 4A.
Residues Gly961-Pro-Arg963 in loop a1b2 have a unique conformation in the A3-
RU5 complex. The peptide bond between Pro962 and Arg963 is flipped with respect to the
conformations observed in free A3. As a result the side chain of Pro962 in the complex is
positioned somewhat further away from the A3 surface.
Residues Asn983-Val-Val-Pro-Glu987 in loop b3a2 have considerable
conformational freedom as is evident from the conformation observed in A3 model B of
Bienkowska et al. (193), which differs dramatically from the conformations observed in the
other models. Considering the seven more similar loops, the orientation of the side chain of
Asn983 shows the most pronounced variation, while residues 984-987 are rather similar.
RU5 interacts with all residues in this loop but the conformations observed in the RU5-A3
complex are not systematically different from the conformations observed in free A3.
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Two conformational extremes exist for residues Thr1019-Ser-Glu-Met-His-Gly-
Ala1025 in loop a3b4, the position of Met1022 being the most prominent difference. In all
three A3-RU5 complexes and in one of the crystal forms of free A3193Met1022 points away
from the A3 surface. In the other crystal form of free A3194 th  side chain of Met1022 packs
against the surface of the molecule and its Ca-atom is shifted by approximately 4 Å. The
same conformation is observed in free (Se-Met) A3 and, therefore, the selenium atom in Se-
Met1022 does not trigger the observed differences. The conformation of loop a3b4 i  the
complex is not induced by the presence of RU5 since similar conformations of this loop are
observed in free A3193. In all available A3 structures at least part of loops b3a2 and/or a3b4
contribute to crystal packing.
Table IV
The epitope of RU5 and loops that show conformational variation

















‡ Residues listed are positioned within 4.0 Å distance from RU5.
† Residues that are also part of the epitope of RU5 are underlined.
Distant from the RU5 epitope in the top face of A3, conformational variation is
observed for residues Ser938-Phe-Pro940 in loop b1a1 (Fig. 4B). Ser938 is part of the
vestigial MIDAS motif. In RU5-A3 complex C Phe939 is solvent exposed as is observed in
all models of free A3. In complexes A and B, however, Phe939 is buried in the hydrophobic
core of A3. The solvent exposed conformation of Phe939 has relatively high B-factors,
whereas the buried conformation has low B-factors. In complexes A and B, the buried
conformation of Phe939 coincides with crystal contacts between residues 940-942 of A3 and
symmetry related RU5 VH domains. In contrast, A3 in complex C lacks these crystal
contacts. The position of Pro940 in complex C and in structures of free A3, would not allow
for the crystal packing observed for complexes A and B.
Residues Gly1078-Pro-Ala-Gly-Asp-Ser1083 in loop a5b6 adopt a range of
conformations (Fig. 4C). This loop is located in a side face of A3 distant from the epitope of
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Fig. 4. The conformation of five loops varies among different crystal structures of A3. Models
compared include free A3 (pdb code 1atz and 1ao3), free (Se-Met) A3 and A3 from the A3-RU5
complex. (A) Stereo picture of loops a1b2 (residues 961-963), b a2 (983-987) and a3b4 (1019-1025).
Residues of A3 in A3-RU5 complex A are shown in thick line. A3 domain A from the structure of
Huizinga et al. (194) is shown in gray. (B) Stereo diagram of residues Ser938-Phe-Pro940 in the top
face of A3. Buried and exposed conformations of Phe939 are labeled. (C) Stereo diagram of loop a5b6
(residues 1078-1083). The aberrant A3 domain B from the structure of Bienkowska et al. (193) is
shown in thick line.
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different conformation. This aberrant conformation coincides with crystal contacts
unique to molecule B. No crystal contacts are present in the other structures. The
conformations observed in the RU5-A3 complex are not systematically different from the
conformations observed in free A3.
Discussion
The current study was aimed at locating the collagen-binding site in the vWf-A3 domain. For
this purpose, we solved the crystal structure of the A3 domain in complex with a Fab
fragment of RU5, that inhibits collagen binding of A3. The structure of the complex shows
that RU5 binds to residues within A3 sequences 962-966, 981-997 and 1022-1026. These
residues are located in a-helix 2 and in loops a1b2, b3a2 and a3b4 at the bottom of the A3
domain (See Fig. 3).
Inhibition of collagen binding by RU5 could be caused by two distinct mechanisms.
Firstly, RU5 could block collagen binding through steric hindrance. Secondly, RU5 could act
by inducing a conformational change in A3 that disrupts the collagen-binding site. Long-
range conformational changes induced upon ligand binding do occur in the structurally
related I domains of integrins aMb2198,206,207,310 and a2b1200, and have been proposed for the
vWf-A1 domain195,196. Identification of the actual mechanism of inhibition is relevant for
localizing the collagen-binding site of A3. In case of steric hindrance the binding site is
expected to lie at or close to the epitope of RU5, while for a mechanism involving a
conformational change the collagen-binding site could also be located distant from the
epitope.
A detailed structural comparison revealed significant, but local, conformational
differences between A3 in the crystal structure of the A3-RU5 complex and in crystal
structures of free A3. Differences of similar magnitude are also observed among different
structures of free A3. Differences are restricted to five loops. Three of these loops are located
in the RU5 epitope, i. . loops a1b2, b3a2 and a3b4. Loop a1b2 has a unique conformation
in the A3-RU5 complex, indicating that its conformation is induced by RU5. Conformations
of loops b3a2 and a3b4 in A3-RU5 are, however, also observed in some of the structures of
free A3, suggesting that their conformation is not induced by RU5. The same argument holds
for loop a5b6, that is located distant from the RU5 epitope. In the top face of A3 close to the
vestigial MIDAS motif structural variation is observed for residues Ser938-Phe-Pro940 in
loop b1a1 (Fig. 3). In A3-RU5 complexes A and B the side chain of Phe939 is buried,
whereas in complex C and in all structures of free A3 its side chain is solvent exposed (See
Fig. 4b). From the fact that both the exposed and buried conformations of Phe939 are
observed in the three A3-RU5 complexes we conclude that the conformation of loop b1a1 is
not influenced by binding of RU5.
In conclusion, analysis of conformational variation in structures of A3 shows that
RU5 does not induce long range conformational changes. This excludes a mechanism in
which collagen binding is inhibited by induction of conformational changes in the collagen-
binding site. Thus, most likely RU5 blocks collagen binding of A3 by steric hindrance,
which implies that the collagen-binding site is located in the vicinity of the epitope of RU5.
Previously, the collagen-binding site of A3 was proposed to be located in its top
face194,297 like it is in the homologous I domains of integrins a1b1 and a2b1200,311-313. Point
mutations introduced in the top face in free A3297 and in full-length vWf201 gave conflicting
results. Our crystal structure now shows that the collagen-binding site is not located in the
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top face of A3. Therefore, collagen binding by vWf-A3 appears to be completely different
from the collagen-binding mechanism of the I domains of integrins a1b1 and a2b1.
Previously, solvent exposure of residue Phe939 was proposed to be important for
the structural stability of the A3 domain, as an alternative for metal-ion binding in the
vestigial MIDAS motif193. It was suggested that solvent exposure of Phe939 opens an
essential water channel to the buried Asp934. Phe939 in A3-RU5 complexes A and B is, now
buried, similar to the conformation of homologues residues in I-domains of integrins 2, aM
and aL197,198,200. This shows that the solvent exposed conformation is not essential for
stability.
As was argued above, RU5 blocks collagen binding by steric hindrance. This does
not require that the epitope of RU5, which comprises 7% of the A3 surface area, overlaps
with the actual collagen binding site. Therefore, in addition to the epitope of RU5 located in
a-helix 2 and loops a1b2, b3a2 and a3b4, also residues that lie somewhat further away
from the epitope could play a role in collagen-binding (Fig. 3). If residues are considered that
are positioned up to 10 Å away from RU5, the location of the collagen-binding site is
confined to 32% of the total surface area of A3. This area includes residues from helices a1
and a3. Previously, regions comprising residues 948-998 (Ref. 314) and 1018-1114 (Ref.
292) of vWf-A3 were implicated in the major collagen-binding site of vWf. These two
regions indeed overlap with regions of A3 that are indicated by the A3-RU5 crystal structure
as potential contributors to the collagen-binding site.
In conclusion, the structure of the A3-RU5 complex shows that the collagen-binding
site of A3 is most likely located in the bottom or side face of A3 in the vicinity of a- lices
1, 2 and 3, and loops a1b2, b3a2 and a3b4, and not in the top face as was previously
proposed. The structure of A3-RU5 provides an excellent starting point for further
exploration of the collagen-binding site by means of site-directed mutagenesis.
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--- Summary ---
The integrity of blood circulation is a prerequisite for life; its malfunctioning is a leading
cause of morbidity and mortality in developed countries. For that reason the haemostatic
system is a critical component of homeostasis. In Chapter Ian overview is given of the
biophysical and biochemical characterization of two human plasma proteins that serve
important functions in haemostasis: b2-glycoprotein I (b2gpI) and von Willebrand factor
(vWf). b2gpI has a proposed role in clearance of thrombogenic apoptotic cells and in
coagulation. Moreover, b2gpI is the key target of auto-antibodies in the auto-immune disease
anti-phospholipid syndrome (APS), resulting in thrombotic complications. b2gpI binds with
its fifth C-terminal short concensus repeat (SCR) domain to anionic lipids. This affinity is
increased by complexation of b2gpI in divalent b2gpI-antibody complexes, which results in
shielding of anionic surfaces that are necessary in coagulation. Binding to anionic lipids is
possibly the primary involvement of b2gpI in coagulation. Multimeric vWf has a key
function in the haemostatic system when an arterial vessel wall is damaged. Multi-domain
vWf contains the binding site for collagen located in its A3 domain. When an arterial vessel
wall is ruptured, binding of the A3 domain to exposed collagen is a first step in haemostasis,
that facilitates recruitment of platelets for formation of a blood clot. The function of vWf can
be disturbed by quantitative and qualitative alterations of the protein and by non-self
compounds that induce spontaneous platelet aggregation. Disturbed vWF function results in
bleeding tendencies or thrombotic complications. Structural insights into adhesion of b2gpI
to lipids and of vWf-A3 to collagen are of valuable help in understanding their role in
homeostasis and in yielding insight into the molecular origin of, for example, coagulation
disorders.
b2-Glycoprotein I
In Chapter II we describe the crystal-structure elucidation of b2gpI fr m human plasma. The
structure is solved at 2.7 Å resolution with the multiple isomorphous replacement method
and reveals that b2gpI has an elongated fish-hook like arrangement of its five globular SCR
domains. Half of the fifth domain has a unique face created by a six-residue insertion and a
19-residue C-terminal extension, together with some rearrangement of parts of the SCR-like
core. Based on this structure and on biochemical data we propose a model for adhesion to
anionic lipids. A large patch of 14 cationic residues provides favorable electrostatic
interactions with anionic surfaces, and an exposed membrane-insertion loop containing a
typical Trp-Lys sequence yields specificity for lipids. The lipid-adhesion site is located at the
tip and outer curve of the b2gpI fish-hook. From the crystal structure we infer that in the
lipid-bound state, domains one to four point away from the lipid layer. Domains three and
four are partly shielded for protein-protein interactions by the four N-glycans attached to
these domains. Domains one and two are fully exposed and may provide binding sites in
apoptosis, APS and coagulation. In Chapter III we address b2gpI-protein complex formation
in solution using gel-filtration chromatography. b2gpI forms a stable complex with IgG 22F6
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which has properties common to auto-antibodies that are active in APS. This indicates that
lipid adhesion is not always a prerequisite for formation of active b2gpI- n body complexes.
b2gpI does not form complexes in solution with protein C and protein S which are
anticoagulants. Complex formation between protein S and its inhibitor C4B binding protein
lowers the concentration of free protein S, which results in inhibition of the anticoagulant
function of protein S. The complex of protein S and C4B binding protein remains stable,
even in the presence of b2gpI. Therefore, our experiments do not reveal further evidence that
supports an anticoagulant function of b2gpI by maintaining the level of free protein S. With
our binding experiments we cannot establish previously reported high-affinity complexation
between b2gpI and calmodulin. Stable complexes putatively only form in vivo whenb2gpI is
bound to lipids. In Chapter IV we describe structural differences between intact b2gpI and an
isoform of b2gpI (denoted b2gpI *1) that has lost its ability to adhere to anionic lipids and
that is present in plasma during oxidative stress. With gas chromatography-mass
spectrometry and thin-layer chromatography we show that b2gpI *1 s bound phosphatidyl-
choline (PC) or choline plasmalogen, and, to a lesser extent, sphingomyelin. The crystal
structure at 3.0 Å resolution of b2gpI *1 indicates a binding pocket for a
glycerophosphorylcholine moiety located within the adhesion site for anionic lipids. The
choline moiety is buried deeply inside the pocket and is surrounded by an anionic residue
and two aromatic residues; these are aspects common to several PC-binding proteins. With
C-terminal sequencing, carbohydrate analysis and mass spectrometry we show that, neither
enzymatic cleavage at Ala314-Phe315, nor mutation Trp316Ser, cleavage of sialic acid
residues, or differences in N-glycan content, account for the observed difference in lipid-
adhesive properties of b2gpI *1. Therefore, specific binding of a neutral lipid seems to be
fully responsible for blocking adhesion to anionic membranes. Based on these findings we
discuss a possible role for b2gpI *1 in defense mechanisms during oxidative stress. The
crystal structure of b2gpI *1, together with the structures of b2gpI, which was partially
cleaved at Lys317-Thr318 (Ref. 250), and of intact b2gpI251, also provides new insights that
contribute to a more detailed anionic lipid-adhesion model. In the App ndix to Chapter IV we
address recently discerned specific structural radiation damage of proteins upon exposure of
crystals to very intense X-ray beams of a third-generation synchrotron. We describe a new
method for refinement of partially broken disulfide bonds which appear to be present in
b2gpI *1. Effects of specific structural radiation damage include complete cleavage of the
carboxyl group of one Glu residue and partial cleavage of all eleven disulfide bonds,
observed in the most severely affected crystal of b2gpI *1. After refinement differences
among disulfide bonds in position of the Sg-atom and in electron density accounting for the
partially broken bonds suggest that solvent-exposed bonds are more susceptible to radiation
than buried bonds. Comparison of the severely affected structure of b2gpI *1 with that of
virtually not damaged b2gpI *1 (Chapter IV) shows that specific structural radiation damage
is localized to acidic residues and cystines. No changes in the global conformation of b2gpI
*1 are observed. This implies that the structural implications presented in Chapter IV are ot
compromised by radiation damage.
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Von Willebrand factor A3-domain
In Chapter V we describe the crystal-structure determination of the vWf (Se-Met) A3-
domain, in its complex with a Fab fragment of antibody RU5, which inhibits binding of vWf
to collagen. With this structure we aimed at locating the collagen-binding site in the A3
domain of vWf. The structure is solved at 2.0 Å resolution by molecular replacement using
the anomalous signal of the seleno methionines. The epitope of RU5 involves residues that
are part of an -helix and three solvent-exposed loops, located at the ‘bottom’ side of A3.
Comparison with other structures of A3 shows that RU5 binding does not induce long-range
conformational changes. Instead, RU5 most likely blocks collagen binding by steric
hindrance, which implies that the collagen-binding site is located at or close to the epitope of
RU5 near the bottom side of A3. Surprisingly, the collagen-binding site of vWf-A3 is located
distant from the top face of the domain where collagen-binding sites are found in
homologous integrin I-domains. Apparently, vWf-A3 and integrin I-domains bind collagen
in fundamentally different ways. The structure of A3-RU5 provides an excellent starting




Het goed functioneren van onze bloedsomloop is een essentiële voorwaarde voor een gezond
bestaan. Dit wordt geïllustreerd door het feit dat hart- en vaatziekten de meeste ziekte- en
sterftegevallen veroorzaken in de ontwikkelde landen. Het haemostase systeem maakt dan
ook een belangrijk onderdeel uit van de homeostase. In Hoofdstuk I wordt een overzicht
gegeven van de biofysische en biochemische karakterisering van twee humane plasma-
eiwitten die een belangrijke functie vervullen in haemostase: b2-glycoproteïne I (b2gpI) en
von Willebrand factor (vWf). Aan b2gpI wordt een functie toegeschreven gerelateerd aan het
verwijderen van trombogene apoptotische cellen uit de bloedbaan en in de proteïne C-
afhankelijke anti-stollingscascade. Daarnaast is b2gpI het belangrijke antigeen voor auto-
antilichamen die aanwezig zijn in personen die lijden aan de auto-immuunziekte ‘anti-
fosfolipiden syndroom’ (APS), een ziekte die onder andere wordt gekenmerkt door een sterk
verhoogd risico voor trombose. Het vijfde C-terminale ‘short concensus repeat’ (SCR)
domein van b2gpI bindt aan anionische lipiden. Deze affiniteit wordt sterk verhoogd onder
invloed van complexvorming van b2gpI in divalente b2gpI-antilichaamcomplexen, wat leidt
tot het afschermen van anionische oppervlakken die belangrijk zijn in anti-
stollingsprocessen. Deze afscherming wijst op de mogelijk belangrijke factor van b2gpI in de
bloedstolling. Multimeer vWf speelt een sleutelrol in het haemostase systeem als een
slagaderlijke vaatwand beschadigd raakt. Multi-domein vWf heeft een bindingsplaats voor
collageen, welke gelokaliseerd is in het A3 domein. Wanneer een bloedvat beschadigd is, is
binding van het A3 domein aan blootgesteld collageen één van de eerste stappen in
haemostase. Deze binding is essentieel voor het rekruteren van bloedplaatjes ten behoeve van
het vormen van een bloedstolsel. Het functioneren van vWf kan verstoord raken door
kwantitatieve en kwalitatieve veranderingen van het eiwit en door bepaalde
lichaamsvreemde stoffen die spontane klontering van bloedplaatjes veroorzaken. Verstoring
van de functie van vWf leidt tot interne bloedingen of tot trombose. Structuurinformatie over
de binding van b2gpI aan lipiden en over binding van vWf-A3 aan collageen is van groot
belang om de rol van deze eiwitten in de homeostase te begrijpen en om inzicht te verkrijgen
in de moleculaire grondslag van, bijvoorbeeld, verstoorde bloedstolling.
b2-Glycoproteïne I
In Hoofdstuk IIwordt de opheldering beschreven van de kristalstructuur van b2gpI dat uit
humaan bloedplasma is gezuiverd. De structuur is bepaald tot een resolutie van 2.7 Å met
behulp van de meervoudige isomorfe vervangingsmethode en laat zien dat de vijf globulaire
SCR domeinen van b2gpI een zeer uitgerekte vishaak-achtige rangschikking hebben. De ene
helft van het vijfde domein vormt een unieke zijde die gevormd wordt door een insertie van
zes aminozuren en een verlenging bestaande uit negentien aminozuren; dit gaat samen met
enige herrangschikking van delen van de SCR basisstructuur. Gebaseerd op deze structuur en
op beschikbare biochemische gegevens stellen wij een model op die de binding van b2gpI
aan anionische lipiden beschrijft. Een groot oppervlak bestaande uit veertien kationische
aminozuren verschaft gunstige elektrostatische interacties met anionische componenten; een
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vrijelijk beschikbaar membraan anker, bestaande uit onder andere een typische tryptofaan-
lysine sequentie, zorgt voor specificiteit van b2gpI voor anionische lipiden. De
bindingsplaats voor membranen bevindt zich aan de punt en tevens aan de buitenzijde van de
kromming van het vishaakje dat b2gpI vormt. Uit de kristalstructuur leiden we af dat
wanneer b2gpI gebonden is aan lipiden, domeinen één tot en met vier ver weg van het
membraanoppervlak en in de oplossing steken. Domeinen drie en vier zijn door hun N-
gebonden suikers gedeeltelijk afgeschermd voor eiwit-eiwit interacties. Domeinen één en
twee zijn volledig beschikbaar voor eiwit-eiwit interacties en bevatten mogelijk
bindingsplaatsen die een rol spelen in apoptose, APS en bloedstolling. In Hoofdstuk I I
richten we ons met behulp van gelfiltratie chromatografie op het bestuderen van de vorming
van b2gpI-eiwit complexen in oplossing. b2gpI vormt een stabiel complex met het
antilichaam ‘22F6’ dat eigenschappen gemeen heeft met die welke waargenomen worden
voor auto-antilichamen die actief zijn in APS. Deze waarneming duidt erop dat de binding
aan membranen niet altijd een vereiste is voor het vormen van actieve complexen tussen
b2gpI en auto-antilichamen. b2gpI vormt in oplossing geen complex met proteïne C of met
proteïne S, die betrokken zijn in anti-stollingsprocessen. Complexvorming tussen proteïne S
en C4B binding protein resulteert in een verlaagde proteïne S concentratie, waardoor de
remmende werking van proteïne S op bloedstolling vermindert. Het complex tussen proteïne
S en C4B bindend eiwit blijft zelfs zeer stabiel in aanwezigheid van b2 pI. Dientengevolge
leveren onze experimenten geen aanvullend bewijs dat een functie voor b2gpI als anti-
stollingsfactor ondersteunt: b2gpI zou de concentratie aan vrij proteïne S reguleren. Met
onze bindingsexperimenten kunnen we niet de eerder gepubliceerde hoge affiniteit van b2 pI
voor calmoduline aantonen. Het is mogelijk dat stabiele complexen alleen in vivo gevormd
worden, als b2gpI gebonden is aan lipiden. In Hoofdstuk IV beschrijven we de waargenomen
verschillen tussen de structuur van intact b2gpI en van een gelijkende vorm van b2gpI
(aangeduid met b2gpI *1) die echter niet meer aan anionische lipiden kan binden en die
gedurende oxidatieve stress aanwezig is in het bloed. Met behulp van gaschromatografie
gecombineerd met massaspectrometrie en met dunne-laag chromatografie laten we zien dat
b2gpI *1 een fosfatidylcholine (PC) of een choline plasmalogeen molecuul gebonden heeft
en in mindere mate een sfingomyeline molecuul. De kristalstructuur van het b2gpI-lipide
complex, die bepaald is tot een resolutie van 3.0 Å, suggereert dat zich een bindingsplaats
voor een glycerofosfaatcholine eenheid bevindt in het midden van de bindingsplaats voor
anionische membranen. De choline eenheid bevindt zich op de bodem van de bindingsplaats
en wordt omringd door een anionisch aminozuur en twee aromatische aminozuren; deze
aspecten worden algemeen waargenomen voor meerdere PC-bindende eiwitten. Door middel
van C-terminale aminozuurbepaling, suikeranalyse en massaspectrometrie tonen we aan dat
noch een enzymatische knip tussen Ala314 en Phe315, noch de mutatie Trp316Ser, noch het
wegknippen van siaalzuur, noch mogelijke verschillen in het gehalte aan N-gebonden
suikers, een rol spelen in de waargenomen verminderde affiniteit van b2gpI *1 voor
anionische lipiden. Daarom lijkt de specifieke binding van een neutraal lipide volledig
verantwoordelijk te zijn voor het blokkeren van de mogelijkheid om aan anionische
membranen te binden. Gebaseerd op deze bevindingen halen we in de discussie een
mogelijke rol aan voor het b2gpI-lipide complex in het verdedigingssysteem gedurende
oxidatieve stress. Naast de gedetailleerde structuurinformatie die we verkregen hebben over
de aspecten die van invloed zijn op de binding aan anionische lipiden, verschaft de
kristalstructuur van b2gpI *1, te zamen met de structuren van b2gpI, dat gedeeltelijk geknipt
was tussen Lys317 en Thr318 (Ref. 250) en intact b2gpI251, nieuwe inzichten die bijdragen
aan een meer gedetailleerd model voor de adhesie van b2gpI aan anionische lipiden. In de
Appendix bij Hoofdstuk IV richten we ons op recent onderkende specifieke stralingsschade
aan de structuur van eiwitten, die veroorzaakt wordt door het bestralen van kristallen met
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zeer intense röntgenbundels van een derde-generatie synchrotronbron. We beschrijven een
methode voor de verfijning van zwavelbruggen die gedeeltelijk verbroken zijn; deze zijn
namelijk aanwezig in b2gpI *1. De effecten van specifieke stralingsschade op de structuur
zijn onder andere het volledig afsplitsen van een carboxyl groep van één Glu residu en het
gedeeltelijke verbreken van alle elf zwavelbruggen, zoals is waargenomen voor het zwaarst
aangetaste kristal van b2gpI *1. De na de verfijning waargenomen verschillen tussen
zwavelbruggen voor wat betreft de positie van de Sg-atomen en de electronendichtheid ter
plekke van de gedeeltelijk verbroken zwavelbruggen, suggereren dat zwavelbruggen die in
de periferie van de eiwitstructuur liggen meer vatbaar zijn voor stralingsschade dan
zwavelbruggen die zich binnenin de eiwitstructuur bevinden. Wanneer de zwaar aangetaste
structuur van b2gpI *1 vergeleken wordt met die van b2gpI *1, die niet noemenswaardig is
aangetast (Hoofdstuk IV), blijkt dat de specifieke stralingsschade beperkt blijft tot anionische
aminozuren en cystines. We nemen geen veranderingen waar van de globale conformatie van
b2gpI *1. Dit houdt in dat de gevolgtrekkingen op basis van de structuur van b2gpI *1, zoals
beschreven in Hoofdstuk IV, niet gecompromitteerd zijn door niet-verdisconteerde effecten
van stralingsschade.
Von Willebrand factor A3-domein
In Hoofdstuk Vbeschrijven we de bepaling van de kristalstructuur van het vWf (seleno-
methionine) A3-domein in complex met een Fab fragment van het antilichaam ‘RU5’ dat de
binding van vWf aan collageen remt. Met behulp van deze structuur proberen we de
bindingsplaats voor collageen in het A3 domein te lokaliseren. De structuur is bepaald op een
resolutie van 2.0 Å met behulp van de moleculaire vervangingsmethode, die ondersteund
werd door het gebruik van het anomaal signaal van seleno-methionine residuen in A3. Het
epitoop van RU5 omvat residuen die deel uitmaken van een a-helix en van drie lussen die
aan het oppervlak van het A3 molecuul liggen. Al deze residuen liggen in de onderzijde van
A3. Na vergelijking met andere A3 structuren blijkt dat binding van RU5 geen conformatie-
veranderingen over lange afstand bewerkstelligt. In plaats daarvan lijkt RU5 collageen
binding te voorkomen door middel van sterische hindering. Dit impliceert dat de
bindingsplaats voor collageen zich binnen of dichtbij het epitoop van RU5 bevindt en dus in
de buurt van de onderzijde van A3. Het is opmerkelijk dat de bindingsplaats van vWf-A3
voor collageen zich ver van de bovenzijde van het A3 domein bevindt omdat hier de
bindingsplaatsen voor collageen aangetoond zijn in homologe I domeinen van integrines. Het
is dus aannemelijk dat vWf-A3 en de I domeinen van integrines collageen op fundamenteel
uiteenlopende wijzen binden. De structuur van A3-RU5 verschaft een uitstekend startpunt
voor een verder onderzoek naar de bindingsplaats voor collageen, door middel van plaats-
specifieke mutagenese.
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